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ABSTRACT OF DISSERTATION 
 
GENETIC IMMUNIZATION IN THE HORSE: THE POTENTIAL FOR ENHANCED 
IMMUNE RESPONSES WITH DEACYLATED POLYETHYLENEIMINE (PEI) AND 
IMMUNOSTIMULATORY CYTOKINES AS VACCINE ADJUVANTS 
 
DNA vaccines in larger animals, such as horses, are generally less effective and elicit 
significantly weaker immune responses, than in small animal model systems. To provide 
optimal protection against pathogenic microorganisms, the induction of both humoral and 
cellular immune responses from DNA vaccination may be necessary. One limitation to 
DNA immunization in the horse is the difficulty in generating high levels of antigen-
specific antibody and CTL responses. Previous work in the laboratory has demonstrated 
that expression constructs containing native sequences encoding the surface unit (SU) 
envelope glycoprotein (pCiSU) of the Equine Infectious Anemia Virus (EIAV) are 
ineffective at stimulating immune responses in the horse. This was attributed to an 
unusual codon-usage bias of the EIAV genome that significantly limits the expression of 
SU sequences. Optimizing the codon usage of pCiSU (pSYNSU) in DNA vaccines 
stimulated low-titer immune responses in inoculated ponies. Another plausible 
explanation for the reduced effectiveness of these DNA vaccines may be transfection 
deficiency and low level expression elicited by plasmid vectors in the horse. These 
studies investigated if the addition of a cationic polymer, deacylated polyethyleneimine 
(PEI), and/or codon optimized molecular immune-stimulatory cytokines could augment 
the relatively weak immunogenicity of pSYNSU in DNA vaccination of horses/ponies. 
Administration of DNA in formulation with PEI resulted in the robust production of very 
long-lived humoral (15 months after vaccination) responses and induced cell-mediated 
IFN-y responses five days after immunization.. Additionally, the co-expression of a 
family of IL-15 cytokines expanded the repertoire of T cell recognition to SU-specific 
peptides, in terms of lymphoproliferation. DNA vaccination incorporating one IL-15 
family member, IL-15 (SSLSS) significantly enhanced serum antibody levels of IgGA 
and IFN-y mRNA expression levels. These responses were distinctly different from 
results seen with vaccinates that received „naked‟ pSYNSU DNA vaccines. It is evident 
from these vaccine studies that PEI can enhance DNA vaccine-elicited antibody and 
CTL-associated responses in the horse and IL-15 (SSLSS) can dramatically augment 
these responses. These results demonstrate an important role for PEI in promoting the 
longevity of immune responses to genetic immunization, which has not been reported 
previously in any large animal model.
KEYWORDS: DNA Vaccination, Horse, Cytokines, Polyethyleneimine, Immune 
Responses 
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Chapter I:   Background and Literature Review 
 
“It's clear that prevention will never be sufficient.  That's why we need a vaccine that will 
be safe.”  Luc Montagnier  
 
I. Introduction 
Since the demonstration in the early 1990‟s that immune responses are inducible 
by inoculation of plasmid DNA expression vectors encoding foreign antigens (Tang, 
DeVit et al. 1992), there has been considerable interest in using this technology to 
develop vaccines.  DNA vaccination involves the direct introduction of a plasmid or 
DNA sequence encoding the antigen(s) against which an immune response is sought into 
appropriate tissues.  The effectiveness of this technique is dependent on the in situ 
production of antigen after introduction of DNA.  This approach offers a number of 
potential advantages over traditional approaches, including the stimulation of both B- and 
T-cell responses, improved vaccine stability, the absence of any infectious agent, and the 
relative ease of large-scale manufacture.As proof of principle of this genetic-based 
approach, immune responses in humans and animals have been generated using genes 
from a variety of viral, bacterial, parasitic, and tumor agents (Cox, Zamb et al. 1993; 
Ulmer, Donnelly et al. 1993; Wang, Ugen et al. 1993; Sedegah, Hedstrom et al. 1994).  
Scientific advances in immunology, molecular biology, and infectious disease 
pathogenesis have revolutionized this radical new approach to vaccination, and much 
focus has shifted toward the development of strategies to further augment immune 
responses to any number of infectious microorganisms using DNA vaccination.   
 
Advantages of Gene-Based Vaccine Protocols 
Genetic or DNA vaccines offer a number of potential advantages over traditional 
approaches ranging from the fact that they are (1) easy to engineer and manipulate at the 
molecular level, (2) capable of expressing highly modified or even completely novel 
antigens, (3) inexpensive to manufacture, and (4) are intrinsically stable, thereby reducing 
the necessity for maintenance of a “cold chain” during distribution.  One of the major 
advantages of using DNA expression vectors as immunogens is the capability to 
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stimulate both humoral and cell-mediated arms of the immune system.  In contrast, most 
conventional inactivated vaccine products predominantly induce antibody responses 
(Tang, DeVit et al. 1992; Ulmer, Donnelly et al. 1993; Xiang, Spitalnik et al. 1994).  
DNA vaccines are also inherently safe, possessing none of the risks associated with 
conventional vaccines, such as the possibility of incomplete inactivation in the case of 
“killed” vaccines or a reversion to virulence associated with live-attenuated products.  In 
addition, one of the early fears that DNA vaccines would integrate into the genome 
inducing tumors or other metabolic disorders has not been realized after almost two 
decades of extensive research involving very large numbers of experimental animals 
(Kutzler and Weiner 2008). 
 
Processing of Antigens Expressed from Plasmid DNA 
To produce specific DNA components for genetic vaccination studies, target 
genes are inserted into molecular expression vectors, with transcription of these 
sequences usually regulated by a strong constitutive mammalian promoter (Wolff, 
Malone et al. 1990; Cox, Zamb et al. 1993; Ulmer, Donnelly et al. 1993).  Upon injection 
of genetic vaccines, plasmid DNA is endocytosed into nearby cells, and genes are 
subsequently transcribed into RNA after nuclear translocation.  Single stranded mRNA is 
then exported into the cytoplasm, where it is bound by ribosomes, translated into protein, 
and modified in the ER and Golgi Apparatus.  One important potential advantage of 
DNA vaccinations compared with alternative recombinant technologies, such as 
exogenous antigen production in bacteria, yeast, or baculovirus systems is that the 
expressed proteins will contain the correct post-translational modifications for the species 
being vaccinated.  Some of these proteins may then be routed to cellular proteosomes 
where they are degraded into multiple peptides.  Subsequent binding of these peptides to 
major histocompatibility complexes (MHC) class I molecules occurs in the cytoplasm, 
and results in insertion of the MHC I/peptide antigen complexes into the plasma 
membrane of the cell, with the peptide bound to the extracellular portion of the molecule.  
In this bound form, the peptide can interact with T lymphocytes, such as CD8+ cytotoxic 
T lymphocytes (CTL), to stimulate specific cellular immune responses.  Therefor-e, DNA 
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immunization and antigen processing through the MHC I pathway may favor the 
induction of cell-mediated immunity (CMI).   
 
DNA Vaccine Delivery Methods 
A number of different methods have been used to introduce DNA into animal 
tissues.  The two most common methods involve intradermal (i.d.) or intramuscular (i.m.) 
injection with a hypodermic needle or gene gun delivery, although tattooing and 
electroporation are also viable methods to introduce DNA antigen into animal tissue.  
Electroporation has gained popularity in recent years as a technique to facilitate DNA 
delivery in vivo to antigen presenting cells and enhance immune responses to DNA.  
Several alternative delivery methods, such as topical administration of plasmid DNA to 
the eye (Daheshia, Kuklin et al. 1997) and vaginal mucosa (Lewis and Babiuk 1999)
 
 and 
aerosol instillation of naked DNA on nasal and mucosal surfaces (Lewis and Babiuk 
1999) have also been used to deliver plasmid DNA, although with marginal success.  The 
injection of DNA alone into a tissue, without chemical agents or physical force, has 
resulted in gene expression in skin (Choate and Khavari 1997), muscle (Wolff, Malone et 
al. 1990), liver (Hickman, Malone et al. 1994; Budker, Zhang et al. 1996; Zhang, Vargo 
et al. 1997), or into the airways (Meyer, Thompson et al. 1995).   
The simplicity of delivering immunizations containing only plasmid DNA, as 
well as the safety associated with the technique makes this an appealing vaccination 
approach.   An ideal DNA vaccine will initiate prompt stimulation of both humoral and 
cellular arms of the immune system, with minimal doses of the vaccine, and enable a 
sustainable immunity over time.   
 
Challenges with DNA Vaccination 
Unfortunately, a major limitation of DNA vaccines is that while they generally 
produce strong protective immune responses in small rodent animal models, results are 
generally much less favorable in large animals including humans (Manoj, Babiuk et al. 
2004; van Drunen Littel-van den Hurk, Babiuk et al. 2004; Forde 2005).  The primary 
reason for this is that expression of selected antigens in vivo by immunization with 
unprotected or naked plasmid vector DNA is an extremely inefficient process.  Possible 
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reasons for this poor efficacy of DNA vaccines in large animals may be reduced 
transfection efficiency, low level gene expression, and suboptimal protein production 
elicited by some plasmid vectors.  Some of the barriers encountered by using DNA as a 
vaccine approach stem from the large size of the palsmids and genes and the hydrophilic 
tendencies of the DNA constructs.  This poses an issue with the transfection of plasmids 
into some target cells.   
DNA is also extremely susceptible to degradation by cellular nucleases and 
extracellular enzymes.  Although it is difficult to quantitate, it is believed that 90% of the 
DNA is washed away by the bloodstream or degraded by nucleases, prior to cellular 
uptake.  Nucleic acids distributed by the circulatory system do not appear to be taken up 
by cells but instead are rapidly degraded, becoming undetectable in most organs by two 
days post inoculation (Parker, Borellini et al. 1999).  Of the remaining DNA in the 
cytoplasm, less than 1% may be translocated into the nucleus (Parker, Borellini et al. 
1999).  Intact DNA is necessary for nuclear translocation and subsequent transcription 
and translation into protein.   
Even if DNA molecules survive to enter a cell, their translocation from the 
cytoplasm to the nucleus is a “perilous journey” (Lechardeur and Lukacs 2006).  The 
cytoskeleton often impedes diffusion of large DNA molecules through the cytoplasm 
thereby increasing the probability of nuclease degradation (Dauty and Verkman 2005) 
such that in some cell types 50% of all unprotected DNA is degraded within two hours 
(Lechardeur, Sohn et al. 1999).  Furthermore, for DNA molecules larger than 250 bp, 
entry into the nucleus requires active transport via the nuclear pore complex or 
disassembly of the nuclear membrane prior to cell division (Lechardeur and Lukacs 
2006).  Finally, once inside the nucleus, access of exogenous DNA molecules to the 
optimum transcriptional microenvironment may be restricted by high-affinity interactions 
with nuclear proteins such as scaffold attachment factor-A (SAF-A) (Baiker, Maercker et 
al. 2000; Mearini, Nielsen et al. 2004).  
 
EIAV pSU and pSYNSU in DNA Vaccination 
Because of the poor intrinsic efficiency of conventional genetic immunization 
techniques, the presence of additional factors diminishing either cellular uptake or 
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expression level of an experimental DNA vaccine may completely abolish detectable 
immune responses, especially in large animals.  This was demonstrated in ponies 
inoculated with plasmid DNA (pCi Native SU) containing native sequences, encoding the 
surface unit (SU) envelope glycoprotein of equine infectious anemia virus (EIAV) (Zhou, 
Cook et al. 2002).  Although a single i.m. inoculation containing 100μg of this plasmid 
was sufficient to induce easily detectable immune responses to pCi native SU DNA in 
mice, no responses were apparent in ponies after three i.m. doses containing 1.5mg pCi 
native SU (Zhou, Cook et al. 2002).  Native viral sequences encoding SU are poorly 
expressed in mammalian systems, probably because of an usual codon-usage bias, 
possession of multiple RNA splice sites, and the presence of  motifs with homology to 
adenosine-rich instability elements (Zhou, Cook et al. 2002).  Removal of these 
inhibitory features using the techniques of codon optimization and synthetically produced 
DNA sequences (pCi SYNSU) results in a 30-fold increase in SU expression in 
transfected cell cultures (Cook, Cook et al. 2005).   
Furthermore, humoral immune responses were detectable in some ponies 
following just two i.d. inoculations with 250μg plasmid DNA (pCi SYNSU) containing 
codon optimized SU sequences (Cook, Cook et al. 2005).  However, despite a significant 
increase in expression levels and immunogenicity compared to native SU sequences, 
immune responses to SU in pCi SYNSU vaccinated ponies were substantially lower than 
those typically found in EIAV infected equids.  In addition, these responses failed to 
provide measurable protection from infection or disease following challenge with a 
virulent virus strain (Cook, Cook et al. 2005), clearly demonstrating the need for major 
improvements in immunogenicity before genetic vaccines against a wide range of 
pathogenic organisms are suitable for routine usage in large animals such as the horse. 
 
Equine DNA Vaccine against West Nile Virus 
Although the DNA vaccine platform has driven significantly weaker immune 
responses in large animals compared with mice, a successful, commercially available, 
plasmid-based vaccine (West Nile-Innovator
®
, Fort Dodge Animal Health, Overland 
Park, KS) is currently licensed in the United States for use against West Nile Virus 
(WNV) for horses.  This DNA vaccine was developed in conjunction with scientists at 
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the Centers for Disease Control and Prevention (Davis, Chang et al. 2001) and encodes 
the viral pre-membrane (prM) and envelope (E) proteins.  The efficacy of this vaccine, a 
single 1 mg plasmid DNA dose protects horses from challenge with a virulent strain of 
WNV (Davis, Chang et al. 2001), results from some highly unusual and fortuitous 
properties.  Following synthesis in transfected cells, the two proteins aggregate to form 
prM-E particles that are both highly immunogenic and contain viral neutralizing epitopes.  
Another advantageous characteristic of this system is that protection against WNV is 
relatively easy to achieve because it is conferred by low serum titers of virus neutralizing 
antibodies.  In the original studies of Davis et al. (Davis, Chang et al. 2001), serum 
antibodies in DNA vaccinated horses to WNV were barely detectable by immunoblotting 
at a dilution of 1:25, and the geometric mean neutralizing antibody titer prior to challenge 
in the four recipient horses were  1:5, 1:20, 1:20, and 1:40 (Davis, Chang et al. 2001).  
Although protective in this specific case, these levels of antibody reactivity might be 
considered „low-titer‟ humoral responses in most experimental situations.  Therefore, this 
demonstration of a successful development of a DNA vaccine against WNV in the horse 
represents an exception and not the rule. 
 
Correlates of Immune Protection against Viral Infection 
Unlike WNV, obvious correlates of immune protection are unknown against 
many other equine diseases, such as Equine Herpes Virus- 1 or EIAV.  This has impeded 
the development of prophylactic vaccines, especially against retroviral disease, where 
safe and effective vaccination strategies seem elusive.  In humans, protection against HIV 
is associated with the induction of CTL (Gallimore, Cranage et al. 1995; Rowland-Jones, 
Tan et al. 1997), CD4+ lymphocyte (Rosenberg, Billingsley et al. 1997), chemokine 
(Garzino-Demo, DeVico et al. 1998) and/or antibody responses (Burton 1997).  Other 
factors, such as high titer antibody responses or the induction of CMI responses may be 
necessary to provide adequate protection against some equine pathogens.   
An ideal goal for the design of a vaccine against EIAV may be the production of 
long-lived host immune responses that provide protection against diverse strains of EIAV 
introduced through natural routes of infection.  In EIAV infected animals, the emergence 
of non-neutralizing antibodies and virus-specific CD8+ CTL correspond with the 
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clearance of primary infectious plasma viremia (McGuire, Fraser et al. 2002).  While this 
may resolve acute disease, the virus mutates rapidly to evade immune surveillance.  
Therefore, a broadening of humoral and cellular immune responses may be necessary to 
recognize an increased number of viral epitopes.  In HIV infected individuals, expansion 
of the T cell repertoire to recognize multiple CTL epitopes has been shown after acute 
infection (Yu, Addo et al. 2002).  Similarly, in horses after infection with an attenuated 
strain of EIAV, increased numbers of CTL and T-helper cell epitopes within the viral 
envelope glycoproteins were identified, indicative of an expansion of immune responses 
in these animals (Tagmyer, Craigo et al. 2007).  Furthermore, the induction of 
neutralizing antibody (nAb) responses from DNA immunization may be a key element in 
the successful development of a protective gene-based vaccine against EIAV, especially 
since broadly reactive nAb responses correlate with virus control during infection in 
horses (Hammond, Cook et al. 1997; Hammond, Li et al. 2000; Belshan, Baccam et al. 
2001; Sponseller, Sparks et al. 2007).  Recently, In SCID foals, the protective effects of 
broadly nAb responses against EIAV infection was demonstrated (Taylor, Leib et al. 
2011).  However, since the precise correlates of protection against natural EIAV infection 
are still unknown, a number of vaccine strategies have been investigated to broaden 
equine immune responses and provide protection against disease. 
 
Cationic Polymers and Lipids in DNA Vaccination 
A frequently used approach to enhance the efficacy of plasmid DNA 
administration for genetic vaccination or gene therapy experiments involves the 
utilization of liposomal or polymer compounds.  These can both protect DNA from 
nuclease degradation and improve uptake by target cells.  A number of these compounds 
have been tested in both large and small animal systems (Klavinskis, Barnfield et al. 
1999; Ochiya, Takahama et al. 1999; Thomas and Klibanov 2002; Liu, Fong et al. 2003; 
Thomas and Klibanov 2003; Anderson, Peng et al. 2004; Thomas, Lu et al. 2005).  In 
horses, the proprietary cationic lipid DMRIE-DORE (Vical, San Diego, CA) enhanced 
the induction of humoral responses in a genetic vaccination experiment involving 
plasmid expression vectors encoding rabies glycoprotein (Fischer, Minke et al. 2003).  
Unfortunately, these improved responses were relatively short-lived, and anti 
8 
 
glycoprotein G antibody titers declined almost 75% in some animals within 14 days 
(Fischer, Minke et al. 2003).  
The cationic polymer, polyethyleneimine (PEI) can significantly enhance cellular 
transfection and improve DNA translocation to the nucleus, both in vitro and in vivo 
(Boussif, Lezoualc'h et al. 1995; Pollard, Remy et al. 1998; Godbey, Wu et al. 1999).  In 
genetic engineering experiments involving the transfection of lung tissues, PEI promoted 
10- to 100-fold greater reporter gene expression than many cationic lipid, including DC-
cholesterol:DOPE or DMRIE:DOPE (Densmore, Orson et al. 2000).  Therefore, high 
molecular mass polyethylenimines (PEIs) represent a very promising and readily 
commercially available class of compounds for enhancing the efficiency of DNA 
delivery in vivo (Diebold, Kursa et al. 1999; Thomas and Klibanov 2002; Manoj, Babiuk 
et al. 2004).  
However, commercial preparations of PEIs contain residual N-acyl groups that 
severely restrict the ability of these molecules to bind DNA and facilitate its delivery into 
cells.  Removal of these N-acyl groups from linear 25kDa PEI by acid hydrolysis 
increased the ability of this polymer to mediate transfection of DNA in vitro by 21-fold 
and produced a 10,000 fold enhancement in the delivery of plasmid DNA in an in vivo 
mouse model (Thomas, Lu et al. 2005).  However, the efficacy of fully deacylated 
preparations of PEI has yet to be evaluated in large animal models.  Therefore, deacylated 
PEI was utilized in a DNA vaccination regimen with EIAV SYNSU plasmid DNA 
(pSYNSU) to determine its effect on enhancement of gene delivery in the equine, 
compared to naked DNA alone.  With all of the obvious advantages to using PEI as a 
gene delivery system, toxicity in small animals has been a major concern seen in some 
model systems.  However, because of the vastly increased body mass in large animals, 
this is not predicted to be a significant problem in the horse.   
 
Immunostimulatory Molecules to Augment DNA Vaccine-Elicited Immune Responses 
The hypothesis that co-administration of immunostimulatory molecules will 
enhance immune responses to gene-based vaccines has been studied extensively, 
especially in small animal models (Scheerlinck 2001; Manoj, Babiuk et al. 2004).  
Provision of these immunostimulatory agents in protein form involves high production 
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and purification costs with the result that many researchers rely on in vivo expression of 
exogenously delivered genes encoding these molecules.  Examples of these 
immunomodulatory molecules include cytokines (GM-CSF (Xiang and Ertl 1995), IL-12 
(Kim, Nottingham et al. 1999; Sin, Kim et al. 1999)) and chemokines (eg. CCL2, CCL3, 
reviewed in (Luther and Cyster 2001)) that can enhance or modify specific immune 
responses elicited by DNA immunization.  Genes encoding co-stimulatory molecules, 
such as B7.2, CD80, or CD86, may aid in the recruitment of antigen presenting cells and 
help induce more robust immune responses against a selected panel of antigens 
recognized as immunodominant in the context of natural infection.  Cytokine adjuvants, 
including IL-2, IL-7, and IL-15 have also been extensively utilized in gene-based 
immunization as immunomodulatory elements to augment humoral and cellular immune 
responses to antigens expressed from plasmid DNA in mice and monkeys. 
Numerous cytokines have been shown to significantly modulate the inflammatory 
process.  They can act as pro-inflammatory mediators and anti-inflammatory mediators.  
Moreover, cytokines can stimulate the proliferation of a variety of immune cell types, 
thereby enabling memory immune responses to pathogens.  The production of effector 
molecules or cellular receptors can also be induced by cytokines.  Cytokines assist the 
immune response in determining the ideal response to pathogens and the magnitude of 
the response, by signaling immune cells, such as T cells and macrophages, to travel to 
sites of infection and also by stimulating them to produce more cytokines (Murphy, 
Travers et al. 2007).  In the vaccine treatment groups described in this dissertation, 
specific cytokines were incorporated into pSYNSU DNA vaccination regimens with PEI 
to evaluate as immunomodulators in horses and ponies on humoral and CMI responsed.   
There is now a substantial body of published evidence that certain cytokines act 
as potent molecular adjuvants for enhancing immune responses to DNA vaccines in at 
least some, albeit predominately small, animal models.  It is now important to determine 
if equine homologs of these cytokines can produce similar improvements in the 
immunogenicity of DNA vaccines in the horse, where the potential exposure to nucleases 
are likely to be greatly enhanced more so than in any mouse or even non-human primate 
system and the transfection efficiency of plasmid DNA is expected to be reduced.  The 
cytokines selected for this study include the equine homologs of IL-2, IL-7 and IL-15.  In 
10 
 
addition, IL-12 was used in combination with IL-18, as these cytokines act synergistically 
to enhance IFN-  production (Micallef, Ohtsuki et al. 1996; Ahn, Maruo et al. 1997). 
 
IL-2 as a Vaccine Adjuvant 
IL-2 is a member of a common γ-chain (γc) family of cytokines that share 
structural and functional properties, with IL-7 and IL-15, which all consist of a bundle of 
four alpha helices.  Signaling of IL-2 involves a three subunit receptor expressed by 
lymphocytes, composed of specific IL-2 receptor alpha and beta chains and a common 
gamma chain (Robb, Munck et al. 1981; Leonard, Depper et al. 1982; Sharon, Klausner 
et al. 1986; Teshigawara, Wang et al. 1987; Tsudo, Kozak et al. 1987; Takeshita, Ohtani 
et al. 1992). Members of this family all signal through the same common gamma chain 
(Takeshita, Ohtani et al. 1992).  When IL-2 binds to its receptor, numerous downstream 
signaling pathways, such as MAPK, PI-3K, or STAT-5, are activated that cause increased 
transcription of pro-inflammatory mediators (Friedmann, Migone et al. 1996).  Upon 
receptor interaction, IL-2 stimulates the growth, differentiation, and survival of antigen-
specific cytotoxic T lymphocytes. 
IL-2 is a leukocytotrophic hormone and has been well documented as a T-cell 
growth factor (Smith 1988).  Expression of IL-2 is limited to T cells.  It is produced in 
response to antigenic or mitogenic stimulation in the host (Cantrell and Smith 1984; 
Smith 1988).  IL-2 is secreted after antigen binds to the T-cell receptor, which causes an 
upregulation in IL-2 receptor (IL-2R) expression.  The IL-2/IL-2R interaction stimulates 
the growth, differentiation and survival of antigen-selected CTL by activating the 
expression of specific genes (Stern and Smith 1986; Beadling, Johnson et al. 1993; 
Beadling and Smith 2002).  IL-2 directly induces T cell proliferation and potentiates a 
very robust cellular response in the initial stages of T cell activation.  It also contributes 
significantly to T-cell immunological memory by expanding the population of antigen-
specific T cell populations (Yuan, Gallardo et al. 2006).  In addition to its role in T-cell 
proliferation, IL-2 regulates the magnitude of the immune response by inhibiting T cell 
expansion via induction of the synthesis of FAS and its ligand, FasL (Shrikant and 
Mescher 2002; Blattman, Grayson et al. 2003).  A cascade of intracellular events is 
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initiated by the binding of Fas to FasL, which ultimately results in the apoptotic cell death 
(Shrikant and Mescher 2002; Blattman, Grayson et al. 2003).   
 
IL-2/Immunoglobulin G1 (IL-2/Ig) Fusion Construct as a Vaccine Adjuvant 
IL-2 has been tested as an adjuvant in many DNA vaccine systems.  Simultaneous 
immunization with plasmid vectors encoding this interleukin has augmented humoral and 
cellular immune responses to a number of DNA vaccines expressing HIV-1 gp120 (Xin, 
Hamajima et al. 1998), hepatitis C virus core protein (Geissler, Gesien et al. 1997), 
hepatitis B virus surface antigen (Chow, Huang et al. 1997), and HSV type 2 
glycoprotein D (Sin, Kim et al. 1999).  DNA vaccines co-expressing IL-2/Ig were 
substantially more effective than native IL-2 at inducing immune responses in mice 
(Barouch, Santra et al. 1998), presumably because the half-life of expressed cytokine 
fusion construct and avidity was increased, thereby enhancing its potency.  IL-2/Ig also 
modulated cell-mediated responses to SHIV DNA vaccination in monkeys and induced 
some protective effects against SHIV virus challenge (Barouch, Craiu et al. 2000; 
Barouch, Santra et al. 2000).  Additionally, co-expression of IL-2/Ig with measles DNA 
vaccination in monkeys also enhanced cellular immunity and facilitated some protection 
from viral challenge (Premenko-Lanier, Rota et al. 2003).  DNA vaccines incorporating 
IL-2/Ig has also stimulated mucosal and systemic humoral and CMI against SHIV in 
macaques (Wang, Bertley et al. 2004).  In additional DNA vaccine studies, IL-2/Ig 
induced broad and robust HIV-1 specific murine IFN-  and CMI responses, more so than 
with the DNA antigen expression construct alone (Aggarwal, Kumar et al. 2005).   
The aforementioned trials in mice and monkeys suggest that the strategy of using 
IL-2/Ig plasmid could be a highly effective method for the induction of cellular immune 
responses in the horse to DNA vaccination.  To date, only plasmid DNA encoding native 
IL-2 has been inoculated in horses as part of a DNA vaccine study against EAV (Giese, 
Bahr et al. 2002).  Although low level neutralizing antibodies were detectable for one 
year post immunization, the fact that no Equine Arteritis Virus (EAV) DNA only 
immunization group was included to evaluate the relative benefits of IL-2 and the 
DMRIE-DOPE adjuvant detracts from the value of this study.  Therefore, the approach of 
12 
 
using IL-2/Ig in the horse has not been investigated prior to the studies described in this 
dissertation 
 
IL-15 as a Vaccine Adjuvant 
Interleukin-2 and IL-15 share an extensive amount of structural and some 
functional similarities, despite a lack of significant amino acid homology (Waldmann 
2006).  Interleukin-15 plays an important role early in the course of innateimmune 
responses (Ohteki 2002).  IL-15 mRNA is synthesized by activated monocytes and 
mononuclear phagocytes (Grabstein, Eisenman et al. 1994), but its expression is 
detectable in a broad range of cell and tissue types (Grabstein, Eisenman et al. 1994).  In 
contrast to IL-2, IL-15 is not produced by activated peripheral blood T lymphocytes 
(Grabstein, Eisenman et al. 1994). 
Signaling of IL-15 and IL-2 through the same β and γ chain receptor subunits (IL-
2R/IL-15Rβγ/γc chains) explains some of the functional similarities between these 
cytokines (Carson, Giri et al. 1994; Giri, Ahdieh et al. 1994).  However, IL-15 utilizes its 
own specific receptor alpha chain for signaling.  This alpha chain selectively binds to IL-
15 with an affinity, over 1000-fold higher than that observed between IL-2 and its alpha 
chain receptor (Giri, Kumaki et al. 1995; de Jong, Farner et al. 1996).   
The production of antibodies from plasma B cells is facilitated by both IL-2 and 
IL-15, and they can also both affect natural killer cells by stimulating proliferation and 
differentiation (Waldmann and Tagaya 1999; Waldmann 2006).  Similarly to IL-2, IL-15 
is also a T cell growth factor.  Initially, the two cytokines were thought to be 
interchangeable for stimulating immune responses, but they were later discovered to have 
very distinct functions (Grabstein, Eisenman et al. 1994; Armitage, Macduff et al. 1995).  
The most profound functional differences between these two cytokines are seen in their 
effects in adaptive immunity.  While IL-2 has more of a role in preventing autoimmunity 
by eliminating self-reactive T cells and also in maintaining regulatory T (Treg) cell 
populations in the thymus, IL-15 is required for the survival of CD4+ and CD8+ T-
lymphocytes important in the adaptive immune response.  IL-15 is also important for 
inducing the activation and proliferation of T cells and the costimulation of B cells with 
the CD40 B-cell receptor (Grabstein, Eisenman et al. 1994; Armitage, Macduff et al. 
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1995).  However, one of the most distinct roles of IL-15 is its influence in maintaining 
memory CD8+ T cell populations in the absence of antigenic stimulation and promoting 
the expansion of these cell populations upon subsequent encounters with the antigens 
(Lai, Gelfanov et al. 1999).  IL-15 is an important survival factor that stimulates T cell 
proliferation and prevents apoptosis, primarily by exerting its effects on effector memory 
CD8+ T cells (Kanai, Thomas et al. 1996).  In addition, IL-15 can also stimulate APCs 
directly, thereby activating a downstream signaling cascade of cytokine induction and 
secretion of IL-12 and IFN-  which further activate APCs and enhance CD8+ T cell 
stimulation (Kutzler, Robinson et al. 2005).  This powerful cytokine also plays a role in 
innate immune responses by stimulating cytokine production and natural killer (NK) cell 
proliferation in vivo. 
IL-15 is very efficient at stimulating immunological memory in rodent and 
primate model systems (Sprent and Surh 2001; Kaech, Wherry et al. 2002; Rocha and 
Tanchot 2004), although there are no reports concerning the efficacy of this cytokine on 
memory T cell responses to DNA vaccines in very large animals, such as horses.  This 
has been demonstrated in mice and monkeys (Kim, Trivedi et al. 1998; Sin, Kim et al. 
1999; Xin, Hamajima et al. 1999; Bolesta, Kowalczyk et al. 2006; Boyer, Robinson et al. 
2007; Rosati, Valentin et al. 2008; Dubie, Maksaereekul et al. 2009; Hu, Chen et al. 
2010; Eickhoff, Vasconcelos et al. 2011).  In monkey models, IL-15 induced antigen-
specific polyclonal CD8+ T cell responses and increased the frequency of SIV-specific 
CD8+ T cell responses against SIV DNA vaccination (Dubie, Maksaereekul et al. 2009).  
It has also been shown to strongly induce vaccine-specific IFN-  producing CD4+ and 
CD8+ effector cells and protection from ongoing SHIV infection with plasmid gag 
vaccination (Boyer, Robinson et al. 2007).  Furthermore, in rhesus monkeys, cellular 
immune responses were enhanced by the co-inoculation of IL-15 DNA with pHIV gag 
DNA facilitating control of SIV viremia, and IL-15 also increased memory recall 
responses to SIV antigens (Rosati, Valentin et al. 2008).  IL-15 has also been shown to 
increase the frequency of effector memory CD8+ T cells with HIV DNA vaccination in 
monkeys (Li, Qi et al. 2010).  
In mice, IL-15 has been reported to produce similar effects, as seen in monkeys, 
and significantly promote the expansion of CD8+ memory T cell pools and enhance 
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CD8+ T cell function independent of CD4+ T cell help (Bolesta, Kowalczyk et al. 2006).  
IL-15 co-delivery with DNA vaccination also has been shown to increase the number of 
antigen-specific IFN-  producing total and CD8+ T cells (Hu, Chen et al. 2010; Eickhoff, 
Vasconcelos et al. 2011) in mice.  Since the induction of immunologic memory and the 
establishment and maintenance of memory CD8+ T cells may be critical for protection 
against infectious microorganisms (Li, Demirci et al. 2001; Tan, Ernst et al. 2002), IL-15 
was predicted to be a powerful molecular adjuvant for incorporation in equine gene-based 
vaccine studies.  Therefore, its immunomodulatory effects on SYNSU DNA vaccines 
(formulated with PEI) were investigated in the horse.   
 
Sushi IL-15 as a Vaccine Adjuvant or an Antagonist 
In DNA vaccine studies with the IL-15 cytokine, soluble component regions of 
the IL-15 receptor alpha chain were observed to suppress the induction of arthritis in 
mouse model systems (Ruchatz, Leung et al. 1998) and also prolong the survival rate of 
certain transplanted heart tissues (Smith, Bolton et al. 2000).  Further analysis of the 
alpha chain region of IL-15 revealed a common motif known for protein-protein 
interactions in the extracellular region (Wei, Orchardson et al. 2001).  This motif of 
approximately 60 amino acids, known as the Sushi domain, is prevalent on a number or 
protein-binding molecules and contains four cysteine residues forming two disulfide 
bonds (Bottenus, Ichinose et al. 1990; Kato and Enjyoji 1991; Ranganathan, Male et al. 
2000).  Work done by Wei et al., 2001, has determined that the IL-15 receptor alpha is 
dependent on the Sushi domain for binding and protein functionality (Wei, Orchardson et 
al. 2001) and these domains have been identified on many different protein-binding 
molecules.  In vivo, IL-15 is normally presented on the cell surface as a complex 
formation with IL-15Rα, instead of being secreted as a soluble cytokine (Nguyen, 
Salazar-Mather et al. 2002; Schluns, Stoklasek et al. 2005; Van Belle and Grooten 2005). 
Trans-presentation of cell-bound IL-15 to NK and T cells ensues and subsequent 
recognition by the cellular receptors for the IL-15 β/γ chains results in survival and 
proliferation effects.  Interaction of IL-15 and its alpha-receptor have been shown to 
dramatically improve the biological activity of soluble IL-15 and induce strong and 
specific memory CD8+ T cell and NK cell responses in mice (Rubinstein, Kovar et al. 
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2006).  Because the Sushi domain is contained within IL-15Rα, this motif might 
contribute significantly to the superagonist effects seen with IL-15/IL-15Rα complexes in 
Rubenstein et al., 2006.  In light of these studies, an equine IL-15 Sushi construct was 
generated for administration in DNA vaccination studies in horses.  
 
IL-7 as a Vaccine Adjuvant  
The immunostimulatory effects of IL-7 on equine immune responses to pSYNSU 
immunization were also investigated.  IL-7 has a non-redundant role in lymphopoiesis, 
and has been coined the „Master Regulator of T-cell Homeostasis‟ (Fry and Mackall 
2001).  Furthermore, in contrast to many other interleukins, IL-7 is not produced by T 
cells, B cells, or NK cells.  However, it is produced by a wide array of cell types, such as 
dendritic cells (Kroncke, Loppnow et al. 1996), keratinocytes (Heufler, Topar et al. 
1993), hepatocytes (Sawa, Arima et al. 2009), neurons and endothelial cells (Watanabe, 
Ueno et al. 1995).  Stromal cells located in the thymus and red bone marrow secrete IL-7 
(Sudo, Ito et al. 1989; Watanabe, Ueno et al. 1995), and it plays many important roles in 
differentiating pluripotent hematopoietic stem cells into lymphohoid progenitor cells, as 
well as inducing proliferation of all cells in the lymphoid lineage (Collins and Dorshkind 
1987; Hunt, Robertson et al. 1987; Whitlock, Tidmarsh et al. 1987; Ogawa, Nishikawa et 
al. 1988).  
The IL-7 cytokine can have dominant effects in both B cell and T cell 
development in different species.  It has been described as an important cytokine in early 
B cell development in bone marrow (Baird, Gerstein et al. 1999), and it is largely known 
as a pre-B-cell growth factor, derived from the stromal cells of bone marrow (Namen, 
Lupton et al. 1988; Goodwin, Lupton et al. 1989).  In mice, IL-7 seems to affect both 
types of lymphocyte development, while it is indispensable for T cell development in 
humans.  Although IL-7 is not required for human B cell development, it can have 
modulatory effects.  The development of CTL responses are also strongly influenced by 
IL-7 in some model systems.  In vivo, this cytokine appears to also be able to drive 
immune responses towards a TH2 pathway.  It can also influence T-lymphocyte 
differentiation and is an important factor in maintaining viability of embryonic and early 
adult T cells (Murray, Suda et al. 1989; Wiles, Ruiz et al. 1992).  The survival of T cells 
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is promoted by the IL-7-dependent activation of anti-apoptotic proteins (Kim, Lee et al. 
1998; Opferman, Letai et al. 2003) and the inhibition of pro-apoptotic proteins (Khaled, 
Li et al. 2002; Li, Jiang et al. 2004; Pellegrini, Bouillet et al. 2004).  
As stated above, interleukin-7 is unique and its function in the immune system 
cannot be replicated by any other cytokine.  Primary T-cell development in humans is 
largely impacted by IL-7 (Puel, Ziegler et al. 1998).  When it is absent in gene knockout 
mouse models, B-cells and T-cells are unable to survive and regenerate, thereby 
demonstrating a critical role for IL-7 in lymphopoiesis (Grabstein, Waldschmidt et al. 
1993; Peschon, Morrissey et al. 1994; Bhatia, Tygrett et al. 1995; von Freeden-Jeffry, 
Vieira et al. 1995).  In work done by Bolotin et al. and Fry et al., IL-7 serum levels were 
shown to be inversely correlated with the numbers of lymphocytes present in human and 
murine model systems (Bolotin, Annett et al. 1999; Fry, Connick et al. 2001).  Clearly, 
this cytokine profoundly influences the development of immune responses in mammals, 
but the effects of IL-7 on B cell and T cell lymphopoiesis in horses are unknown.  
However, based on the well established importance of IL-7 in mice and humans, it was 
investigated as a potential immunomodulatory cytokine in equine DNA vaccination with 
pSYNSU and PEI. 
 
IL-12 as a Vaccine Adjuvant 
The cytokine IL-12 is also known as natural killer cell stimulatory factor (NKSF) 
and enhances NK cells and T-lymphocyte activity.  Largely B-cells and some T-cells 
produce IL-12, but it is also secreted by activated monocytes, macrophages, dendritic 
cells, peripheral lymphocytes, and some lymphoblastoid cells in an immune response to 
antigenic stimulation (D'Andrea, Rengaraju et al. 1992; Macatonia, Hosken et al. 1995; 
Kato, Hakamada et al. 1996; Reis e Sousa, Hieny et al. 1997).  Secretion of IL-12 
influences the development of T-lymphocytes during antigen priming by eliciting the 
maturation of type I T-cells from uncommitted TH0 cells, which can skew the immune 
response towards a TH-1 profile (Kobayashi, Fitz et al. 1989; Gately, Wolitzky et al. 
1992; Robertson, Soiffer et al. 1992; Germann, Gately et al. 1993).  The bioactive form 
of IL-12 is a heterodimeric 70 kiloDalton (kDa) glycoprotein, composed of 2 unrelated 
glycoproteins of approximately 40 kDa mol wt (p40) and 35 kDa mol wt (p35) that are 
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covalently linked together by disulfide bonds (Podlaski, Nanduri et al. 1992).  For the 
SYNSU DNA vaccine trials described int his dissertation, IL-12 subunits were connected 
by a flexible linker domain and administered with pSYNSU + PEI to investigate effects 
on immune responses in equids.  Production of a biologically active form of equine IL-12 
in which the p35 and p40 subunits are linked by a “flexible” glycine/serine rich chain has 
been described previously (McMonagle, Taylor et al. 2001).  A similar codon optimized 
equine IL-12 construct was synthesized for use in the preliminary DNA vaccine study. 
 
Synergy of IL-12 and IL-18 in DNA vaccination 
IL-12 functions cooperatively by binding to interleukin-18 (IL-18) to induce CMI 
responses, through the IL-18 receptor (Micallef, Ohtsuki et al. 1996; Kohno, Kataoka et 
al. 1997; Tominaga, Yoshimoto et al. 2000).  IL-18 alone is unable to enhance IFN-γ 
production by NK cells (Walker, Aste-Amezaga et al. 1999), however, synergistically 
with IL-12, both cytokines stimulate gamma interferon (IFNγ) production (Ahn, Maruo et 
al. 1997; Barbulescu, Becker et al. 1998; Chang, Segal et al. 2000).  Interleukin-18 is a 24 
kDa nonglycosylated protein, produced during an acute immune response by immature 
dendritic cells and activated macrophages, and it acts as a pro-inflammatory cytokine by 
inducing IFN-γ production (Okamura, Tsutsi et al. 1995).  Due to the synergistic nature 
of both cytokines for function, they were used in combination in a pilot DNA vaccination 
trial.   
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Summary 
In summary, genetic vaccines have stimulated robust immune responses against 
many pathogen and tumor antigens in small rodent models.  However, with the exception 
of highly specialized cases, such as the DNA vaccine against WNV, results in larger 
animal species have generally been disappointing.  This is most likely attributed to 
increased nuclease activity, higher blood volumes that dilute plasmid DNA, and 
decreased transfection efficiency of DNA into target cells.  Consequently, it is predicted 
that immune responses to gene-based vaccines in very large animals, such as horses, will 
be enhanced significantly by improving the uptake of the component nucleic acids by 
target host cells and/or by protecting them from degradation by nucleases.  Furthermore, 
it has been demonstrated that immune responses to genetic vaccines are also enhanced by 
co-administration of certain immunostimulatory molecules, including the IL-2, IL-7, IL-
12, IL-15, and IL-18 cytokines. 
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II. Hypothesis and Specific Aims 
We hypothesized that complex formation with a completely deacylated form of 
the cationic polymer PEI would improve the intracellular uptake of nucleic acid based 
expression vectors and/or their resistance to in vivo nucleases and consequently result in 
significantly enhanced adaptive immune responses to gene-based vaccinations in large 
animal systems, including the horse.  Additionally, we predict, based on a multitude of 
experimental results from different animal species, that immune responses to gene-based 
vaccines in horses will be further augmented by co-administration of expression vectors 
encoding equine homologs of IL-2, IL-7, IL-15, or combinations of IL-12 and IL-18. 
Correlates of immune protection against EIAV are unknown; however, recent 
work suggests that a broadening of humoral or cellular immune responses may afford 
protection against disease.  The most immunogenic viral protein expressed by EIAV is 
the gp90 or Surface Unit (SU) glycoprotein.  The SU glycoprotein is not only highly 
immunogenic, but contains one of the very few CTL epitopes identified in horses as 
being specifically bound by MHC of animals possessing the ELA-A1 haplotype.  
Therefore, Codon optimized nucleic acid sequences encoding the extensively 
characterized Surface Unit envelope glycoprotein of EIAV (pSYNSU) were used as the 
source of a model antigen to test these hypotheses,  
Initial testing of these hypotheses was conducted under three Specific Aims: 
(1) A pilot study with ponies possessing the ELA-A1 haplotype to examine potential 
toxic effects of PEI and determine if humoral and/or cellular immune responses are 
enhanced relative to pSYNSU alone, by immunizations with pSYNSU and PEI, with or 
without the co-administration of plasmid vectors encoding equine IL-2 + IL-15 or IL-15. 
(2) Assuming support for this hypothesis is provided by the pilot study: Investigate 
enhancement of immune responses to pSYNSU DNA vaccinations by PEI along with a 
more comprehensive panel of plasmid expression vectors encoding equine homologs of 
IL-2, IL-7, IL-15, and IL-12 in conjunction with IL-18 in horse/pony populations with 
diverse ELA haplotypes. 
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(3) Investigate anamnestic humoral and cell-mediated memory recall responses 15 
months after four DNA immunizations in animals from different vaccine groups 
following re-inoculation with pSYNSU and/or PEI. 
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CHAPTER II:   MATERIALS AND METHODS 
2.1. Interleukin construction, modifications and analysis 
 
Molecular Cloning of Native Equine IL-2 in pCi 
Plasmid DNA (pIL-2) containing the complete native equine IL-2 coding 
sequence including the N-terminal 20 amino acid signal peptide was obtained from Dr D. 
W. Horohov (Gluck Equine Research Center).  These sequences have been previously 
characterized at the nucleotide level and the protein they encode expressed and found to 
be biologically active in terms of stimulating equine lymphocyte proliferation in a dosage 
dependent manner (Vandergrifft and Horohov 1993).  The restriction endonuclease sites 
flanking the Equine IL-2 (IL-2) sequences in pIL-2 were not compatible with the strategy 
of simple excision and ligation into the mammalian plasmid expression vector pCi 
(Promega Corporation, Madison WI).  Therefore, equine IL-2 sequences were amplified 
in conjunction with the Expand High Fidelity PCR system (Roche Molecular 
Biochemicals, Indianapolis, IN) using the oligonucleotide primers native IL-2 F and 
native IL-2 R (Figure 2.1., IDT, Coralville, IA).  In addition to the Xho1 restriction 
endonuclease recognition site, the native IL-2 F primer contained a consensus Kozak 
motif immediately upstream from the initiation codon while a UGA termination codon 
was inserted into primer native IL-2 R prior to the EcoR1 site (Figure 2.1).  The reactions 
(50μl) were prepared as recommended by the manufacturer with 1.5mM MgCl2 and 
subjected to 35 cycles of melting at 94
o
C for 10 s. annealing at 54
o
C for 30 s with an 
extension at 68
o
C for 120 s.  The amplified product was digested with Xho1/EcoR1, 
separated by agarose gel electrophoresis and visualized by ethidium bromide staining.  
Following electrophoresis the single visible DNA band was excised from the gel, 
extracted using Agar Ace (Promega) and ligated into Xho1/EcoR1 digested pCi.  The 
ligated products were used to transform One Shot ® Stbl3 Chemically Competent E. coli 
cells (Invitrogen, Carlsbad,CA).  The resultant pCi vector DNA encoding equine IL-2 
(pCiIL-2) was purified using the Pure Yield
TM
 Plasmid Midi Prep System (Promega) and 
sequenced to ensure that disruptions to the open reading frame had not been introduced 
by either PCR or molecular cloning procedures, using a Thermo Sequenase Cy5.5 Dye 
Terminator kit (GE Healthcare UK Limited, Little Chalfont, United Kingdom).  
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Oligonucleotide primers for these reactions consisted of the forward and reverse PCR 
primers along with IL-2 SEQ1 and IL-2 SEQ2 (Figure 2.1) 
 
 
Figure 2.1 
 
Oligonucleotide Primers for Molecular Cloning and Modification of Equine 
Interleukins 
 
A) Equine IL-2 
 
Native IL-2 (F) 
CAGCTCCAG-GCCACC-ATGTACAGGATGCAACTCCTGTCTT 
 Xho1      Kozak 
 
Native IL-2 (R) 
AGGAATTCTCACGTCAGTGTTGAGATGATGCTTTGA 
       EcoR1 
 
Native IL-2 (R) Psp1406 
GTCAACGTTCGTCAGTGTTGAGATGATGCTTTGA 
          Psp1406 
 
SYN IL-2 (F) 
CAGCTCGAGA-GCCACC-ATGTACCGGATGCAGCTGCTG 
            Xho1            Kozak 
 
SYN IL-2 (R) 
GTCAACGTTGGTCAGGGTGCTGATGATGCTCTGGC 
        Psp1406 
 
 
IGHC1: Molecular cloning and Site-Directed Mutagenesis 
 
IGHC1 (F) Psp1406 
 N      V      Q       E 
GTCAAC-GTT-CAG-GAG-GCCTCCACCACCGCCCCGAAGGTCTTC 
        Psp1406 
 
IGHC1 (R) 
ATAAGAATGCGGCCGCTCATTTACCCGGGTTCTTGGAGACGTTCTT 
                            Not1 
 
IGHC1 ΔC1Q (F) 
CAGGACTGGCTGTCAGGAAAGGCGTTCGCGTGTGCGGTCAACAACCAAGCCCTCCCA 
 
IGHC1 ΔC1Q (R) 
TGGGAGGGCTTGGTTGTTGACCGCACACGCGAACGCCTTTCCTGACAGCCAGTCCTG 
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Figure 2.1 con’t. 
Oligonucleotide Primers for Molecular Cloning and Modification of Equine 
Interleukins 
 
IGHC1 ΔFc (F) 
CAGCTCCTGAGCTCGAGGGAGGGCCTTC 
 
IGHC1 ΔFc (R) 
GAAGGCCCTCCCTCGAGCTCAGGAGCTG 
 
 
Confirmatory Sequencing Primers 
 
Equine IL-2 SEQ 1 
ACAGGATGCAACTCCTGTCTTGCAT 
 
Equine IL-2 SEQ 2 
CTCTCGAAAGATATCAAGGAATTAATGAGCA 
 
IGHC1 168 
CCTGCAGTCCTCAGGGTTCTACTCC 
 
IGHC1 474 
CCCTGATGTCAAGTTCAACTGGTAC 
 
 
B) Equine IL-15 
 
SYN R to S (plus strand) 
CATCCTGGCCAACAGCTCCCTGAGCTCGAACGGC 
 
SYN R to S (minus strand) 
GCCGTTCGAGCTCAGGGAGCTGTTGGCCAGGAT 
 
SYNSushi IL-15 L+1* 
BamH1 
gga tcc gga ggc gga gga agc ggc ggc ggg agt ggc ggt ggc gga tct ggc ctg cag aac tgg cag gac gtg 
atc a 
         Bcl1 
 
SYNSushi IL-15 L+2* 
BamH1 
gga tcc gga ggc gga gga agc ggc ggc ggg agt ggc ggt ggc gga tct ggc ggt ctg cag aac tgg cag gac 
gtg atc a 
                  Bcl1 
 
*oligonucleotides were synthesized as double stranded “mini genes” although only the 
plus strand is shown 
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Molecular Cloning of a Native IL-2 and Equine Immunoglobulin gamma 1 Heavy Chain 
Fusion Construct 
To prolong the known short (15-30min) half-life in vivo of interleukin 2 (Malek 
and Castro 2010) an in-frame fusion construct between IL-2 and the equine 
immunoglobulin gamma 1 heavy chain IGHC1 (GenBank Accession Number AJ300675 
kindly donated by Dr Bettina Wagner, Baker Institute for Animal Health, Cornell 
University, Ithaca, NY) was produced.  The IGHC1 amino acid sequence contains motifs 
completely homologous with the high affinity Fc receptor and C1q binding sites 
identified on human IgG molecules (Duncan and Winter 1988; Duncan, Woof et al. 
1988).  As with IL-2/IgG fusion constructs developed for use in other animal systems, the 
putative Fc receptor and C1q binding sites were mutated to prevent the immunoligand 
from directing antibody dependent cell-mediated cytotoxicity and complement-directed 
cytolysis (Zheng, Steele et al. 1995; Barouch, Santra et al. 1998; Barouch and Letvin 
2000; Barouch, Santra et al. 2000).  Specific nucleotide mutations were introduced into 
IGHC1 using the QuickChange
TM
 site-directed mutagenesis kit (Stratagene, La Jolla, CA) 
in conjunction with the oligonucleotide primer pairs IGHC1 ΔFc F/R and IGHC1 ΔC1q 
F/R (Table).  The separate reactions (50μl) featuring these primer pairs were prepared as 
recommended by the manufacturer and subjected to 16 cycles of melting at 95
o
C for 30 s, 
annealing at 64
o
C for 60 s and 68
o
C for 11 min.  The successful introduction of specific 
mutations into the Fc and C1q binding sites was confirmed by nucleotide sequencing 
using primers IGHC1 168 and IGHC1 474 respectively (Figure 2.1).  Amplification by 
PCR of native IL-2 and IGHC1 ΔFc, ΔC1q sequences to produce an IL-2/IgG fusion 
construct was achieved using the primers Native IL-2 F/Native IL-2 R Psp1406 and 
IGCH1 F Psp1406/IGHC1 R (Figure 2.1) respectively.  The Native IL-2 R Psp1406 
primer was designed with the six nucleotide recognition sequence for the restriction 
endonuclease Psp1406.  Similarly, this recognition sequence was included within the 5‟ 
terminus of IGHC1 F Psp1406.  In addition, six additional nucleotides were included 
within the 5‟terminus of this primer so that when combined with the Psp1406 site the 
sequence asparagine (N), valine (V), glutamine (Q) and glutamic acid (E) was encoded 
producing the large hydrophilic, hydrophobic, hydrophilic, hydrophilic amino acid motif 
commonly observed within the variable-diversity-joining (VDJ) domains of 
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immunoglobulins (Landolfi 1991).  PCR conditions for the Native IL-2 F/Native IL-2 R 
Psp1406 primer pair comprised of an initial denaturation step of 94
o
C for 60 s followed 
by 30 cycles of 94
o
C for 10 s, 52
o
C for 30 s and 68
o
C for 2 min.  Similar conditions were 
employed for the IGCH1 F Psp1406/IGHC1 R primer pair except the annealing 
temperature was 60
o
C for 30 s.  Following electrophoresis in 0.8% agarose gels the 
resultant PCR products were extracted using AgarAce and ligated via a three-way 
reaction into Xho1/Not1 digested pCi to create native IL-2/Ig. 
 
Synthesis of Codon Optimized Equine IL-2 and molecular cloning of IL-2 and Equine 
Immunoglobulin gamma 1 Heavy Chain Fusion Construct (IL-2/Ig) 
Each codon in native IL-2 was evaluated and if necessary modified to conform to 
the codon-usage bias of highly expressed equine and human genes as described by Cook 
et al. (2005) (Cook, Cook et al. 2005).  The redesigned sequences were synthesized in 
vitro and inserted into the pCi mammalian expression vector (GenScript Corp. 
Piscataway, NJ) using Xho1/Not1 restriction endonuclease sites.  The codon optimized 
IL-2/IGHC1ΔFc, ΔC1q fusion construct was produced by PCR amplification of codon 
optimized IL-2 using the SYNIL-2 F/SYNIL-1 R primer pair (Figure 2.1).  Reaction 
conditions consisted of an initial denaturation step of 94
o
C for 60 s followed by 30 cycles 
of 94
o
C for 10 s, 63
o
C for 30 s and 68
o
C for 2 min.  The resultant PCR product was 
digested with Xho1 and Psp1406, separated by electrophoresis in 0.8% agarose and 
extracted using AgarAce.  This purified fragment was substituted for native IL-2 
sequences in native IL-2/Ig using the Xho1 and Psp1406 sites to create codon optimized 
IL-2/Ig. 
 
Synthesis of Codon Optimized Equine IL-7 (IL-7) 
The molecular cloning, nucleotide sequence characterization and expression of 
native equine IL-7 was previously reported from this laboratory (Cook, Cook et al. 2008).  
Although four isoforms of equine IL-7 generated by alternative RNA splicing events are 
present in normal horse lymphoid tissue only the largest molecular weight form was 
selected for these experiments because compared to the other variants it induces the 
highest proliferative responses in ex vivo horse PBMC (Cook, Cook et al. 2008).  To 
26 
 
investigate if codon optimization could improve the expression level of native IL-7 a 
synthetic version of the coding sequence (IL-7) was designed and manufactured as 
described for codon optimized IL-2 (GenScript Corp.). 
 
Synthesis of Codon Optimized Equine IL-12 (IL-12) 
IL-12 is a heterodimeric cytokine composed of disulphide linked p35 and p40 
subunits.  The fact the the intact molecule is encoded by two genes differentially 
expressed in various cell types poses difficulties for the design of IL-12 expression-based 
molecular constructs.  In addition, to ensure that synthesis of the subunits occurs in 
equimolar quantities following transfection, care must be taken to avoid the intracellular 
formation of homodimeric p40 molecules, as these act as antagonists of IL-12 p70 
activity (Ling, Gately et al. 1995).  These problems have been circumvented by 
production of equine IL-12 from expression vectors containing p35 and p40 cDNAs 
linked by sequences encoding a glycine/serine rich “flexible” chain to form a single open 
reading frame.  The resultant fusion molecule was shown to be biologically active when 
conditioned medium from mammalian cells transiently transfected with this construct 
stimulated gamma interferon production in cultures of horse lymph node derived 
mononuclear cells (McMonagle, Taylor et al. 2001).  The amino acid sequence of the 
equine IL-12 fusion construct tested as a DNA vaccine adjuvant, including the length of 
the glycine/serine rich linker chain, was as described previously (McMonagle, Taylor et 
al. 2001).  The nucleic acid sequence encoding the equine IL-12 fusion product was 
codon optimized, as described above, to maximize its intracellular expression potential. 
 
Synthesis of Codon Optimized Equine IL-15 (IL-15) 
Native equine IL-15 was molecularly cloned and sequenced in this laboratory 
(Cook unpublished).  However, protein expression was poor  expressed in vitro and 
conditioned medium obtained from human embryonic kidney 293 (HEK293, CRL-1573, 
ATCC Manassas, VA) cells transiently transfected with mammalian expression vectors 
encoding native equine IL-15 failed to stimulate proliferative activity in ex vivo equine 
PBMC cultures (Cook unpublished).  Therefore, a codon optimized version of equine IL-
15 was designed in which the unusually long (48 amino acids) signal peptide is replaced 
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with that from human tissue plasminogen activator (TPA, (Berg and Grinnell 1991).  The 
modified equine IL-15 nucleic acid sequences were synthesized commercially (The 
Midland Certified Reagent Company, Midland, TX).  During the molecular 
characterization of native equine IL-15 cDNA nucleotide position 363 was automatically 
read as Guanine (G) in one sequencing reaction whereas Cysteine (C) was present in 
others.  This resulted in a predicted arginine (R) residue (AGG) at amino acid position 
121 instead of serine (S) (AGC).  Therefore, equine IL-15 was initially thought to either 
possess serine, arginine, lysine, serine, serine (SRLSS) or (SSLSS) at amino acid 
positions 120 to 124.  It was not immediately obvious the SRLSS variant was a 
sequencing artifact, because there is extensive conservation of the LSS motif in IL-15 
molecules from many different mammalian species.  Therefore, the preceding two amino 
acids are subject to variation.  The codon optimized version of the SRLSS variant was 
submitted for gene synthesis (IL-15 (SRLSS)), however when it was discovered that this 
clone was poorly expressed following transient transfection in HEK293 cells R121 was 
replaced by S using site directed mutagenesis (QuickChange
TM
, Stratagene) in 
combination with the SYN R to S oligonucleotide primer pair ((Figure 2.1), IDT) to 
generate IL-15 (SSLSS). 
 
Synthesis of Codon Optimized Equine Sushi IL-15 (Sushi IL-15) 
With the advent of relatively inexpensive gene synthesis technology it is 
becoming increasingly feasible to generate genetic constructs encoding novel molecules.  
The biological activity in vitro of human IL-15 is increased 10-fold by covalently 
attaching the sushi domain from the human IL-15 receptor α chain, via a glycine/serine 
rich linker to the amino-terminus (Mortier, Quemener et al. 2006).  Production of an 
equivalent equine IL-15 fusion molecule was initiated by identification of sequences 
homologous to the sushi domain of the human IL-15 receptor α chain in the horse 
genome (Broad Institute Genome Sequencing Platform, (Wade, Giulotto et al. 2009).  In 
the design of Sushi IL-15 the homologous equine sushi sequences were codon optimized 
and attached as described previously (Mortier, Quemener et al. 2006) via a 20 amino acid 
glycine/serine rich linker molecule to the amino terminus of codon optimized IL-15 
(SSLSS).  However, the signal peptide from human TPA was incorporated into this 
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equine fusion protein instead of that from the human IL-15 receptor α chain signal 
peptide used in the human sushi IL-15 construct (Mortier, Quemener et al. 2006).  The 
Sushi IL-15 construct was synthesized and incorporated into the gWiz mammalian 
expression vector (Gene Therapy Systems Inc, San Diego, CA) by GenScript.  The 
extended glycine/serine linker chain variants Sushi IL-15 L+1 and Sushi IL-15 L+2 were 
produced by substitution of double stranded adapter oligonucleotides ((Figure 2.1.), 
GenScript) using unique BamH1 and Bcl1 restriction endonuclease sites.  The predicted 
molecular weight of the mature equine Sushi IL-15 fusion protein is 21686.11 Da 
assuming complete removal of the TPA signal peptide.   
 
Synthesis of Codon Optimized Equine IL-18  
The nucleotide sequence and molecular cloning of native equine IL-18 has been 
described previously (Nicolson, Penha-Goncalves et al. 1999).  This cytokine is 
synthesized as a biologically inactive precursor protein that only becomes active and 
secreted from the cell following cleavage with caspase 1 (Fantuzzi and Dinarello 1999).  
Therefore, secretion of functional IL-18 is reliant on cellular injury and apoptosis.  To 
overcome this problem the mature form of equine IL-18 was fused with the signal peptide 
from human TPA.  A similar strategy has shown that following expression of the 
resultant recombinant gene, a biologically active form of this equine interleukin is 
secreted from transiently transfected mammalian cell cultures (O'Donovan, McMonagle 
et al. 2004).  A codon optimized version of equine IL-18 containing the TPA signal 
peptide (IL-18) was synthesized and inserted into the pCi mammalian expression vector 
by GenScript. 
 
Expression of Recombinant Horse Interleukins Following Transient Transfection in HEK 
293 Cell Cultures 
Following molecular cloning into mammalian expression vectors all native and 
synthetic horse interleukins described above were transfected in triplicate into HEK 293 
cell cultures (American Type Culture Collection) maintained in 6-well culture plates 
(Becton Dickinson and Company, Franklin Lakes, NJ).  For transfection of each well, a 
total of 2µg of plasmid DNA was combined with 20µg Lipofectamine 2000 (Invitrogen) 
29 
 
in 500µl OptiMEM (Invitrogen).  The resultant DNA/cationic lipid complexes were 
added to HEK 293 cells according to the manufacturer‟s instructions and incubated at 
37
o
C in 5% CO2 for 72h after which cell culture fluids were harvested, aliquoted into 
0.5ml amounts and stored at -80
o
C prior to analysis.  The volume of each 0.5ml aliquot 
was reduced to 35μl using a 3K Amicon Ultra Centrifugal Filter Unit (Millipore, Cork, 
Ireland), as recommended by the manufacturer and dried using a Centrivap Concentrator 
(Labconco, Kansas City Mo).  It was then resuspended in 10μl “cracking buffer” (3.55M 
β-mercaptoethanol, 10% sodium dodecyl sulfate [SDS], 25% glycerol in 0.5M Tris/HCl 
pH 6.8) and heated for 10 m at 95
o
C.  The denatured protein samples were separated 
electrophoretically in a 12% SDS-polyacrylamide gel (Laemmli, 1970) using a Bio-Rad 
mini-Protean
®
 II Dual Slab gel system (Bio-Rad).  To examine intracellular expression in 
the case of IL-18, Brefeldin A (Sigma-Aldrich, St Louis, MO) was added (10µg/ml) to 
the cell cultures at 64h post transfection and incubation continued at 37
o
C in 5% CO2 for 
a further 8h.  After completion of the incubation period the cells were washed in PBS and 
lysed by the addition of 500µl 1X Reporter Gene Assay Lysis Buffer (Roche Applied 
Science) containing an EDTA-free protease inhibitor cocktail (Complete, Mini, EDTA-
free, Roche Applied Science).  Following lysis for 30min at room temperature insoluble 
material was removed by centrifugation at 16,000xg for 5 min, the protein concentration 
determined using the Bio-Rad protein reagent (Bio-Rad, Hercules, CA) and 100µg of 
each lysate separated electrophoretically as outlined above. 
In all cases after SDS-PAGE, proteins were transferred onto nitrocellulose 
membranes (Schleicher & Schuell, Keene, NH) using a Mini-Trans-Blot
®
 Electrophoretic 
Transfer System (Bio-Rad) and the membranes blocked with PBS containing 5% non-fat 
milk (Bio-Rad) for 2h and then incubated for 1h with 0.5μg/ml (in PBS containing 1% 
non-fat milk) of the appropriate polyclonal antiserum.  The antisera used for expression 
analysis were as follows: goat anti equine IL-2 (anti-eqIL-2 R&D Systems, Minneapolis, 
MN); rabbit anti human IL-7 (Antigenix America Inc, Huntington Sta, NY); goat anti 
human IL-12 (Antigenix); rabbit anti human IL-15 (Antigenix) and goat anti human IL-
18 (R&D Systems).  Bound antibodies were detected using horseradish peroxidase (HRP) 
conjugated goat anti-rabbit IgG (h+l) or rabbit anti-goat IgG (Bethyl Laboratories Inc, 
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Montgomery, TX) diluted 1:500 in PBS containing 1% non-fat milk and visualized with 
TMB stabilized substrate (Promega). 
The biologically active form of IL-18 is reliant on cellular degredative changes 
such as apoptosis because cleavage of the signal peptide is mediated by a caspase-1.  
Therefore, to overcome this specific requirement the signal peptide sequences were 
replaced with those from human TPA in the synthetic equine IL-18 coding sequence.  To 
determine if this sequence was cleaved, Brefeldin A was added to IL-18 transfected HEK 
293 cultures and the cell lysates compared by immunoblot analysis using goat anti human 
IL-18 to proteins secreted into the medium from equivalently transfected non-Brefeldin-
A treated cells.  Equine TPA-IL-18 contains no potential N-linked glycosylation sites 
(Figure 3.10).  Therefore, the full-length, non-cleaved variant of this protein is predicted 
to have a molecular weight of 22 k Da whereas removal of the TPA signal peptide 
reduces the size of the mature form to 18 kDa (Vector NTI).   
 
Proliferative Assays Using Conditioned Medium from HEK Cells Transfected with Native 
and Synthetic Variants of Equine IL-2, IL-7 and IL-15 
Conditioned medium collected 72h following separate transfections of HEK 293 
cells with native IL-2, IL-2, native IL-2/Ig, IL-2/Ig, native IL-7, IL-7, native IL-15, IL-15 
(SRLSS), IL-15 (SSLSS), Sushi IL-15, Sushi IL-15 L+1 or Sushi IL-15 L+2 was 
harvested, filtered (0.22μM) to remove cellular debris and stored at -80oC prior to 
analysis.  PBMC were isolated from donor horses by discontinuous density gradient 
centrifugation (Ficoll-Paque™ Plus, GE Healthcare Bio-Sciences AB, Uppsala, Sweden) 
and resuspended in RPMI 1640 (Invitrogen) maintenance medium containing 5% fetal 
equine serum (CELLect™, MP Biomedicals United States, Solon, OH), 100 units/ml 
penicillin, 100μg/ml streptomycin (Invitrogen) and 55μM 2-mercaptoethanol (Invitrogen) 
at 2x10
6
 cells/ml.  Filtered culture fluids from transfected and mock transfected cells (pCi 
without an insert) were diluted in RPMI maintenance medium and added (100μl/well) to 
96-well plates (Becton Dickinson and Company).  Finally, 100μl PBMC plus sub-
stimulatory amounts of concanavalin A (Sigma-Aldrich) at a final concentration of 
2μg/ml were added to each well and the plates incubated at 37oC in 5% CO2 for 72h.  In 
addition, to media from mock transfected cells, controls consisted of PBMC incubated 
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with and without concanavalin A in the presence of RPMI maintenance medium.  All 
assays were performed in triplicate.  Following the 72h incubation period 1μCi of 
tritiated (
3
H)-thymidine (MP Biomedicals, Inc, Irvine, CA) was added to each well in a 
volume of 50μl RPMI maintenance medium and incubation continued for an additional 
8h.  PBMC were harvested onto glass fiber filters (TomTec, Orange, CT) and [
3
H]-
thymidine incorporation determined by liquid scintillation counting (Wallac 1205 
Betaplate, Turku, Finland).  The proliferative responses were expressed in the form of a 
stimulation index (SI) representing the average [
3
H] thymidine incorporation of replicate 
PBMC cultures incubated with culture fluids from cells transfected with horse interleukin 
constructs divided by the average [
3
H] thymidine incorporation of replicate PBMC 
cultures incubated in the presence of culture fluids from mock transfected cells.  The 
PBMC plus culture fluids from mock transfected cells, PBMC plus concanavalin A and 
PMBC without concanavalin A all incorporated only low levels of [
3
H] thymidine, (< 
750cpm per 2x10
5
 cells). 
 
2.2.  Experimental Subjects   
 
Animals 
All horses and ponies utilized in the following vaccine trials were maintained on 
pasture at the Department of Veterinary Science‟s Maine Chance Farm, Lexington, Ky, 
in accordance with the Guide for the Care and Use of Agricultural Animals in 
Agricultural Research.  The animal handling protocols and experimental procedures were 
approved by the University of Kentucky Institutional Animal Care and Use Committee 
(IACUC).  Thorough veterinary exams were conducted on all animals to exclude animals 
with evidence of illness, trauma, lameness, weight loss, or abnormal coat shedding.  
Vaccinations for rabies and tetanus toxoid (Merck, Sharp and Dohme, Rahway, NJ) were 
administered yearly, as well as routine treatment with Ivermectin (Merck) for intestinal 
parasites.  Six ponies possessing the ELA-A1 haplotype were used in the first study 
(mean age 5.7 years; range, 4-10 years) (Table 2.1).  Thirty horses or ponies with diverse 
ELA haplotypes (Table 2.2) were used in the second study (mean age 4.8 years; range, 3-
16 years). 
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Assessment of Physical Responses to DNA Immunization 
Physical responses at the injection sites and in the surrounding area were 
monitored after each DNA immunization for redness, heat, soreness, and swelling.  
Discoloration or redness of the skin was visually assessed as an indication of infection.  
The evaluation of heat was determined by touching the skin to monitor for warmth 
radiating from the skin.  Soreness was determined by touching the skin and monitoring 
sudden flinching or adverse behavioral reactions, such as pinning back of the ears, as an 
indication of pain.  Swelling at and around the injection sites was measured in mm. 
 
Sample Collection and Processing   
Serum samples were collected prior to each inoculation and weekly thereafter for 
eight weeks in the pilot study (Figure 5.1.), for four weeks after V1-V4 (Figure 5.2), and 
weekly or monthly after V5 (Figure 5.3.) until SU-specific antibodies were no longer 
detectable by ELISA or immunoblotting.  Samples were centrifuged at 2500 rpm in a 
MSE Mistral 3000i for ten min at 22ºC to allow for serum separation, divided into single-
use aliquots, and stored at -20ºC for use in serological assays.   
Heparinized blood samples were collected aseptically by jugular venipuncture 
from each inoculated horse/pony, prior to inoculation, seven days, and 14 days, for the 
pilot study (Figure 5.1.) and V1-V4 (Figure 5.2).  Following the V5, heparinized blood 
was collected prior to inoculation and five days post inoculation (Figure 5.3.).  Peripheral 
blood mononuclear cells (PBMC) were purified by overlaying the buffy coat on Ficoll-
Paque Plus 
TM
 (Amersham Biosciences, Piscataway, NJ) for density gradient 
centrifugation.  PBMC were washed in sterile PBS, pH 7.2 (Gibco, Grand Island, NY) 
and enumerated using a ViCell-XR instrument (Beckman Coulter, Miami, Fl). PBMC 
aliquots were cryopreserved in c-RPMI 1640 (Gibco) media supplemented with 40% 
fetal equine serum (FES, Sigma-Aldrich, St. Louis, MO) and 10% dimethyl sulfoxide 
(DMSO, Sigma) in 2 ml Nalgene® cryogenic vials (Nalgene Co., Rochester, NY).  Cells 
were frozen overnight at -80ºC in Nalgene freezing containers and held in liquid nitrogen 
for storage until needed for lymphocyte proliferation and cell stimulation assays. 
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ELA-A Typing 
PBMC from all horses and ponies were typed with an antibody-mediated, 
complement-dependent, microcytotoxicity assay, using previously described alloantisera 
specific for haplotypes expressed on the ELA-A locus (Bailey 1980; Bailey 1983; Bailey, 
Antczak et al. 1984).  This locus includes the serological haplotypes recognized by the  
International ELA Workshops namely A1–A10, A14, A15, A19.  Antisera were available 
to determine A1–A10 haplotypes, in addition to the less well characterized W11.   
Six ponies possessing the ELA-A1 haplotype were identified for the initial pilot 
study, using this technique (Table 2.1).  ELA typing was also utilized to assess the 
diverse haplotypes of 30 horses and ponies utilized in the expanded preliminary study 
(Table 2.2).  Horses and ponies were assigned to ten different pSYNSU immunization 
groups, with three animals per group, such that no two animals possessing the same ELA 
haplotype were placed together in the same treatment group (Table 2.2). 
 
 
Table 2.1 
 
ELA Typing of DNA Immunized Ponies from the Pilot Study 
 
Animal Identification ELA-Type 
B33 A1/A5 
D47 A1/A8 
B29 A1/A9 
D49 A1/A3 
9954 A1/A3 
D55 A1/A7 
 
The ELA haplotpye for each pony was determined as described by Bailey et al., 1984. 
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Table 2.2 
 
ELA haplotype determination of animals in the expanded DNA vaccine study 
 
Vaccine Group Animal ID MHC Type 
Naked DNA 
 
600 
F37 
F41 
A1/A2 
A6/A7 
A5/A10 
PEI 
 
F36 
C06 
C10 
A8/A10 
A1/A3 
A2 
IL-2/Ig 
 
D07 
D15 
E13 
A1/ 
A3/A10 
A6/A9 
IL-7 
 
G22 
G23 
G30 
A9 
A2/A7 
A4/A5 
IL-12 + IL-18 
 
G21 
G26 
G35 
A1/A2 
A4 
A5/A9 
IL-15 (SRLSS) 
 
E03 
E08 
D77 
A3/A5 
A5/W11 
A8/A9 
IL-15 (SRLSS) + IL-2/Ig 
 
309 
F84 
F85 
A5/A6 
A2/A9 
A3/W11 
IL-15 (SSLSS) 
 
311 
D16 
G75 
A5/W11 
A2 
A2/A10 
IL-15 (SSLSS) + IL-2/Ig 
 
E05 
E12 
E15 
A2 
W11 
A3/A5 
Sushi IL-15 
 
F06 
F18 
G04 
A2/A5 
A1 
A4/A10 
 
The ELA haplotpye for each horse/pony was determined as described by Bailey et al., 
1984. 
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2.3.  DNA Immunization Protocols 
 
Formulation of Polyethyleneimine for DNA Immunization 
The linear, cationic polymer polyethyleneimine (PEI) (MW 25,000) was obtained 
from Polysciences, Inc, Warrington, PA.  PEI (1.2 g).  It was deacylated by refluxing 
with 24% wt/vol HCl at 110
o
C for 96hr with complete removal of acyl groups confirmed 
using NMR spectroscopy conducted by Professor Jurgen Rohr, Department of 
Pharmaceutical Sciences, University of Kentucky, Lexington, Ky. Each DNA plasmid 
used for immunization was formulated with PEI at a PEI nitrogen (N):DNA phosphate 
(P) molar ratio of 10:1 in sterile, nuclease-free, endotoxin-free water. 
 
Immunization Protocol for ELA-A1 Pilot Study 
For the first DNA vaccine trial (pilot study), 250 µg pSYNSU suspended in 500 
µl nuclease-free water was administered intradermally (i.d.) in the neck of each pony, 
near the prescapular lymph node at 0 (V1), 2 (V2), and 12 (V3) weeks (Table 2.3).  Prior 
to DNA inoculation, blood samples were collected from the ponies, and sera was 
examined for the presence of EIAV specific antibodies by immunoblot analysis to ensure 
that these animals were seronegative.  In the initial pilot study, two ponies (B29, D47) 
received three i.d. injections at weeks 0, 2, and 12 (Figure 2.2), each consisting of 250 µg 
pSYNSU formulated with PEI (Table 2.3).  As a control and to verify a previous study 
(Cook et al., 2005) demonstrating weak immune responses to SU following multiple 
inoculations with unprotected plasmid DNA, a single animal (B33) received three i.d. 
inoculations of pSYNSU at the same intervals (Figure 2.2, Table 2.3).  In addition, two 
horses (D55, 9954) received three equivalent i.d. inoculations with pSYNSU + PEI along 
with pIL-2/Ig (250 µg/dose) and pIL-15 (SRLSS) (Figure 2.2, Table 2.3).  It was 
unknown at the start of this study that equine IL-15 (SRLSS) expression was lower in 
transiently transfected HEK293 cells than equine IL-15 (SSLSS).  However, when the 
significantly superior biological activity of the SSLSS variant was discovered an 
additional horse, D49, was included in the initial pilot study and co-inoculated with three 
doses (at weeks 0, 2, and 12) of pSYNSU (250 µg) plus pIL-15 (SSLSS) (250 µg) 
(Figure 2.2, Table 2.3). 
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Figure 2.2 
 
Schedule of DNA Immunization and Sample Collection for ELA-A1 Ponies in the 
Pilot Study 
 
 
DNA vaccines were administered at 0 (V1), 2 (V2), and 12 weeks (V3), as indicated by 
the arrows.  Heparinized blood samples were collected immediately prior to each 
immunization and two weeks thereafter.  Serum samples were collected at weeks 0-8 and 
12-18. 
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Table 2.3 
 
Animal Assignments and pSYNSU Immunization Groups for the Pilot Study 
 
pSYNSU Immunization 
Group 
Animal 
Number 
Inoculum 
Naked DNA B33 pSYNSU 
PEI B29, D47 pSYNSU and PEI 
IL-15 (SSLSS) D49 pSYNSU, pIL-15 (SSLSS) and PEI 
IL-15 (SRLSS) + IL-2/Ig D55, 9954 pSYNSU, pIL-2/Ig, pIL-15 (SRLSS) and 
PEI 
 
All i.d. injected plasmid DNAs were formulated in endotoxin-free, nuclease-free, sterile 
water.  All experimental subjects received four i.d. inoculations at 0 (V1), 2 (V2), and 12 
weeks (V3). Each plasmid was used at a concentration of 250 µg per dose and, unless 
otherwise stated, formulated with fully deacylated, linear PEI at an N:P ratio of 10:1  
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Immunization Protocol for Animals with Diverse ELA Haplotypes  
Every animal received a series of four intradermal inoculations near the 
prescapular lymph node on alternating sides of the neck at 0 (V1), 2 (V2), 12 (V3), and 
24 (V4) weeks (Figure 2.3).  Each animal was inoculated with 500 µg pSYNSU DNA 
immunizations in 1 ml sterile, nuclease-free water.  Control ponies were immunized with 
the SYNSU plasmid (Table 2.5).  All nine remaining groups received pSYNSU DNA 
vaccines formulated with 1225 µg PEI (N:P ratio of 10:1) per SYNSU or 500 µg 
cytokine expression plasmid (Table 2.5).  One vaccine group only received pSYNSU 
immunizations in formulation with PEI (Table 2.5).  Cytokine recipient vaccine groups 
also received vaccines expressing pIL-2/Ig, pIL-7, pIL-12 + pIL-18, pIL-15 (SRLSS), 
pIL-15 (SRLSS) + pIL-12/Ig, pIL-15 (SSLSS), pIL-15 (SSLSS) + pIL-2/Ig, or pSushi IL-
15 (Table 2.5).   
Blood samples were collected prior to each immunization and up to four weeks 
after V3 and V4 (Figure 2.3), for serum analysis by Western blot and ELISA.  
Heparinized blood samples were also collected prior to each immunization and at one 
week after each inoculation for isolation of PBMC for cellular assays (Figure 2.3).  
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Figure 2.3 
 
Schedule of Vaccination and Blood Collection for animals with divergent ELA 
haplotypes administered pSYNSU DNA Vaccine Protocols 
 
 
 
DNA vaccines were administered at 0 (V1), 2 (V2), 12 (V3), and 24 (V4) weeks.  
Heparinized blood was collected for PBMC isolation at weeks 0, 2, 3, 12, 13, 24, and 25.  
Serum samples were collected at weeks 0-6, 12-16, and 24-28. 
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Table 2.5 
 
Animal Assignments and pSYNSU Immunization Groups for the 30 Horse 
DNA Vaccination Trial 
 
pSYNSU Immunization 
Group 
Animal Number Inoculum 
Naked DNA 600, F37, F41 pSYNSU 
PEI C06, C10, F36 pSYNSU and PEI 
IL-2/Ig D07, D15, E13 pSYNSU, pIL-2/Ig and PEI 
IL-15 (SRLSS) D77, E03, E08 pSYNSU, pIL-2/Ig, pIL-15 (SRLSS) and PEI 
IL-15 (SSLSS) 311, D16, G75 pSYNSU, pIL-15 (SSLSS) and PEI 
Sushi IL-15 F06, F18, G04 pSYNSU, pSushi IL-15 and PEI 
IL-7 G22, G23, G30 pSYNSU, pIL-7, and PEI 
IL-12 + IL-18 G21, G26, G35 pSYNSU, pIL-12 + IL-18 and PEI 
IL-15 (SRLSS) + IL-2/Ig 309, F84, F85 pSYNSU, pIL-2/Ig, pIL-15 (SRLSS) and PEI 
IL-15 (SSLSS) + IL-2/Ig E05, E12, E15 
 
pSYNSU, pIL-2/Ig, pIL-15 (SSLSS) and PEI   
 
All i.d. injected plasmid DNAs were formulated in endotoxin-free, nuclease-free, sterile 
water.  All experimental subjects received four ID inoculations at 0 (V1), 2 (V2), 12 
(V3), and 24 weeks (V4).  Each plasmid was used at a concentration of 500 µg per dose 
and, unless otherwise stated, formulated with fully deacylated, linear PEI at an N:P ratio 
of 10:1.  
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Immunization protocol for animals possessing diverse ELA haplotypes maintained for 
long-term observation 
After V4, it was only possible to retain fifteen animals, representative of eight 
different pSYNSU immunization groups, for long term observation (Table 2.6).  These 
horses or ponies were administered a fifth vaccination (V5) consisting of 500 µg 
pSYNSU (naked DNA group) in 1 ml sterile, nuclease-free water or 500 µg pSYNSU + 
PEI (all other pSYNSU immunization groups) (1225 µg) in 1 ml sterile, nuclease-free 
water, 15 months after V4 (Figure 2.4).  Blood samples were collected prior at week 90, 
prior to V5, and weekly/monthly thereafter until SU-specific antibodies were no longer 
detectable by immunoblotting (Figure 2.4). 
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Table 2.6 
 
Animal Assignments and pSYNSU Immunization Groups for V5 recipients 
 
pSYNSU 
Immunization Group 
Animal Number 
naked DNA 600, F37, F41 
PEI C10, F36 
IL-2/Ig D07 
IL-15 (SRLSS) D77, E03, E08 
IL-15 (SSLSS) 311, D16, G75 
Sushi IL-15 F06, F18, G04 
IL-7 G22, G23 
IL-12 + IL-18 G26, G35 
 
All i.d. injected plasmid DNAs were formulated in endotoxin-free, nuclease-free, sterile 
water.  Each experimental subject retained after V4 received a fifth ID inoculation at 90 
weeks (V5). pSYNSU was used at a concentration of 500 µg per dose and formulated 
with fully deacylated, linear PEI at an N:P ratio of 10:1 to all animals except for those in 
the naked DNA group.  
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Figure 2.4 
 
Schedule of Vaccination and Blood Collection from horses or ponies 
receiving a fifth Vaccination (V5) 
 
 
 
V5 was administered at week 90 to the animals retained for long-term observation.  
Heparinized blood was collected for PBMC isolation at weeks 90 and 91.  Serum samples 
were collected at week 90 and weekly/monthly thereafter (indicated by the dashed lines), 
until antibody responses were no longer detectable. 
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2.4.  Analysis of immune responses 
 
Immunoblot Analysis 
Gradient-purified EIAVPV (Rwambo, Issel et al. 1990) or antigens derived from 
transfected cell cultures were separated by SDS-PAGE and electrophoretically 
transferred to supported nitrocellulose membranes (Bio Rad, 0.2 microns) through wet 
transfer with a Mini-Trans-Blot
®
 Electrophoretic Transfer System (Bio-Rad 
Laboratories).  Non-specific binding of proteins to the nitrocellulose membranes was 
blocked by Blotting-Grade Blocker, non-fat dry milk (Bio Rad).  A reference anti-EIAV 
polyclonal antiserum was prepared from an EIAV-infected horse by Sheila Cook (MSc).   
Horseradish peroxidase (HRP)-conjugated antibodies (rabbit anti-Mouse IgG, rabbit anti-
horse IgG, or goat anti-mouse IgG) were purchased from Sigma.  The TMB Stabilized 
Substrate (3,3´, 5,5´-tetramethylbenzidine (Promega)) was used in Western blots as a 
color development substrate for localization of horseradish peroxidase-conjugated 
antibodies. 
 
Description of SU-specific peptides and generation of peptide pools 
Forty-four 20mer peptides overlapping by 10 amino acid residues (generously 
provided by Dr. R.C. Montelaro and described in Tagmyer et al., 2008 and Table 2.7 
(Tagmyer, Craigo et al. 2008)), representing the entire EIAVPV SU (GenBank accession 
no AF016316) were synthesized in the Biomedical Research Support Facility Peptide 
Synthesis Core Center of the University of Pittsburgh, using a Chemtech model 396 
Omega synthesizer.  The SU-specific peptides produced at the University of Pittsburgh 
were dissolved in 100% DMSO and maintained at a final concentration of 2 mg/ml.  
Individual 20mer peptides were combined into seven different pools (I-VII) for the 
lymphocyte proliferation assays (Table 2.8).  For the Real-Time RT-PCR assays, SU-
specific peptides were assembled into all even numbered peptides (Even), all odd 
numbered peptides (Odd), and a composite pool consisting of all 44 overlapping peptides 
(Total).  The RW-12 peptide was also utilized in lymphocyte proliferation assays with 
PBMC from ELA-A1 ponies in the pilot study, since it contained a CTL epitope 
recognized by animals with this genetic haplotype (McGuire, Leib et al. 2003).   
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Table 2.7 
 
Peptide sequences of 44 20mer peptides overlapping by 10 amino acid residues, 
representing the entire EIAVPV (GenBank accession no AF016316) SU and the RW-
12 peptide 
 
gp90 peptide Peptide sequence* 
1 MVSIAFYGGIPGGISTPITQ 
2 PGGISTPITQQSEKSKCEEN 
3 QSEKSKCEENTMFQPYCYNN 
4 TMFQPYCYNNDSKNSMAESK 
5 DSKNSMAESKEARDQEMNLK 
6 EARDQEMNLKEESKEEKRRN 
7 EESKEEKRRNDWWKIGMFLL 
8 DWWKIGMFLLCLAGTTGGIL 
9 CLAGTTGGILWWYEGLPQQH 
10 WWYEGLPQQHYIGLVAIGGR 
11 YIGLVAIGGRLNGSGQSNAI 
12 LNGSGQSNAIECWGSFPGCR 
13 ECWGSFPGCRPFQNYFSYET 
14 PFQNYFSYETNRSMHMDNNT 
15 NRSMHMDNNTATLLEAYHRE 
16 ATLLEAYHREITFIYKSSCT 
17 ITFIYKSSCTDSDHCQEYQC 
18 DSDHCQEYQCKKVNLNSSDS 
19 KKVNLNSSDSSNPVRVEDVM 
20 SNPVRVEDVMNTTEYWGFKW 
21 NTTEYWGFKWLECNQTENFK 
22 LECNQTENFKTILVPENEMV 
23 TILVPENEMVNINDTDTWIP 
24 NINDTDTWIPKGCNETWARV 
25 KGCNETWARVKRCPIDILYG 
26 KRCPIDILYGIHPIRLCVQP 
27 IHPIRLCVQPPFFLVQEKGI 
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Table 2.7 con’t. 
 
gp90 peptide Peptide sequence* 
28 PFFLVQEKGIANTSRIGNCG 
29 ANTSRIGNCGPTIFLGVLED 
30 PTIFLGVLEDNKGVVRGNYT 
31 NKGVVRGNYTACNVSRLKIN 
32 ACNVSRLKINRKDYTGIYQV 
33 RKDYTGIYQVPIFYTCNFTN 
34 PIFYTCNFTNITSCNNEPII 
35 ITSCNNEPIISVIMYETNQV 
36 SVIMYETNQVQYLLCNNNNS 
37 QYLLCNNNNSNNYNCVVQSF 
38 NNYNCVVQSFGVIGQAHLEL 
39 GVIGQAHLELPRPNKRIRNQ 
40 PRPNKRIRNQSFNQYNCSIN 
41 SFNQYNCSINNKTELETWKL 
42 NKTELETWKLVKTSGITPLP 
43 VKTSGITPLPISSEANTGLI 
44 ISSEANTGLIRHKRDFGISA 
RW-12 RVEDVTNTAEYW 
 
Peptide sequences of 44 20mer peptides overlapping by 10 amino acid residues, 
representing the entire EIAVPV (GenBank accession no AF016316) SU (generously 
provided by Dr. R.C. Montelaro and described in Tagmyer et al., 2008 (Tagmyer, Craigo 
et al. 2008)) and the EIAV RW-12 peptide (McGuire, Leib et al. 2003).  The SU-specific 
peptides produced at the University of Pittsburgh were dissolved in 100% DMSO and 
maintained at a final concentration of 2 mg/ml. 
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Table 2.8 
 
EIAV SU Peptide Pools 
 
I II III IV V VI VII 
1 3 5 7 9 11 13 
15 17 19 21 23 25 27 
29 31 33 35 37 39 41 
43 2 4 6 8 10 12 
14 16 18 20 22 24 26 
28 30 32 34 36 38 40 
42 44 1 17 33 6 22 
 
 
Odd Pool: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43 
 
 
Even Pool: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 
 
 
Total Pool: Peptides 1-44 
 
Forty-four peptides comprising the entire extracellular region of EIAV Env (SU) were 
divided into seven peptide pools (A), Odd Pool (B), Even Pool (C), or Total Pool (D).  
The peptides (generously provided by R.C. Montelaro) were synthesized at the 
University of Pittsburgh and by GenScript and described in Tagmyer et al., 2008 and 
Table 3.4. 
A. 
B. 
C. 
D. 
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[
3
H]-thymidine incorporation assay 
Lymphocyte proliferation assays were performed using cryopreserved PBMC to 
assess the total S-phase activity by measuring the uptake of [
3
H]-thymidine on stimulated 
cells (Hammond et al., 1997).  Isolated PBMC (2 x 10
5
 cells/ml) were plated in triplicate 
wells of 96-well flat bottomed, polystyrene plates (TPP, Trasadingen, Switzerland).  For 
the ELA-A1 pilot study, PBMC cultures collected prior to V1 (week 0) and at 2 weeks 
post V3 (week 14) were analyzed.  However, for the expanded study, PBMC cultures 
collected at week 0, 1 week post V3 (week 13), 1 week post V4 (week 25), and 1 week 
post V5 (week 91) were analyzed.  Lymphocytes were stimulated with media alone, 
Concanavalin A (Con A) (Sigma) at 10 µg/ml, gradient purified EIAVPV at 10 µg/ml, or 
EIAVPV peptide pools 1-7 at 21 µg/ml (for the expanded study) for 72 hours at 37ºC in 
humidified 5% CO2 incubator.  PBMC were then pulsed with 1 µCi of [
3
H]-thymidine 
(MP Biomedicals, Solon, Ohio) for the final 18 hours.  Total nuclear DNA was collected 
using a Tomtec harvester (J/B Industries, Inc., IL) onto glass fiber filter pads for liquid 
scintillation counting (Wallac Inc., Gaitheisburg, Md) to determine [
3
H]-thymidine 
incorporation.  The average corrected counts per minute (CCPM) was determined by 
subtracting the background for the instrument.  A stimulation index (SI) was used to 
determine EIAV-specific lymphocyte proliferative responses, by using the dividend of 
the mean CCPM value of [
3
H]-thymidine of replicate stimulated PBMC cultures for each 
treatment over the mean CCPM value of [
3
H]-thymidine of replicate unstimulated PBMC 
cultures.  Con A was used as a positive control, and the results were only considered 
valid if Con A stimulation indexes were greater than 10. 
 
Determination of DMSO and Cryopreservation Effects on Viability and 
Lymphoproliferation of Equine PBMC Cultures 
Heparinized blood samples were obtained from the long-term EIAV infected 
horse, D64, and processed by Ficoll-Paque density gradient centrifugation to isolate 
PBMC populations.  Optimization experiments were conducted on either freshly 
collected or cryopreserved PBMC populations maintained in liquid nitrogen.  To evaluate 
the effect of cryopreservation on the subsequent proliferative ability of equine PBMC, a 
comparative study was conducted with 
 
freshly collected and cryopreserved PBMC.  
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PBMC populations (2 x 10
5
) collected from an EIAV infected horse, D64, were harvested 
and cryopreserved for two days.  Additional blood was collected two days later and 
PBMC were harvested to run in a parallel assay with the cryopreserved PBMC.  The 
overall cell viability, in terms of trypan blue exclusion, was determined by a ViCell cell 
viability analyzer after PBMC isolation for the freshly isolated cells and after thawing for 
the cryopreserved cell population.  Differences in lymphoproliferation to mitogenic Con 
A (10 µg/ml), EIAVPV (10 µg/ml) and SU-specific peptide pool (21 µg/ml) stimulation 
were also assessed.  Cell populations of 2 x 10
5
 PBMC were incubated with stimulants 
for 72 h and subsequently labeled with [
3
H]-thymidine for 18 h, in a standard [
3
H]-
thymidine incorporation assay.  In addition, the blastogenic potential of fresh and frozen 
lymphocytes was observed microscopically.  Each peptide pool was used at a 
concentration of 21 µg/ml, resulting in a final DMSO concentration of 1.05% per well.   
 
In vitro PBMC Stimulation 
All cryopreserved PBMC used in the in vitro stimulation assays were thawed in 
cRPMI 1640 supplemented with 10% FES.  Cells were pelleted by centrifugation at 300 
G x 10 minutes and resuspended in medium (c-RPMI 1640 supplemented with FES 
(2.5% for Real-Time RT-PCR assays and 5% for lymphoproliferation assays), 100 U/ml 
penicillin/streptomycin [Sigma], 55 µM 2-mercaptoethanol [GIBCO, Grand Island, NY]) 
and enumerated on the ViCell-XR instrument.  For all lymphocyte proliferation assays, 2 
x 10
5 
PBMC were plated as four replicates in a 96-well plate format for each treatment 
(200 µl total volume of medium).  For the Real-Time RT-PCR assays, 3 x 10
6 
PBMC 
were plated in single wells in a 24-well plate format for each treatment (one ml total 
volume of medium). 
For the pilot study, sufficient cryopreserved PBMC stocks collected prior to V1 
(Pre-vacc.) and at two weeks post V3 (Post-vacc.) were available from B33, B29, D47, 
D49, 9954, and D55 to determine if detectable amounts of IFN-γ mRNA were produced 
following incubation with the SU RW-12 peptide, which interacts specifically with the 
ELA-A1 MHC class I antigen (McGuire, Leib et al. 2003).  PBMC cultures were >90% 
viable upon thawing and maintained viability throughout the assays, as measured by 
trypan blue exclusion.  To stimulate PBMC cultures for the lymphocyte proliferation 
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assay, PBMC were incubated with 1, 5, and 10 µg/ml gradient purified EIAVPV or 10 
µg/ml Con A as a positive control for 72 h.  Unstimulated PBMC cultures were used as a 
negative control to account for background stimulation for each pony.  PBMC were 
assayed in four replicates in complete RPMI 1640 medium (5% fetal equine serum, 1% 
penicillin/streptomycin, 1 % L-glutamine, 55 μM β-mercaptoethanol).  To determine IFN-
 mRNA expression levels after PBMC stimulation, PBMC were incubated with 10 
µg/ml RW-12 peptide, or phorbol 12-myristate 13-acetate (PMA; 25ng/ml; Sigma) and 
ionomycin (lµM; Sigma) as a positive control for cell stimulation.  Untreated PBMC 
cultures were used as negative control wells. 
For the expanded 30 horse/pony study, PBMC were incubated for 24 h at 37ºC in 
humidified 5% CO2 incubator to allow the PBMC to recover from the thaw before 
treatment with any stimulants.  To stimulate PBMC cultures for the lymphocyte 
proliferation assay, PBMC were incubated with 21 µg/ml of each peptide pool 1-7, 10 
µg/ml gradient purified EIAVPV or 10 µg/ml Con A as a positive control for 72 h.  For 
the Real-Time RT-PCR experiments, PBMC cultures were incubated with 21 µg/ml of 
each Odd, Even, or Total peptide pool.  The total concentration of each peptide pool used 
to stimulate PBMC (21 µg/ml) was consistent with previous work (Tagmyer, Craigo et al. 
2008).  PBMC were treated with medium alone, or medium supplemented with DMSO 
(1.05%), Con A (10 µg/ml), or each peptide pool.  For the optimization experiments, 
PBMC cultures were inoculated with individual peptides 20 or RW-12 at a concentration 
of 10 µg/ml, described in Tagmyer et al., 2007 (Tagmyer, Craigo et al. 2007).  Con A 
mitogen was used as a positive control, and lymphoproliferative responses to peptide 
pools were only examined if SI values for Con A were greater than 20, as this was 
consistent with SI values observed following Con A stimulation of fresh, non-
cryopreserved PBMC cultures. 
 
Effects of Priming with Equine IL-2 on Lymphoproliferative Responses 
Experiments were also conducted to „prime‟ the lymphocyte populations in the 
PBMC cultures to determine if this would augment proliferative responses to SU-specific 
peptide pools.  Recombinant equine IL-2 was added to 2 x 10
5
 PBMC cultures at 
concentrations of 0.1-1.0 ng/ml for 72 h and media was removed by careful aspiration 
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and replaced with either media containing 21 µg/ml of each peptide pool or 0.1-1.0 ng/ml 
IL-2 as positive controls.  For negative control wells, PBMC were initially stimulated 
with IL-2 (0.1-1.0 ng/ml) and re-supplemented with media only after the media change.  
The viability of PBMC cultures varied between 87-91%.  Stimulation indexes were 
calculated by dividing the mean of replicate wells for peptide stimulated PBMC 
populations by the mean of their respective media control (non-peptide stimulated 
PBMC).  An SI of 2 or above was statistically determined to be a significant increase in 
lymphocyte proliferation. 
 
Effects of Priming with Gradient Purified EIAV or Con A on Lymphoproliferative 
Responses 
The priming potential of gradient purified EIAVPV or Con A on PBMC from D64 
was also determined.  The 2 x 10
5
 PBMC cultures were incubated with 0, 2, 4, 6, 8, or 10 
µg/ml concentrations of EIAVPV or Con A at 10 µg/ml.  After 72 h, the media was 
changed and cells were supplemented with fresh media containing peptide pool 5 or 8 (21 
µg/ml).  Peptide pool 5 was utilized because previous results suggested that PBMC from 
D64 exhibited the highest proliferative responses to stimulation with this pool (data not 
shown), and peptide pool 8 was selected because it was composed of newly synthesized 
peptides from GenScript with a known purity. 
PBMC from D64 (EIAV long-term infected carrier) were incubated with 10 
µg/ml virus for 0-5 days in vitro and then incubated with either media, virus, Con A at 10 
µg/ml, or peptide pools 1-7 at 21 µg/ml for 1-7 more days, after media change to remove 
virus.  In a parallel assay, cells were also incubated with EIAVPV or individual peptide 
pools alone for 1-7 days.  RNA was isolated at each of these time points, reverse 
transcribed into cDNA, and real time RT-PCR was performed.  
 
RNA isolation and quantification 
Total cellular RNA was extracted from PBMC in culture after 24 h or 96 h with 
MagMAX™- 96 Total RNA Isolation Kit, according to manufacturer‟s instructions with 
a MagMAX™ Express Magnetic Particle Processor.  RNA quantifications were 
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performed with a NanoDrop ND-1000 at OD260 nm wavelength with 1 µl of each RNA 
sample.  
 
Relative Quantification of Cytokine Gene Expression using TaqMan
®
 Real-Time RT-PCR 
Real Time RT-PCR assays were performed to examine relative levels of IL-2 and 
IFN-γ gene expression from PBMC in response to stimulation with each peptide pool.  
For relative quantification of cytokine mRNA expression of IL-2 and IFN-γ, the reverse 
transcription reaction was performed with 0.5 μg of total RNA using RT random primers 
and a MultiScribe™ reverse transcriptase (High Capacity cDNA Reverse Transcription 
kit with RNase inhibitor [Applied Biosystems, Foster City, CA]) according to the 
manufacturer‟s instructions.  The reactions were incubated at 25°C for 10 min, 37°C for 
120 min and 85°C for 5 min (optimized and unpublished method by Y.Y. Go and Dr. 
Udeni Balasuriya, University of Kentucky).  The resultant cDNA was diluted 1:1 with 
nuclease-free water to allow for measurement of multiple cytokine genes by real-time 
RT-PCR.  Samples of cDNA were stored at -20ºC until further analysis by Real-Time 
RT-PCR. 
The Real-Time RT-PCR reactions were set up using the CAS-1200 (Corbett Life 
Science) automated PCR setup machine.  For cytokine gene expression, equine specific 
intron-spanning IFN-γ, IL-2, and beta-glucuronidase (β-GUS) specific primer/probe sets 
(Breathnach, Sturgill-Wright et al. 2006) were utilized.  Briefly, PCR amplification was 
carried out using a 10μl reaction mixture containing 4.5 μl of diluted cDNA, 0.5 μl of 
20× assay mix for the primer/probe set of interest (Applied Biosystems, Foster City, CA) 
and 5 μl of TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City, 
CA).  Samples were incubated in duplicate wells at 95°C for 10 min followed by 40 
cycles at 95°C for 15 s and 60°C for 60 s using an Applied Biosystems 7500 Fast Real-
Time PCR System.   
LinReg analysis was used to analyze the quantitative RT-PCR data by 
determining a baseline fluorescence, with a baseline subtraction (Ramakers, Ruijter et al. 
2003), followed by analysis with the ΔΔCT method (Livak and Schmittgen 2001) where 
ΔΔCT = (mean IFNγ CT – mean β-GUS CT)stimulant of interest – (mean IFN IFNγ CT – 
β-GUS CT)media („„the calibrator‟‟) to assess relative quantification of gene expression.  
53 
 
A stably expressed reference gene, beta-glucuronidase (B-GUS), was used as an internal 
control to determine variations in RNA levels between samples.  The calibrator used was 
the mean ΔCT of the media control for each animal for each individual gene.  The results 
are calculated as 2
- ΔΔC
T, expressed as relative quantity (RQ), and represent fold change 
increases in relative gene expression. 
 
Determination of Serum Immunoglobulins to EIAV SU-specific IgGA and IgGT 
Murine monoclonal antibodies to equine IgGA and IgGT were used in an ELISA 
format to determine the endpoint titers of these IgG subclasses induced by each of the 
DNA immunization protocols (Lunn, Holmes et al. 1995; Lunn, Holmes et al. 1996; 
Soboll, Horohov et al. 2003).  Serum samples were analyzed from each immunized 
individual at weeks 0, 3, 12-16, and 24-28 weeks post V1 for quantitative levels of EIAV 
SU-specific IgGA and IgGT antibodies, using an ELISA assay that has been previously 
described (Lunn, Soboll et al. 1999)..  Statistical analysis of the ELISA data was 
performed by Xia Yu and Keith Kohrs at the University of Kentucky, Department of 
Statistics, using the mixed procedure analysis with SAS.  Briefly, gradient purified 
EIAVPV at 2 µg/ml was coated onto 96-well polystyrene flat bottom Immulon Microtiter 
plates (Thermo Fisher Scientific) in 0.05M carbonate/bicarbonate buffer (pH 9.6) and 
incubated overnight at 4ºC.  Subsequently, the plates were washed with PBS/0.05% 
IGEPAL (CA-630 Sigma-Aldrich, St. Louis, MO) and blocked with 5% Blotting-grade 
Blocker Serum (Biorad) in ELISA wash buffer supplemented with 0.05% IGEPAL (CA-
630 Sigma-Aldrich, St. Louis, MO) for 2 h at 37ºC and washed again.  Serum samples 
diluted 1:40 and 1:80 in ELISA wash buffer were incubated in single wells for 30 min at 
22ºC.  Each plate included positive control serum samples (from EIAV infected horse) 
incubated at 1:40 and 1:80.  Plates were washed with PBS/0.05% IGEPAL and incubated 
for 1 h at 22ºC with murine monoclonal antibodies specific for anti-equine IgGA ((clone 
CVS48), Sheoran et al, 1998) and IgGT ((clone CVS38), Sheoran et al, 1998) for 30 min 
at 22ºC.  Following washes with PBS/0.05% IGEPAL, plates were incubated with 
horseradish peroxidase-conjugated goat anti-mouse IgG antibody (Sigma-Aldrich) for 30 
min at 22ºC.  Plates were washed again, developed by the addition of substrate o-
phenylene-diamine hydrochloride (Sigma Fast tablet sets, Sigma-Aldrich), and stopped 
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by the addition of 3N HCl.  Colorimetric changes were measured at A450 by a 
spectrophotometer, to determine relative serum antibody concentrations.   
Virus Neutralization Assay 
An virus-specific neutralization assay was used to measure antibody 
concentrations against EIAV in horse serum, to assess the loss of infectivity through 
reaction of the virus with specific antibodies.  The EIAV neutralization assay was 
performed by Dr. R. Frank Cook and Sheila Cook (MSc) according to a published 
method (Cook et al, 1995).  Two dilutions of horse serum were incubated for 3 weeks 
with 100 tissue culture infectious doses (TCID50) of EIAVPV.  The level of neutralizing 
antibody present was determined by the highest serum dilution that could render reverse 
transcriptase activity undetectable by radiolabelling. 
Statistics 
The mixed procedures of SAS program was used to analyze all EIAV SU-specific 
IgGA and IgGT titers determined in the ELISA assay, IFN-  expression levels in the pilot 
study, and the entirety of the lymphocyte proliferation data (analyzed by Xia Yu and 
Keith Kohrs, from the Department of Statistics at the University of Kentucky).  For the 
lymphocyte proliferation assay, corrected counts per minute (CCPM) were compared 
relative to media controls to determine positive proliferation over time in response to 
DNA vaccination.  Proliferation results to treatments were assessed at each time point 
and between vaccination time points, for both vaccination groups and for all 30 
individual animals.  Statistically significant differences were determined at the level of 
P<0.05.  Descriptive statistics (Mann 1995) were used to analyze IL-2 and IFN-  mRNA 
expression levels after four and five immunizations, with a minimal level of significance 
determined to be an RQ value of 2. 
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Chapter III:   Results 
 
3.1:  Recombinant Equine Interleukins 
 
Equine Interleukin Construction and Analysis 
As a result of the codon modifications made to pCiIL-2, the G + C content was 
increased from 46.2% in native IL-2 to 59.1% in the synthetic variant (Table 3.1).  The 
predicted molecular weight of the equine IL-2/IGHC1 fusion protein is 54817.22 (Vector 
NTI) for the precursor form and 52512.70 for the mature species assuming removal of the 
20 amino acid signal peptide.  An alignment between the IL-2 sequences is shown in 
Table 3.2.  The 36% GC content of native equine IL-7 cDNA was increased to 58.2% by 
codon optimization.  An alignment between these sequences is shown in Table 3.3.  
Codon optimization of the equine IL-12 sequences changed the G/C content from 52.4% 
with the native sequences to 53.1% in the synthetic gene (Table 3.4).  The G/C content of 
the codon optimized equine IL-18 construct was increased 15.1% compared to native 
sequences encoding this interleukin (Table 3.5).  The process of codon optimization also 
increased the G/C content of the IL-15 (SRLSS) and IL-15 (SSLSS) from 35% to 55.8% 
(Table 3.6).  However, addition of the Sushi domain and linker molecules (L+1 and L+2) 
to the IL-15 (SSLSS) construct did not alter the amino acid sequence of this interleukin 
(Table 3.7). 
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Figure 3.1 
 
Comparison between Native and Codon Optimized Equine IL-2 Nucleotide 
Sequences 
 
                    1                                               50 
Native IL-2     (1) -------ATGTACAGGATGCAACTCCTGTCTTGCATCGCACTAACTCTTG 
IL-2            (1) AGCCACCATGTACCGGATGCAGCTGCTGAGCTGCATCGCCCTGACCCTGG 
Consensus       (1)        ATGTAC GGATGCA CT CTG   TGCATCGC CT AC CT G 
                    51                                             100 
Native IL-2    (44) CAGTCCTTGCAAACAGTGCACCTACTTCAAGCTCTAAGAGGGAAACACAG 
IL-2           (51) CCGTGCTGGCCAACAGCGCCCCCACCAGCAGCAGCAAGCGGGAGACCCAG 
Consensus      (51) C GT CT GC AACAG GC CC AC    AGC   AAG GGGA AC CAG 
                    101                                            150 
Native IL-2    (94) CAACAACTGAAGCAATTACAGATGGATTTAAAGTTGCTTTTGGAAGGAGT 
IL-2          (101) CAGCAGCTGAAGCAGCTGCAGATGGACCTGAAGCTGCTGCTGGAGGGCGT 
Consensus     (101) CA CA CTGAAGCA  T CAGATGGA  T AAG TGCT  TGGA GG GT 
                    151                                            200 
Native IL-2   (144) TAATAATAACAAGAATCCCAAACTCTCCAAGATTCTCACATTTAAAATTA 
IL-2          (151) GAACAACAACAAGAACCCCAAGCTGAGCAAGATCCTGACCTTCAAGATCA 
Consensus     (151)  AA AA AACAAGAA CCCAA CT   CAAGAT CT AC TT AA AT A 
                    201                                            250 
Native IL-2   (194) ACATGCCCAAGAAGGCCACAGAATTGAAACATCTTCAGTGTCTAGAAGAA 
IL-2          (201) ACATGCCCAAGAAGGCCACCGAGCTGAAGCACCTGCAGTGCCTGGAGGAG 
Consensus     (201) ACATGCCCAAGAAGGCCAC GA  TGAA CA CT CAGTG CT GA GA  
                    251                                            300 
Native IL-2   (244) GAACTCAAACCTCTGGAGGAAATGCTAAAAAACTTTCTCTCGAAAGATAT 
IL-2          (251) GAGCTGAAGCCCCTGGAGGAGATGCTGAAGAACTTCCTGAGCAAGGACAT 
Consensus     (251) GA CT AA CC CTGGAGGA ATGCT AA AACTT CT    AA GA AT 
                    301                                            350 
Native IL-2   (294) CAAGGAATTAATGAGCAATATCAATGTAACAGTTCTGGGACTAAAGGGGT 
IL-2          (301) CAAGGAGCTGATGAGCAACATCAACGTGACCGTGCTGGGCCTGAAGGGCA 
Consensus     (301) CAAGGA  T ATGAGCAA ATCAA GT AC GT CTGGG CT AAGGG   
                    351                                            400 
Native IL-2   (344) CTGAAACAAGATTCACATGTGAATATGATAATGAGACAGAAACAATTGTA 
IL-2          (351) GCGAGACCCGGTTCACCTGCGAGTACGACAACGAGACCGAGACCATCGTG 
Consensus     (351)   GA AC  G TTCAC TG GA TA GA AA GAGAC GA AC AT GT  
                    401                                            450 
Native IL-2   (394) GAATTTCTGAACAAATGGATTACCTTTTGTCAAAGCATCATCTCAACACT 
IL-2          (401) GAGTTCCTGAACAAGTGGATCACCTTCTGCCAGAGCATCATCAGCACCCT 
Consensus     (401) GA TT CTGAACAA TGGAT ACCTT TG CA AGCATCATC   AC CT 
                    451 
Native IL-2   (444) GACG 
IL-2          (451) GACC 
Consensus     (451) GAC  
 
The additional seven nucleotides and the 5‟ terminus of  IL-2 represent a consensus 
Kozak motif. 
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Figure 3.2 
 
Equine IL-2 and IL-2/Immunoglobulin (Ig) Fusion Protein Constructs 
 
                    1                                               50 
Native IL-2     (1) MYRMQLLSCIALTLAVLANSAPTSSSKRETQQQLKQLQMDLKLLLEGVNN 
IL-2            (1) MYRMQLLSCIALTLAVLANSAPTSSSKRETQQQLKQLQMDLKLLLEGVNN 
IL-2-Ig         (1) MYRMQLLSCIALTLAVLANSAPTSSSKRETQQQLKQLQMDLKLLLEGVNN 
IgG-Fc/C1q      (1) -------------------------------------------------- 
IGHC1           (1) -------------------------------------------------- 
Consensus       (1) MYRMQLLSCIALTLAVLANSAPTSSSKRETQQQLKQLQMDLKLLLEGVNN 
                    51                                             100 
Native IL-2    (51) NKNPKLSKILTFKINMPKKATELKHLQCLEEELKPLEEMLKNFLSKDIKE 
IL-2           (51) NKNPKLSKILTFKINMPKKATELKHLQCLEEELKPLEEMLKNFLSKDIKE 
IL-2-Ig        (51) NKNPKLSKILTFKINMPKKATELKHLQCLEEELKPLEEMLKNFLSKDIKE 
IgG-Fc/C1q      (1) -------------------------------------------------- 
IGHC1           (1) -------------------------------------------------- 
Consensus      (51) NKNPKLSKILTFKINMPKKATELKHLQCLEEELKPLEEMLKNFLSKDIKE 
                    101                                            150 
Native IL-2   (101) LMSNINVTVLGLKGSETRFTCEYDNETETIVEFLNKWITFCQSIISTLT- 
IL-2          (101) LMSNINVTVLGLKGSETRFTCEYDNETETIVEFLNKWITFCQSIISTLT- 
IL-2-Ig       (101) LMSNINVTVLGLKGSETRFTCEYDNETETIVEFLNKWITFCQSIISTLTN 
IgG-Fc/C1q      (1) -------------------------------------------------- 
IGHC1           (1) -------------------------------------------------- 
Consensus     (101) LMSNINVTVLGLKGSETRFTCEYDNETETIVEFLNKWITFCQSIISTLT  
                    151                                            200 
Native IL-2   (150) -------------------------------------------------- 
IL-2          (150) -------------------------------------------------- 
IL-2-Ig       (151) VQEASTTAPKVFALAPGCGTTSDSTVALGCLVSGYFPEPVKVSWNSGSLT 
IgG-Fc/C1q      (1) ---ASTTAPKVFALAPGCGTTSDSTVALGCLVSGYFPEPVKVSWNSGSLT 
IGHC1           (1) ---ASTTAPKVFALAPGCGTTSDSTVALGCLVSGYFPEPVKVSWNSGSLT 
Consensus     (151)    ASTTAPKVFALAPGCGTTSDSTVALGCLVSGYFPEPVKVSWNSGSLT 
                    201                                            250 
Native IL-2   (150) -------------------------------------------------- 
IL-2          (150) -------------------------------------------------- 
IL-2-Ig       (201) SGVHTFPSVLQSSGFYSLSSMVTVPASTWTSETYICNVVHAASNFKVDKR 
IgG-Fc/C1q     (48) SGVHTFPSVLQSSGFYSLSSMVTVPASTWTSETYICNVVHAASNFKVDKR 
IGHC1          (48) SGVHTFPSVLQSSGFYSLSSMVTVPASTWTSETYICNVVHAASNFKVDKR 
Consensus     (201) SGVHTFPSVLQSSGFYSLSSMVTVPASTWTSETYICNVVHAASNFKVDKR 
                    251                                            300 
Native IL-2   (150) -------------------------------------------------- 
IL-2          (150) -------------------------------------------------- 
IL-2-Ig       (251) IEPIPDNHQKVCDMSKCPKCPAPELEGGPSVFIFPPNPKDTLMITRTPEV 
IgG-Fc/C1q     (98) IEPIPDNHQKVCDMSKCPKCPAPELEGGPSVFIFPPNPKDTLMITRTPEV 
IGHC1          (98) IEPIPDNHQKVCDMSKCPKCPAPELLGGPSVFIFPPNPKDTLMITRTPEV 
Consensus     (251) IEPIPDNHQKVCDMSKCPKCPAPEL GGPSVFIFPPNPKDTLMITRTPEV 
                    301                                            350 
Native IL-2   (150) -------------------------------------------------- 
IL-2          (150) -------------------------------------------------- 
IL-2-Ig       (301) TCVVVDVSQENPDVKFNWYMDGVEVRTATTRPKEEQFNSTYRVVSVLRIQ 
IgG-Fc/C1q    (148) TCVVVDVSQENPDVKFNWYMDGVEVRTATTRPKEEQFNSTYRVVSVLRIQ 
IGHC1         (148) TCVVVDVSQENPDVKFNWYMDGVEVRTATTRPKEEQFNSTYRVVSVLRIQ 
Consensus     (301) TCVVVDVSQENPDVKFNWYMDGVEVRTATTRPKEEQFNSTYRVVSVLRIQ 
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Figure 3.2 con’t. 
 
 
                    351                                            400 
Native IL-2   (150) ------------------------------------------------- 
IL-2          (150) -------------------------------------------------- 
IL-2-Ig       (351) HQDWLSGKAFACAVNNQALPQPIERTITKTKGRSQEPQVYVLAPHPDELS 
IgG-Fc/C1q    (198) HQDWLSGKAFACAVNNQALPQPIERTITKTKGRSQEPQVYVLAPHPDELS 
IGHC1         (198) HQDWLSGKEFKCKVNNQALPQPIERTITKTKGRSQEPQVYVLAPHPDELS 
Consensus     (351) HQDWLSGK F C VNNQALPQPIERTITKTKGRSQEPQVYVLAPHPDELS 
                    401                                            450 
Native IL-2   (150) -------------------------------------------------- 
IL-2          (150) -------------------------------------------------- 
IL-2-Ig       (401) KSKVSVTCLVKDFYPPEINIEWQSNGQPELETKYSTTQAQQDSDGSYFLY 
IgG-Fc/C1q    (248) KSKVSVTCLVKDFYPPEINIEWQSNGQPELETKYSTTQAQQDSDGSYFLY 
IGHC1         (248) KSKVSVTCLVKDFYPPEINIEWQSNGQPELETKYSTTQAQQDSDGSYFLY 
Consensus     (401) KSKVSVTCLVKDFYPPEINIEWQSNGQPELETKYSTTQAQQDSDGSYFLY 
                    451                                  490 
Native IL-2   (150) ---------------------------------------- 
IL-2          (150) ---------------------------------------- 
IL-2-Ig       (451) SKLSVDRNRWQQGTTFTCGVMHEALHNHYTQKNVSKNPGK 
IgG-Fc/C1q    (298) SKLSVDRNRWQQGTTFTCGVMHEALHNHYTQKNVSKNPGK 
IGHC1         (298) SKLSVDRNRWQQGTTFTCGVMHEALHNHYTQKNVSKNPGK 
Consensus     (451) SKLSVDRNRWQQGTTFTCGVMHEALHNHYTQKNVSKNPGK 
 
Predicted amino acid sequences (single letter code) of native equine IL-2, codon 
optimized equine IL-2, and an equine IL-2/Immunoglobulin heavy chain (IGHC1) fusion 
protein (IL-2-Ig).  Codon optimization had no effect on the predicted amino acid 
sequence of equine IL-2.  Comparison of IL-2-Ig, IGHCI following site directed 
mutagenesis (IgG-Fc/C1q) and IGHC1 (GenBank accession number AJ300675) 
demonstrates relative positions of L to E along with EFKCK to AFACA substitutions to 
inactivate high affinity Fc receptor and C1q binding sites respectively. 
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Figure 3.3 
 
Comparison Between Native IL-7 and Codon Optimized IL-7 Nucleotide Sequences 
 
A 
                    1                                               50 
Native IL-7     (1) ATGTTCCATGTTTCTTTTAGGTATATCTTTGGAATTCCTCCCCTGATCCT 
IL-7            (1) ATGTTCCACGTGAGCTTCAGGTACATCTTCGGCATCCCCCCCCTGATCCT 
Consensus       (1) ATGTTCCA GT    TT AGGTA ATCTT GG AT CC CCCCTGATCCT 
                    51                                             100 
Native IL-7    (51) TGTTCTGTTGCCAGTAGCATCGTCTGACTGTGATATTGAAGGTAAAGATG 
IL-7           (51) GGTGCTGCTGCCCGTGGCCAGCAGCGACTGCGACATCGAGGGCAAGGACG 
Consensus      (51)  GT CTG TGCC GT GC       GACTG GA AT GA GG AA GA G 
                    101                                            150 
Native IL-7   (101) GCAAAGAATATCAGAATGTTCTAATGATCAGCATCGATGAATTGGACAGC 
IL-7          (101) GCAAGGAGTACCAGAACGTGCTGATGATCAGCATCGACGAGCTGGACAGC 
Consensus     (101) GCAA GA TA CAGAA GT CT ATGATCAGCATCGA GA  TGGACAGC 
                    151                                            200 
Native IL-7   (151) ATGATAGAAATTGATAGCAATTGCCTGAATAATGAATCTAACTTTTTTAA 
IL-7          (151) ATGATCGAGATCGACAGCAACTGCCTGAACAACGAGAGCAACTTCTTCAA 
Consensus     (151) ATGAT GA AT GA AGCAA TGCCTGAA AA GA    AACTT TT AA 
                    201                                            250 
Native IL-7   (201) AAAACATTCATGTGATGATAATAAGGAACCTCTGTTTTTAAATCGTGCTG 
IL-7          (201) GAAGCACAGCTGCGACGACAACAAGGAGCCCCTGTTCCTGAACAGAGCCG 
Consensus     (201)  AA CA    TG GA GA AA AAGGA CC CTGTT  T AA  G GC G 
                    251                                            300 
Native IL-7   (251) CTCGCAAGATGAGGCAATTTCTTAAAATGAATATCAGTGAGGATTTCAAT 
IL-7          (251) CCCGGAAGATGAGGCAGTTCCTGAAGATGAACATCAGCGAGGACTTCAAC 
Consensus     (251) C CG AAGATGAGGCA TT CT AA ATGAA ATCAG GAGGA TTCAA 
                    301                                            350 
Native IL-7   (301) CTCCACTTAGCAAGAGTTTCACAGGGCACATTAAAGCTGTTGAACTGCAC 
IL7           (301) CTGCACCTGGCCAGAGTGAGCCAGGGCACCCTGAAGCTGCTGAACTGCAC 
Consensus     (301) CT CAC T GC AGAGT    CAGGGCAC  T AAGCTG TGAACTGCAC 
                    351                                            400 
Native IL-7   (351) CACCAAGGGTAAAGGAAGAAAACCACCTTCTCTAGGTGAAGCCCAACCCA 
IL-7          (351) CACCAAGGGCAAGGGCAGGAAGCCCCCCAGCCTGGGCGAGGCCCAGCCCA 
Consensus     (351) CACCAAGGG AA GG AG AA CC CC    CT GG GA GCCCA CCCA 
                    401                                            450 
Native IL-7   (401) CTAAGAATTTGGAAGAGAATAAATCTTTAAAGGAACAGAAAAAACAGAAT 
IL-7          (401) CCAAGAACCTGGAGGAGAACAAGAGCCTGAAGGAGCAGAAGAAGCAGAAC 
Consensus     (401) C AAGAA  TGGA GAGAA AA     T AAGGA CAGAA AA CAGAA  
                    451                                            500 
Native IL-7   (451) GACTTGTGTTTCCTAAAGATACTACTACAAAAGATAAAAACTTGTTGGAA 
IL-7          (451) GACCTGTGCTTCCTGAAGATCCTGCTGCAGAAGATCAAGACCTGCTGGAA 
Consensus     (451) GAC TGTG TTCCT AAGAT CT CT CA AAGAT AA AC TG TGGAA 
                    501                         531 
Native IL-7   (501) TAAAATTTTGAGGGACGCTAAAGAACACTGA 
IL-7          (501) CAAGATCCTGAGGGACGCCAAGGAGCACTGA 
Consensus     (501)  AA AT  TGAGGGACGC AA GA CACTGA 
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B 
                    1                                               50 
Native IL-7     (1) MFHVSFRYIFGIPPLILVLLPVASSDCDIEGKDGKEYQNVLMISIDELDS 
IL-7            (1) MFHVSFRYIFGIPPLILVLLPVASSDCDIEGKDGKEYQNVLMISIDELDS 
Consensus       (1) MFHVSFRYIFGIPPLILVLLPVASSDCDIEGKDGKEYQNVLMISIDELDS 
                    51                                             100 
Native IL-7    (51) MIEIDSNCLNNESNFFKKHSCDDNKEPLFLNRAARKMRQFLKMNISEDFN 
IL-7           (51) MIEIDSNCLNNESNFFKKHSCDDNKEPLFLNRAARKMRQFLKMNISEDFN 
Consensus      (51) MIEIDSNCLNNESNFFKKHSCDDNKEPLFLNRAARKMRQFLKMNISEDFN 
                    101                                            150 
Native IL-7   (101) LHLARVSQGTLKLLNCTTKGKGRKPPSLGEAQPTKNLEENKSLKEQKKQN 
IL-7          (101) LHLARVSQGTLKLLNCTTKGKGRKPPSLGEAQPTKNLEENKSLKEQKKQN 
Consensus     (101) LHLARVSQGTLKLLNCTTKGKGRKPPSLGEAQPTKNLEENKSLKEQKKQN 
                    151                     177 
Native IL-7   (151) DLCFLKILLQKIKTCWNKILRDAKEH- 
IL-7          (151) DLCFLKILLQKIKTCWNKILRDAKEH- 
Consensus     (151) DLCFLKILLQKIKTCWNKILRDAKEH  
 
 
(A) Nucleotide sequence.  (B) Predicted amino acid sequence represented by the single 
letter code 
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Figure 3.4 
 
Equine IL-12 p40 and p35 Fusion Constructs 
 
A 
                    1                                               50 
Native IL-12    (1) -------------ATGGGTCACCAGTGGTTGGTCCTCTCCTGGTTTTCCC 
IL-12           (1) GAATTCAGCCACCATGGGACACCAGTGGCTGGTGCTGAGTTGGTTCTCCC 
Consensus       (1)              ATGGG CACCAGTGG TGGT CT    TGGTT TCCC 
                    51                                             100 
Native IL-12   (38) TGGTTTTGCTGGCGTCTCCCCTCATGGCCATATGGGAACTGGAGAAAGAT 
OptIL12        (51) TGGTGCTGCTGGCCAGTCCACTGATGGCTATTTGGGAGCTGGAGAAGGAC 
Consensus      (51) TGGT  TGCTGGC   TCC CT ATGGC AT TGGGA CTGGAGAA GA  
                    101                                            150 
Native IL-12   (88) GTGTATGTTGTAGAATTGGATTGGTACCCTGATGCCCCTGGAGAAATGGT 
OptIL12       (101) GTGTACGTGGTGGAGCTGGATTGGTATCCAGACGCTCCAGGCGAGATGGT 
Consensus     (101) GTGTA GT GT GA  TGGATTGGTA CC GA GC CC GG GA ATGGT 
                    151                                            200 
Native IL-12  (138) GGTCCTCACCTGCAATACCCCTGAAGAAGAAGGCATCACCTGGACCTCGG 
OptIL12       (151) GGTGCTGACATGCAACACTCCCGAGGAAGAGGGGATCACTTGGACATCCG 
Consensus     (151) GGT CT AC TGCAA AC CC GA GAAGA GG ATCAC TGGAC TC G 
                    201                                            250 
Native IL-12  (188) CCCAGAGCAATGAGGTCTTAGGCTCTGGCAAAACCTTGACCATCCAAGTC 
OptIL12       (201) CTCAGTCCAATGAAGTGCTGGGCAGCGGCAAGACACTGACAATTCAGGTG 
Consensus     (201) C CAG  CAATGA GT  T GGC   GGCAA AC  TGAC AT CA GT  
                    251                                            300 
Native IL-12  (238) AAAGAGTTTGGAGATGCTGGCTGGTACACCTGTCACAAAGGAGGCGAGGT 
OptIL12       (251) AAGGAGTTTGGGGATGCCGGATGGTACACCTGCCATAAGGGAGGAGAGGT 
Consensus     (251) AA GAGTTTGG GATGC GG TGGTACACCTG CA AA GGAGG GAGGT 
                    301                                            350 
Native IL-12  (288) TCTGAGCCATTCTCACCTGCTGCTTCACAAGAAGGAAGATGGAATTTGGT 
IL-12         (301) GCTGTCCCACAGTCACCTGCTGCTGCACAAGAAAGAGGATGGGATTTGGT 
Consensus     (301)  CTG  CCA   TCACCTGCTGCT CACAAGAA GA GATGG ATTTGGT 
                    351                                            400 
Native IL-12  (338) CCACTGACATTTTAAAAGACCAGAAAGAATCCAAAAATAAGACCTTTCTA 
IL-12         (351) CCACTGATATTCTGAAAGATCAGAAGGAATCCAAGAATAAGACATTCCTG 
Consensus     (351) CCACTGA ATT T AAAGA CAGAA GAATCCAA AATAAGAC TT CT  
                    401                                            450 
Native IL-12  (388) AAATGTGAGGCAAAGAATTATTCCGGACGTTTCACATGCTGGTGGCTGAC 
IL-12         (401) AAATGTGAGGCCAAAAACTATAGCGGAAGGTTCACTTGTTGGTGGCTGAC 
Consensus     (401) AAATGTGAGGC AA AA TAT  CGGA G TTCAC TG TGGTGGCTGAC 
                    451                                            500 
Native IL-12  (438) AGCAATCAGTACTGATTTGAAATTCAGTGTCAAAAGCAGCAGAGGTTCCT 
IL-12         (451) TGCCATCTCTACTGATCTGAAGTTTTCCGTGAAGTCCAGCCGCGGAAGCA 
Consensus     (451)  GC ATC  TACTGAT TGAA TT    GT AA   CAGC G GG   C  
                    501                                            550 
Native IL-12  (488) CTGACCCCCGAGGGGTGACGTGTGGAGCAGCGACACTCTCCGCAGAGAGG 
IL-12         (501) GCGATCCTAGGGGAGTGACATGTGGGGCCGCCACTCTGTCTGCCGAGAGG 
Consensus     (501)   GA CC  G GG GTGAC TGTGG GC GC AC CT TC GC GAGAGG 
                    551                                            600 
Native IL-12  (538) GTCAGCGTGGACGACAGGGAGTATAAGAAGTACACGGTGGAGTGTCAGGA 
IL-12         (551) GTGTCTGTGGACGACCGGGAGTACAAGAAATACACTGTGGAGTGCCAGGA 
Consensus     (551) GT    GTGGACGAC GGGAGTA AAGAA TACAC GTGGAGTG CAGGA 
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                    601                                            650 
Native IL-12  (588) GGGCAGTGCCTGCCCGGCCGCCGAGGAGAGCCTGCCCATTGAGATCGTGG 
IL-12         (601) GGGGAGTGCTTGTCCCGCCGCCGAAGAGAGCCTGCCAATCGAAATCGTGG 
Consensus     (601) GGG AGTGC TG CC GCCGCCGA GAGAGCCTGCC AT GA ATCGTGG 
                    651                                            700 
Native IL-12  (638) TGGATGCTGTTCACAAGCTCAAGTATGAAAACTACACCAGCGGCTTCTTC 
IL-12         (651) TGGATGCTGTGCATAAGCTGAAGTATGAAAATTATACCTCTGGCTTCTTT 
Consensus     (651) TGGATGCTGT CA AAGCT AAGTATGAAAA TA ACC   GGCTTCTT  
                    701                                            750 
Native IL-12  (688) ATCAGGGACATCATCAAACCAGACCCGCCCAAGAACCTGCAGCTGAAGCC 
IL-12         (701) ATCCGGGATATTATCAAGCCTGACCCCCCTAAGAACCTGCAGCTGAAACC 
Consensus     (701) ATC GGGA AT ATCAA CC GACCC CC AAGAACCTGCAGCTGAA CC 
                    751                                            800 
Native IL-12  (738) ATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCCGAGACCT 
IL-12         (751) TCTGAAGAATAGCCGCCAGGTGGAAGTGAGTTGGGAATATCCAGAGACTT 
Consensus     (751)   T AAGAAT   CG CAGGTGGA GT AG TGGGA TA CC GAGAC T 
                    801                                            850 
Native IL-12  (788) GGAGCACCCCACATTCCTACTTCTCCCTGACATTCTCTATTCAGGTCCAG 
IL-12         (801) GGAGCACCCCACATAGTTATTTCTCTCTGACTTTTAGTATTCAGGTGCAG 
Consensus     (801) GGAGCACCCCACAT   TA TTCTC CTGAC TT   TATTCAGGT CAG 
                    851                                            900 
Native IL-12  (838) GGCAAGAACAAGAAGGAAAGGAAAGACAGACTCTTCATGGATGAGACTTC 
IL-12         (851) GGCAAGAACAAAAAAGAGAGAAAGGATAGGCTGTTCATGGATGAGACATC 
Consensus     (851) GGCAAGAACAA AA GA AG AA GA AG CT TTCATGGATGAGAC TC 
                    901                                            950 
Native IL-12  (888) AGCCACAGTCACATGCCACAAGGATGGCCAGATCCGTGTCCAAGCCAGGG 
IL-12         (901) CGCCACTGTGACTTGCCACAAGGACGGGCAGATTAGAGTGCAGGCTCGGG 
Consensus     (901)  GCCAC GT AC TGCCACAAGGA GG CAGAT  G GT CA GC  GGG 
                    951                                           1000 
Native IL-12  (938) ACCGCTACTACAGCTCATCCTGGAGCGAATGGGCATCCGTATCCTGCAGT 
IL-12         (951) ACCGCTACTATTCTTCCAGTTGGAGCGAGTGGGCTTCTGTGAGCTGCTCT 
Consensus     (951) ACCGCTACTA    TC    TGGAGCGA TGGGC TC GT   CTGC  T 
                    1001                                          1050 
Native IL-12  (988) GGTGGCGGTGGCTCGGGCGGTGGTGGATCCGGTGGCGGCGGATCTAGGAA 
IL-12        (1001) GGCGGCGGAGGATCTGGAGGGGGCGGGAGCGGCGGCGGAGGCTCCCGGAA 
Consensus    (1001) GG GGCGG GG TC GG GG GG GG   CGG GGCGG GG TC  GGAA 
                    1051                                          1100 
Native IL-12 (1038) CCTCCCCACAGCCACACCAGGCCCAGGAATGTTCCAGTGCCTCAACCACT 
IL-12        (1051) CCTGCCTACAGCTACCCCTGGACCAGGCATGTTTCAGTGTCTGAATCATA 
Consensus    (1051) CCT CC ACAGC AC CC GG CCAGG ATGTT CAGTG CT AA CA   
                    1101                                          1150 
Native IL-12 (1088) CCCAAAACCTGCTGAGGACCGTCAGCAACACGCTTCAGAAGGCCAGGCAA 
IL-12        (1101) GTCAGAATCTGCTGAGGACTGTGAGCAACACTCTGCAGAAGGCCAGACAG 
Consensus    (1101)   CA AA CTGCTGAGGAC GT AGCAACAC CT CAGAAGGCCAG CA  
                    1151                                          1200 
Native IL-12 (1138) ACCCTAGAATTCTACTCCTGCACTTCTGAAGAGATCGATCATGAGGATAT 
IL-12        (1151) ACCCTGGAGTTTTACTCTTGCACATCCGAGGAGATCGATCATGAAGACAT 
Consensus    (1151) ACCCT GA TT TACTC TGCAC TC GA GAGATCGATCATGA GA AT 
                    1201                                          1250 
Native IL-12 (1188) CACAAAAGACAAGAGCAGCACCGTGGCGGCCTGCCTCCCCCTGGAACTCG 
IL-12        (1201) CACAAAGGACAAGTCTAGCACTGTGGCCGCCTGCCTGCCACTGGAACTGG 
Consensus    (1201) CACAAA GACAAG   AGCAC GTGGC GCCTGCCT CC CTGGAACT G 
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                    1251                                          1300 
Native IL-12 (1238) CCCCGAACGAGAGTTGCCTGGCTTCCAGAGAGATCTCTTTCATAACTAAT 
IL-12        (1251) CCCCCAACGAGTCCTGTCTGGCTTCTAGGGAGATCAGTTTTATTACAAAT 
Consensus    (1251) CCCC AACGAG   TG CTGGCTTC AG GAGATC  TTT AT AC AAT 
                    1301                                          1350 
Native IL-12 (1288) GGGAGTTGCCTGACCCCCGGAAAGGCCTCTTCTATGATGACGCTGTGCCT 
IL-12        (1301) GGATCCTGCCTGACTCCAGGCAAAGCTAGTTCCATGATGACACTGTGTCT 
Consensus    (1301) GG    TGCCTGAC CC GG AA GC   TTC ATGATGAC CTGTG CT 
                    1351                                          1400 
Native IL-12 (1338) TAGCAGCATCTATGAGGACTTGAAGATGTACCAGGTGGAGTTCAAGGCCA 
IL-12        (1351) GTCTTCCATCTATGAGGACCTGAAGATGTATCAGGTGGAGTTCAAAGCCA 
Consensus    (1351)       CATCTATGAGGAC TGAAGATGTA CAGGTGGAGTTCAA GCCA 
                    1401                                          1450 
Native IL-12 (1388) TGAATGCCAAGCTGTTGATAGATCCTCAGAGGCAGATCTTTCTGGATGAG 
IL-12        (1401) TGAATGCCAAGCTGCTGATTGACCCACAGCGCCAGATCTTTCTGGACGAG 
Consensus    (1401) TGAATGCCAAGCTG TGAT GA CC CAG G CAGATCTTTCTGGA GAG 
                    1451                                          1500 
Native IL-12 (1438) AACATGCTGACAGCCATTGACAAGCTGATGCAGGCCCTGAACTTCAACAG 
IL-12        (1451) AACATGCTGACTGCCATCGACAAGCTGATGCAGGCCCTGAACTTTAACAG 
Consensus    (1451) AACATGCTGAC GCCAT GACAAGCTGATGCAGGCCCTGAACTT AACAG 
                    1501                                          1550 
Native IL-12 (1488) TGAGACTGTGCCACAAAAGCCCTCCCTTGAAGGACTGGATTTTTATAAAA 
IL-12        (1501) TGAAACAGTGCCTCAGAAGCCTTCCCTGGAGGGCCTGGATTTTTACAAAA 
Consensus    (1501) TGA AC GTGCC CA AAGCC TCCCT GA GG CTGGATTTTTA AAAA 
                     1551                                          1600 
Native IL-122 (1538) CTAAAGTCAAGCTCTGCATCCTTCTTCATGCCTTCAGAATCCGCGCAGTG 
IL-12         (1551) CTAAAGTGAAACTGTGCATTCTGCTGCATGCCTTCCGCATTAGAGCTGTG 
Consensus     (1551) CTAAAGT AA CT TGCAT CT CT CATGCCTTC G AT  G GC GTG 
                    1601                                       1647 
Native IL-12 (1588) ACCATCAACAGGATGATGGGCTATCTGAATGCTTCCTAA-------- 
IL-12        (1601) ACCATCAATAGAATGATGGGCTACCTGAATGCCTCCTGAGCGGCCGC 
Consensus    (1601) ACCATCAA AG ATGATGGGCTA CTGAATGC TCCT A         
 
 
(A) Nucleotide sequence of a published equine IL-12 p40/p35 fusion construct (GenBank 
Accession Number AF401989) compared with equivalent codon optimized (Opt) 
sequences.  Predicted amino acid sequences (single letter code) demonstrating codon 
optimization had no effect on the predicted amino acid sequence of the equine IL-12 
fusion protein. 
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Figure 3.5 
 
Comparison Between Native and Codon Optimized Equine IL-18 Nucleotide 
Sequences 
 
 
A 
                    1                                               50 
Native IL-18    (1) -------------ATGGCTGCTGGACCAGTAGAAGACAATTGCATTAGCT 
IL-18           (1) GAATTCAGCCACCATGGACGCCATGAAGCGCGGCCTGTGCTGCGTGCTGC 
Consensus       (1)              ATGG  GC          G        TGC T      
                    51                                             100 
Native IL-18   (38) TGGTGGAAATGAAATTTATTGACAACACACTTTACTTTGTAGCTGAAAAC 
IL-18          (51) TGCTGTGTGGCGCCGTGTTTGTGTCCCCATCTCAGGAAATCCACGCCCGC 
Consensus      (51) TG TG          T  TTG    C CA  T A     T    G    C 
                    101                                            150 
Native IL-18   (88) GATGAAAACCTGGAATCAGATTACTTTGGCAGGCTTGAACCTAAACTCTC 
IL-18         (101) TTCAGGAGGGGAGCTAGATACTTCGGCAGACTGGAGCCTAAGCTGAGCAT 
Consensus     (101)       A     G    A A T C    G   G              C   
                    151                                            200 
Native IL-18  (138) AATCATACGAAATTTGAACGACCAAGTTCTCTTCATTAACCAGGGAAATC 
IL-18         (151) CATTAGGAATCTGAACGACCAGGTGCTGTTCATCAACCAGGGCAACCAGC 
Consensus     (151)  AT A            AC A     T  TC TCA   A        A C 
                    201                                            250 
Native IL-18  (188) AACCTGTGTTTGAGGATATGCCTGATTCTGATTGTACAGACAACGCACCC 
IL-18         (201) CTGTGTTCGAGGACATGCCCGACAGCGACTGCACCGACAATGCCCCTCAG 
Consensus     (201)       T    GA                          A   C C C   
                    251                                            300 
Native IL-18  (238) CAGACCGTATTTATCATATATATGTATAAAGATAGCCTCACTAGAGGTCT 
IL-18         (251) ACCGTGTTTATTATCTATATGTATAAGGATTCCCTGACCAGAGGCCTGGC 
Consensus     (251)        T  TTATC          A  A         CA   G       
                    301                                            350 
Native IL-18  (288) AGCGGTAACCATCTCTGTGAAGTGTGAGAAAACGTCTACTCTCTCCTGTA 
IL-18         (301) CGTGACTATCTCCGTGAAATGCGAGAAGACTTCCACCCTGAGCTGCAAGA 
Consensus     (301)  G G   A C  C             AGA   C  C      CT C   A 
                    351                                            400 
Native IL-18  (338) AGAACAAAATTATTTCCTTTAAGGAAATGAGTCCTCCTGAGAATATCAAT 
IL-18         (351) ACAAGATCATCTCTTTTAAAGAGATGAGTCCACCTGAGAACATTAACGAT 
Consensus     (351) A AA A  AT   TT      AG   A     CCT    A A TA C AT 
                    401                                            450 
Native IL-18  (388) GATGAAGGAAATGACATCATATTCTTTCAGAGAAGTGTTCCAGGACATGA 
IL-18         (401) GAAGGCAACGATATTATCTTCTTTCAGAGATCTGTGCCAGGACACGACGA 
Consensus     (401) GA G      AT   ATC T TT                  A    A GA 
                    451                                            500 
Native IL-18  (438) TGATAAGATACAGTTTGAGTCTTCACTGTATAAAGGATACTTTCTAGCTT 
IL-18         (451) CAAGATCCAGTTCGAATCCTCCCTGTACAAGGGATATTTTCTGGCCTGCG 
Consensus     (451)   A A              TC        A   A   T   T         
                    501                                            550 
Native IL-18  (488) GTGAAAAAGAGAATGATCTTTTCAAACTCATTTTGAAAGAAAAGGATGAA 
IL-18         (501) AGAAGGAGAACGACCTGTTCAAGCTGATTCTGAAGGAGAAGGACGAGAAC 
Consensus     (501)    A  A  A  A     T        T  T   G A  A  A GA  A  
                    551                                            600 
Native IL-18  (538) AATGGGGATAAATCTGTAATGTTCACTGTTCAAAACCAGAACTAG----- 
IL-18         (551) GGCGATAAATCTGTGATGTTCACAGTGCAGAACCAGAACTGAGCGGCCGC 
Consensus     (551)    G   A        T  T           A  A  A      G      
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                    1                                               50 
Native IL-18    (1) -------------ATGGCTGCTGGACCAGTAGAAGACAATTGCATTAGCT 
IL-18           (1) GAATTCAGCCACCATGGACGCCATGAAGCGCGGCCTGTGCTGCGTGCTGC 
Consensus       (1)              ATGG  GC          G        TGC T      
                    51                                             100 
Native IL-18   (38) TGGTGGAAATGAAATTTATTGACAACACACTTTACTTTGTAGCTGAAAAC 
IL-18          (51) TGCTGTGTGGCGCCGTGTTTGTGTCCCCATCTCAGGAAATCCACGCCCGC 
Consensus      (51) TG TG          T  TTG    C CA  T A     T    G    C 
                    101                                            150 
Native IL-18   (88) GATGAAAACCTGGAATCAGATTACTTTGGCAGGCTTGAACCTAAACTCTC 
IL-18         (101) TTCAGGAGGGGAGCTAGATACTTCGGCAGACTGGAGCCTAAGCTGAGCAT 
Consensus     (101)       A     G    A A T C    G   G              C   
                    151                                            200 
Native IL-18  (138) AATCATACGAAATTTGAACGACCAAGTTCTCTTCATTAACCAGGGAAATC 
IL-18         (151) CATTAGGAATCTGAACGACCAGGTGCTGTTCATCAACCAGGGCAACCAGC 
Consensus     (151)  AT A            AC A     T  TC TCA   A        A C 
                    201                                            250 
Native IL-18  (188) AACCTGTGTTTGAGGATATGCCTGATTCTGATTGTACAGACAACGCACCC 
IL-18         (201) CTGTGTTCGAGGACATGCCCGACAGCGACTGCACCGACAATGCCCCTCAG 
Consensus     (201)       T    GA                          A   C C C   
                    251                                            300 
Native IL-18  (238) CAGACCGTATTTATCATATATATGTATAAAGATAGCCTCACTAGAGGTCT 
IL-18         (251) ACCGTGTTTATTATCTATATGTATAAGGATTCCCTGACCAGAGGCCTGGC 
Consensus     (251)        T  TTATC          A  A         CA   G       
                    301                                            350 
Native IL-18  (288) AGCGGTAACCATCTCTGTGAAGTGTGAGAAAACGTCTACTCTCTCCTGTA 
IL-18         (301) CGTGACTATCTCCGTGAAATGCGAGAAGACTTCCACCCTGAGCTGCAAGA 
Consensus     (301)  G G   A C  C             AGA   C  C      CT C   A 
                    351                                            400 
Native IL-18  (338) AGAACAAAATTATTTCCTTTAAGGAAATGAGTCCTCCTGAGAATATCAAT 
IL-18         (351) ACAAGATCATCTCTTTTAAAGAGATGAGTCCACCTGAGAACATTAACGAT 
Consensus     (351) A AA A  AT   TT      AG   A     CCT    A A TA C AT 
                    401                                            450 
Native IL-18  (388) GATGAAGGAAATGACATCATATTCTTTCAGAGAAGTGTTCCAGGACATGA 
IL-18         (401) GAAGGCAACGATATTATCTTCTTTCAGAGATCTGTGCCAGGACACGACGA 
Consensus     (401) GA G      AT   ATC T TT                  A    A GA 
                    451                                            500 
Native IL-18  (438) TGATAAGATACAGTTTGAGTCTTCACTGTATAAAGGATACTTTCTAGCTT 
IL-18         (451) CAAGATCCAGTTCGAATCCTCCCTGTACAAGGGATATTTTCTGGCCTGCG 
Consensus     (451)   A A              TC        A   A   T   T         
                    501                                            550 
Native IL-18  (488) GTGAAAAAGAGAATGATCTTTTCAAACTCATTTTGAAAGAAAAGGATGAA 
IL-18         (501) AGAAGGAGAACGACCTGTTCAAGCTGATTCTGAAGGAGAAGGACGAGAAC 
Consensus     (501)    A  A  A  A     T        T  T   G A  A  A GA  A  
                    551                                            600 
Native IL-18  (538) AATGGGGATAAATCTGTAATGTTCACTGTTCAAAACCAGAACTAG----- 
IL-18         (551) GGCGATAAATCTGTGATGTTCACAGTGCAGAACCAGAACTGAGCGGCCGC 
Consensus     (551)    G   A        T  T           A  A  A      G      
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B 
                                                       
Native IL-18        MAAGPVEDNCISLVEMKFIDNTLYFVAENDENLESDYFGRLEPKLSIIRN 
IL-18               –MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARYFGRLEPKLSIIRN 
                  
                                                                                
Native IL-18        LNDQVLFINQGNQPVFEDMPDSDCTDNAPQTVFIIYMYKDSLTRGLAVTI 
IL-18               LNDQVLFINQGNQPVFEDMPDSDCTDNAPQTVFIIYMYKDSLTRGLAVTI 
                   
                                                                               
Native IL-18        SVKCEKTSTLSCKNKIISFKEMSPPENINDEGNDIIFFQRSVPGHDDKIQ 
IL-18               SVKCEKTSTLSCKNKIISFKEMSPPENINDEGNDIIFFQRSVPGHDDKIQ 
                  
                                                                          
Native IL-18        FESSLYKGYFLACEKENDLFKLILKEKDENGDKSVMFTVQNQN 
IL-18               FESSLYKGYFLACEKENDLFKLILKEKDENGDKSVMFTVQNQN 
 
 
(A) Nucleotide sequence.  (B) Predicted amino acid sequence represented by the single 
letter code. 
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Figure 3.6 
 
Comparison Between Native Equine IL-15 and Codon Optimized Equine IL-15 
Nucleotise Sequences 
 
A 
                   1                                               50 
Native IL15    (1) ATGAGAATTTTGAAACCATATTTGAGAAGTACTTGCATCCAGTGCTACTT 
IL15           (1) ----GAATTC-GCCACCATGGACGCGA------TGAAGCGGGGGCT-CTG 
Consensus      (1)     GAATT  G  ACCAT    G GA      TG A C  G GCT CT  
               51                                                 100 
Native IL15   (51) GTGTTTACTTCTGAACAGTCATTTTTTAACTGAGGCTGGCATTCATGTCT 
IL15          (39) CTGTGTGTTGC-------TCCTGTGT-----GGAGCTGTC-TTCGTGAGT 
Consensus     (51)  TGT T  T C       TC T T T     G  GCTG C TTC TG  T 
              101                                                 150 
Native IL15  (101) TCATTTTGGGCTGTATCAGTGCAGGTCTTCCTAAAACAGAGGCAAACTGG 
IL15          (76) CC-TTCCCAGGAGATCCACGCTAGGTTCCGCCGCGGCGCCCGCAA-CTGG 
Consensus    (101)  C TT    G  G   CA    AGGT    C     C    GCAA CTGG 
             151                                                  200 
Native IL15  (151) CAGGATGTAATAAGTGATTTGAAAAGAATTGAAGATCTTATTCAATCTAT 
IL15         (124) CAGGACGTGATTTCCGATCTCAAGCGTATCGAGGACCTCATCCAGTCTAT 
Consensus    (151) CAGGA GT AT    GAT T AA  G AT GA GA CT AT CA TCTAT 
                   201                                            250 
Native IL15  (201) ACATGTTGATGCCACTTTATATACTGAAAGCGATGCTCATCCCAGTTGCA 
IL15         (174) TCATGTGGATGCCACCCTGTACACCGAGTCCGACGCGCACCCCAGCTGCA 
Consensus    (201)  CATGT GATGCCAC  T TA AC GA   CGA GC CA CCCAG TGCA 
                   251                                            300 
Native IL15  (251) AAGTAGCAGCGATGAAGTGCTTTCTCCTGGAGTTACATGTTATTTTGCAT 
IL15         (224) AGGTGGCCGCCATGAAGTGCTTCCTGCTGGAGCTGCACGTGATCCTGCAC 
Consensus    (251) A GT GC GC ATGAAGTGCTT CT CTGGAG T CA GT AT  TGCA  
                   301                                            350 
Native IL15  (301) GAGTCCAGAAACGAGGACATTAAGGAAACAGTAGAAAACCTTATCATCCT 
IL15         (274) GAGAGCAGAAATGAAGACATCAAAGAGACGGTCGAGAACCTGATCATCCT 
Consensus    (301) GAG  CAGAAA GA GACAT AA GA AC GT GA AACCT ATCATCCT 
                   351                                            400 
Native IL15  (351) AGCAAACAGCAGCTTATCTTCTAATGGGAATGTTACAGAATCTGGATGCA 
IL15         (324) GGCCAACAGCCGGCTGAGCTCGAACGGCAACGTCACTGAGTCAGGCTGCA 
Consensus    (351)  GC AACAGC G  T    TC AA GG AA GT AC GA TC GG TGCA 
                   401                                            450 
Native IL15  (401) AAGAGTGTGAGGAACTGGAGGAAAAAAATATTAAAGAATTTTTGCAGAGT 
IL15         (374) AGGAGTGCGAGGAACTGGAGGAAAAGAACATAAAGGAATTCCTTCAGTCT 
Consensus    (401) A GAGTG GAGGAACTGGAGGAAAA AA AT AA GAATT  T CAG  T 
                   451                              486 
Native IL15  (451) TTTGTACATATCGTGCAAATGTTCATCAACCCTTCT 
IL15         (424) TTTGTGCACATCGTTCAAATGTTCATCAATCCGTCC 
Consensus    (451) TTTGT CA ATCGT CAAATGTTCATCAA CC TC  
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Figure 3.6 con’t. 
 
B 
 
                   1                                               50 
Native IL15    (1) MRILKPYLRSTCIQCYLCLLLNSHFLTEAGIHVFILGCISAGLPKTEANW 
IL15ss         (1) ---MDAMKRGLCCVLLLCGAVFVSPS-QE---------IHARFRRGARNW 
IL15sr         (1) ---MDAMKRGLCCVLLLCGAVFVSPS-QE---------IHARFRRGARNW 
Consensus      (1)    MDAMKRGLCCVLLLCGAVFVSPS QE         IHARFRRGARNW 
                   51                                             100 
Native IL15   (51) QDVISDLKRIEDLIQSIHVDATLYTESDAHPSCKVAAMKCFLLELHVILH 
IL15ss        (38) QDVISDLKRIEDLIQSIHVDATLYTESDAHPSCKVAAMKCFLLELHVILH 
IL15sr        (38) QDVISDLKRIEDLIQSIHVDATLYTESDAHPSCKVAAMKCFLLELHVILH 
Consensus     (51) QDVISDLKRIEDLIQSIHVDATLYTESDAHPSCKVAAMKCFLLELHVILH 
                   101                                            150 
Native IL15  (101) ESRNEDIKETVENLIILANSSLSSNGNVTESGCKECEELEEKNIKEFLQS 
IL15ss        (88) ESRNEDIKETVENLIILANSSLSSNGNVTESGCKECEELEEKNIKEFLQS 
IL15sr        (88) ESRNEDIKETVENLIILANSRLSSNGNVTESGCKECEELEEKNIKEFLQS 
Consensus    (101) ESRNEDIKETVENLIILANSSLSSNGNVTESGCKECEELEEKNIKEFLQS 
                   151      162 
Native IL15  (151) FVHIVQMFINPS 
IL15ss       (138) FVHIVQMFINPS 
IL15sr       (138) FVHIVQMFINPS 
Consensus    (151) FVHIVQMFINPS 
 
(A) Nucleotide sequences for only the SSLSS variants are shown. (B) Predicted amino 
acid sequence represented by the single letter code for Native IL15 and both SRLSS and 
SSLSS variants of IL15.  The two potential cleavage sites within the signal peptide of 
Native IL-15 are italicized and underlined. 
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Figure 3.7 
Amino Acid Content of Codon Optimized IL-15 Constructs 
 
                     1                                               50 
IL15             (1) MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGAR--------------- 
Sushi IL15       (1) MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSITCPTPTSVEHADI 
Sushi IL15 L+1   (1) MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSITCPTPTSVEHADI 
Sushi IL15 L+2   (1) MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSITCPTPTSVEHADI 
Consensus        (1) MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSITCPTPTSVEHADI 
                     51                                             100 
IL15            (36) -------------------------------------------------- 
Sushi IL15      (51) RVKSYNLSSKERYICNSGFKRKAGTSSLTECVLNETTNLAHWTTPNLKCI 
Sushi IL15 L+1  (51) RVKSYNLSSKERYICNSGFKRKAGTSSLTECVLNETTNLAHWTTPNLKCI 
Sushi IL15 L+2  (51) RVKSYNLSSKERYICNSGFKRKAGTSSLTECVLNETTNLAHWTTPNLKCI 
Consensus       (51) RVKSYNLSSKERYICNSGFKRKAGTSSLTECVLNETTNLAHWTTPNLKCI 
                     101                                            150 
IL15            (36) ----------------------NWQDVISDLKRIEDLIQSIHVDATLYTE 
Sushi IL15     (101) SGGSGGGGSGGGSGGGGS--LQNWQDVISDLKRIEDLIQSIHVDATLYTE 
Sushi IL15 L+1 (101) SGGSGGGGSGGGSGGGGSG-LQNWQDVISDLKRIEDLIQSIHVDATLYTE 
Sushi IL15 L+2 (101) SGGSGGGGSGGGSGGGGSGGLQNWQDVISDLKRIEDLIQSIHVDATLYTE 
Consensus      (101) SGGSGGGGSGGGSGGGGSG LQNWQDVISDLKRIEDLIQSIHVDATLYTE 
                     151                                            200 
IL15            (64) SDAHPSCKVAAMKCFLLELHVILHESRNEDIKETVENLIILANSSLSSNG 
Sushi IL15     (149) SDAHPSCKVAAMKCFLLELHVILHESRNEDIKETVENLIILANSSLSSNG 
Sushi IL15 L+1 (150) SDAHPSCKVAAMKCFLLELHVILHESRNEDIKETVENLIILANSSLSSNG 
Sushi IL15 L+2 (151) SDAHPSCKVAAMKCFLLELHVILHESRNEDIKETVENLIILANSSLSSNG 
Consensus      (151) SDAHPSCKVAAMKCFLLELHVILHESRNEDIKETVENLIILANSSLSSNG 
                    201                               237 
IL15           (114) NVTESGCKECEELEEKNIKEFLQSFVHIVQMFINPS- 
Sushi IL15     (199) NVTESGCKECEELEEKNIKEFLQSFVHIVQMFINPS- 
Sushi IL15 L+1 (200) NVTESGCKECEELEEKNIKEFLQSFVHIVQMFINPS- 
Sushi IL15 L+2 (201) NVTESGCKECEELEEKNIKEFLQSFVHIVQMFINPS- 
Consensus      (201) NVTESGCKECEELEEKNIKEFLQSFVHIVQMFINPS  
 
Amino acid (single letter code) content of codon optimized (SSLSS variant) of equine IL-
15 (IL15), Sushi/equine IL-15 fusion construct (SushiIL15) and two extended 
glycine/serine rich “flexible linker” variants of Sushi/equine IL-15 (Sushi IL15 L+1, 
Sushi IL15 L+2) 
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Expression of Native and Codon Optimized Versions of Equine IL-2 and Equine IL-
2/IGHC1 Fusion Constructs 
Culture fluids harvested from HEK 293 cells transiently transfected with native 
IL-2, native IL-2/Ig, IL-2 and IL-2/Ig were analyzed for the presence of IL-2 or the IL-
2/IGHC1 fusion protein by immunoblotting with a polyclonal equine IL-2 antiserum.  
Equivalent culture fluids from mock transfected HEK 293 cells provided the negative 
controls (Figure 3.8).  At least two protein products with a potential third more weakly 
stained band were detectable in cell culture fluids from HEK 293 cells transiently 
transfected with IL-2 (Figure 3.8).  IL-2 contains two potential N-linked glycosylation 
sites; therefore, it is likely the lower form may constitute the non-glycosylated form of 
the molecule, whereas the higher apparent molecular weight species are differentially 
glycosylated.  As expected, it appeared that higher levels of IL-2 were secreted from IL-2 
transfected cells (Figure 3.8), although larger apparent molecular weights species were 
detected than those expressed from native equine IL-2 sequences.  The diffuse staining 
pattern observed in the equine IL-2 species derived from the codon optimized gene 
suggests the presence of differential glycosylation (Figure 3.8).  Therefore, the proteins 
secreted from HEK 293 cells transiently transfected with native IL-2 and synthetic IL-2 
were treated with N-glycosidase F.  In contrast to the two diffuse staining protein species 
detected in untreated material expressed from codon optimized IL-2, there was just a 
single predominant band with similar migrational characteristics to native IL-2 derived 
from the native equine sequences after treatment with N-glycosidase F (Figure 3.9).   
Protein bands consistent with this size and reactive with the equine IL-2 antiserum 
were detectable in the culture fluids from native IL-2/Ig and codon optimized IL-2/Ig 
transfected cells (Figure 3.8).  In contrast to proteins expressed from native IL-2 and 
codon optimized IL-2, those derived from the fusion constructs possessed very similar  
apparent molecular weights (Figure 3.8), suggesting mRNAs containing the IGHC1 
sequences shared the same intracellular destiny following transcription.  Although the 
differences were not dramatic, amounts of the IL-2/Ig fusion protein secreted from codon 
optimized pIL-2/Ig transfected cells were consistently higher in all three separate 
transfection experiments (data not shown) than that from cells transfected with native 
pIL-2/Ig .  
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Figure 3.8 
 
Immunoblot Analysis of Native and Codon Optimized Equine IL-2 Expression 
 
 
 
 
 
 
 
 
 
 
 
HEK 293 cells were transfected with native pIL-2 (A), native pIL-2/Ig (B), codon 
optimized pIL-2 (C) and codon optimized pIL-2/Ig (D).  At 72 h post transfection, cell 
culture fluids were harvested, processed and analyzed by immunoblot using a polyclonal 
equine IL-2 antiserum.  Cell culture fluids from mock transfected HEK 293 cells were 
used as a negative control (E) 
 
 
 
 
Figure 3.9 
 
Deglycosylation of Equine IL-2 Derived from Native IL-2 and Codon Optimized 
Sequences 
 
 
 
 
 
 
 
Cell culture fluids harvested at 72 h following transfection of HEK 293 cells with native 
or codon optimized versions of equine pIL-2 were processed, treated with PNGaseF and 
analyzed by immunoblotting using a polyclonal equine IL-2 antiserum.  Secreted 
glycosylated forms of codon optimized IL-2 (A) and native IL-2 (B) were compared to 
PNGaseF treated native IL-2 (C) and codon optimized IL-2 (D). 
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Expression of Native and Codon Optimized Versions of Equine IL-7 
Culture fluids harvested from HEK 293 cells transiently transfected with native 
pIL-7 and codon optimized pIL-7 were analyzed by immunoblotting with a polyclonal 
rabbit antiserum against human IL-7.  The multiple protein products shown in (Figure 
3.10) with apparent molecular weights in excess of 17,000 Da almost certainly represent 
differentially glycosylated forms of this interleukin.  Although a weakly stained product 
with a molecular weight consistent with the non-glycosylated form of IL-7 is present in 
cell-culture medium from codon optimized pIL-7 transfected cells, there was no 
equivalent detectable product secreted from cells receiving the native sequences (Figure 
3.10).  Instead, a lower molecular weight product was observed (Figure 3.10).  While 
aberrant migrational effects in PAGE might explain this result, similar findings were 
observed in conditioned media from each of the triplicate transfections (data not shown).  
In addition to reducing the potential for alternative RNA splicing events, codon 
optimization also appeared to promote a small increase in expression as evidenced by the 
relative reactivity between native IL-7 and codon optimized IL-7 conditioned media 
preparations to anti human IL-7 (Figure 3.10).  Furthermore, as observed with the 
synthetic IL-2, codon optimization of IL-7 coding sequences promoted more extensive 
glycosylation (Figure 3.10). 
Figure 3.10 
 
Immunoblot Analysis of Native and Codon Optimized Equine IL-7 Expression. 
 
 
 
 
 
 
 
 
HEK 293 cells transfected with native pIL-7 (A) or codon optimized pIL-7 (B) at 72 h 
post transfection cell culture fluids were collected and analyzed by immunoblot using a 
polyclonal rabbit antiserum against human IL-7.  Cell culture fluids from mock 
transfected HEK 293 cells were used as a negative control (C). 
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Expression of Codon Optimized Equine IL-12 
Costs prohibited synthesis of an equivalent fusion protein comprised of native 
sequences for comparison purposes, but immunoblot analysis using goat anti human IL-
12 antiserum demonstrated that secreted equine IL-12 was easily detectable in 
conditioned medium from codon optimized pIL-12 transfected cells (Figure 3.11).  The 
migrational characteristics of the fusion protein in PAGE appeared identical to previously 
published results (McMonagle, Taylor et al. 2001) and were consistent with a predicted 
molecular weight of 57933.71 (Vector NTI) assuming removal of the putative 22 amino 
acid signal peptide. 
 
Figure 3.11 
 
Immunoblot Analysis of Codon Optimized Equine IL-12 Fusion Construct 
Expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three separate transfection experiments (A, B, C) were conducted using the codon 
optimized equine pIL-12 fusion construct in HEK 293 cells.  At 72 h post transfection, 
cell culture fluids were collected and analyzed by immunoblot using a polyclonal goat 
antiserum against human IL-12.  Cell culture fluids from mock transfected HEK 293 cells 
were used as a negative control (D). 
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Expression of Codon Optimized Equine IL-18 
A lower apparent molecular weight anti IL-18 reactive species was detected in 
conditioned medium compared to Brefeldin A treated cell lysates by immunoblot 
analysis, showing that the appropriate cleavage of the TPA signal peptide occurred in 
proteins expressed from the codon optimized pIL-18 construct (Figure 3.12).  
Furthermore, the apparent molecular weights of the proteins binding IL-18 antibodies in 
Brefeldin A lysates and conditioned medium were consistent with sizes of approximately 
22 and 18 kDa, respectively (Figure 3.12). 
 
Figure 3.12 
 
Immunoblot Analysis of Codon Optimized Equine IL-18 Expression 
 
 
        
       MW 
 
 
 
 
 
 
Separate transfections of HEK 293 cells with codon optimized pIL-18 were conducted 
with and without the addition of Brefeldin A.  At 72 h post transfection, lysates from 
Brefeldin A treated cells (B) and culture fluids from untreated cells (C) were collected 
and analyzed by immunoblot using a polyclonal goat antiserum against human IL-18.  
Cell lysates from mock transfected Brefeldin A treated HEK 293 cells (A) and culture 
fluids untreated mock transfected cells were used as negative controls (D). 
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Expression of Equine IL-15 Based Molecular Clones 
Culture fluids harvested from HEK 293 cells transiently transfected with native 
pIL-15 and the codon optimized pIL-15 constructs SRLSS, SSLSS, Sushi IL-15, Sushi 
IL-15 L+1 and Sushi IL-15 L+2 were analyzed by immunoblotting with a polyclonal 
rabbit antiserum against human IL-15.  There was no detectable expression following 
transient transfection of HEK 293 cells of native pIL-15, as determined by immunblot 
analysis of either Brefeldin A treated cell lysates (data not shown) or conditioned 
medium (Figure 3.13).  However, a protein product was detectable in supernatants from 
pIL-15 (SRLSS) transfected cells (Figure 3.13).  Protein expression was detected at 
higher levels in supernatants from the pIL-15 (SSLSS) transfected cells (Figure 3.13).  
The predicted molecular weight of the mature form of equine IL-15 is approximately 13 
kDa (Vector NTI); therefore, it is very likely that the larger, more predominant species 
detected in IL-15 (SRLSS) and IL-15 (SSLSS) are glycosylated (Figure 3.13).  Dramatic 
increases in IL-15 protein expression levels were detected by immunoblot analysis in 
conditioned medium from HEK 293 cells transfected with pSushi IL-15, pSushi IL-
15L+1 and pSushi IL-15L+2 transfected HEK 293 cells (Figure 3.13).  These 22-24 kDa 
protein products were also observed by Ponceau S staining of the nitrocellulose 
membrane following electrophoresis, but they were not observed in mock transfected 
cells or cells receiving native pIL-15, pIL-15 (SRLSS) or pIL-15 (SSLSS) (Figure 3.14).  
It is very likely that the two major species and the diffuse staining higher molecular 
weight species represent differentially glycosylated forms of the fusion protein.  The 
addition of one (Sushi IL-15 L+1) or two (Sushi IL-15 L+2) additional glycine residues 
to the “flexible” linker did not increase the apparent expression of the sushi-equine IL-15 
fusion protein (Figures 3.13, 3.14).   
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Figure 3.13 
 
Immunoblot Analysis of Native, Codon optimized, and Sushi Fusion Construct 
Equine IL-15 Expression Levels 
 
 
 
 
 
 
 
 
HEK 293 cells were transfected with native pIL-15 (B), codon optimized pIL-15 
(SRLSS) (C) codon optimized pIL-15 (SSLSS) (D), Sushi pIL-15 (E) Sushi pIL-15 L+1 
(F) and Sushi pIL-15 L+2 (G).  At 72 h post transfection, cell culture fluids were 
collected and analyzed by immunoblot using a polyclonal rabbit antiserum against human 
IL-15.  Cell culture fluids from mock transfected HEK 293 cells were used as a negative 
control (A). 
 
 
Figure 3.14 
 
Proteins Present in Conditioned Medium Following Transfection of HEK 293 Cells 
with pCi Vectors Encoding IL15 or SushiIL15 Fusion Proteins  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ponceau S stained nitrocellulose membrane showing processed conditioned medium from 
mock HEK 293 cells (A) or with pCi vectors encoding native IL-15 (B), codon optimized 
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IL-15 (SRLSS) (C) codon optimized IL-15 (SSLSS) (D), Sushi IL-15 (E) Sushi IL-15 
L+1 (F) and Sushi IL-15 L+2 (G). 
Biological Activity of Native and Codon Optimized Versions of Equine IL-2 and Equine 
IL-2/IGHC1 Fusion Constructs 
The biological activity present in conditioned medium from HEK 293 cells 
transfected with native pIL-2, codon optimized pIL-2, native pIL-2/Ig, and codon 
optimized pIL-2/Ig was measured in terms of proliferative activity on horse PBMC 
cultures.  As predicted, culture fluids from cells transfected with pIL-2 or pIL-2 
stimulated significant increases in lymphocyte proliferation of equine PBMC cultures 
(Table 3.1).  Higher proliferative activity was observed at medium dilutions of 1:10 
rather than 1:4.  However, it is clear from these results that codon optimization at best 
only resulted in an incremental rather than a wholesale improvement in the expression of 
equine IL-2. 
The conditioned medium harvested from HEK 293 cells transiently transfected 
with the native equine pIL-2/Ig fusion construct induced lower proliferation levels in 
horse PBMC than media from cells transfected under similar conditions with native pIL-2 
or codon optimized pIL-2 (Table 3.1).  However, codon optimization of sequences 
encoding equine pIL-2 in the codon optimized pIL-2/Ig construct appeared to increase 
expression relative to native pIL-2/Ig (Figure 3.2), resulting in a >2-fold increase in the 
PBMC SI at the 1:10 dilution (Table 3.1). 
Table 3.1 
IL-2 Cytokine-Stimulated Proliferation of Equine PBMC in Vitro 
 
Plasmid Construct 1:4 Dilution 1:10 Dilution 
native IL-2 29.2 41.1 
codon optimized IL-2 24.6 44.3 
native IL-2/Ig 9.0 4.8 
codon optimized IL-2/Ig 13.7 11.5 
Proliferation of horse PBMC cultures in response to conditioned medium from HEK 293 
cells transiently transfected with native pIL-2, codon optimized pIL-2, native pIL-2/Ig, 
and codon optimized pIL-2/Ig were determined by [
3
H]-thymidine incorporation.  Results 
are expressed in the form of a stimulation index with culture fluids used at final dilutions 
of 1:4 and 1:10. 
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Biological Activity of Native and Codon Optimized Versions of Equine IL-7 
Despite the differences in IL-7 expression levels, biological activity in terms of 
proliferative effects on horse PBMC cultures between native IL-7 and codon optimized 
IL-7 conditioned medium at dilutions of 1:10 was indistinguishable, with each construct 
producing SIs of 5.5. 
 
Biological Activity of Native and Codon Optimized Versions of Equine IL-15 
Conditioned medium from native equine pIL-15 transfected cells failed to induce 
proliferative responses in horse PBMC cultures during co-stimulation assays with 
concanavalin A (Table 3.2).  However, low proliferative activity in equine PBMC was 
stimulated by conditioned medium from pIL-15 (SRLSS) transfected cells (Table 3.2).  
Although, in terms of protein production this codon optimized synthetic gene confered 
improvements compared with native sequences, higher levels of expression were 
obtained (Figure 3.6) with a concomitant 5-fold increase in horse PBMC proliferative 
activity present in conditioned media from cells transfected with pIL-15 (SSLSS) (Table 
3.2).  The very high expression level observed for the sushi-equine IL-15 fusion protein 
was mirrored by its biological activity with proliferative activity on horse PBMC 
cultures, readily detectable at dilutions of 1:1280 in conditioned medium from pSushi IL-
15 transfected HEK 293 cells (Table 3.2).  The addition of one (Sushi IL-15 L+1) or two 
(Sushi IL-15 L+2) additional glycine residues to the “flexible” linker did not increase 
either the biological activity (Table 3.2.) of the sushi-equine IL-15 fusion protein.  
Therefore, increasing the linker length within the fusion protein does not appear to confer 
additional advantages at least as measured by the in vitro assays employed in this study. 
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Table 3.2 
 
In Vitro Biological Activity of Equine IL-15 Constructs 
 
Dilution         IL15            15SR             15SS          Sushi15       Sushi15L+1      Sushi15L+2 
1:4                  1.0               2.1               ND             ND                ND                  ND 
1:10                1.0               1.0               2.1              4.4                 4.1                   4.0 
1:20                1.0               1.0               2.1              6.0                 5.8                   5.5 
1:40                ND              ND              1.6               6.0                 4.8                   6.1 
1:80                ND              ND              1.6               6.2                 7.0                   6.6 
1:160              ND              ND              1.3               6.6                 6.0                   6.9 
1:320              ND              ND              1.2               5.4                 5.4                   5.9 
1:640              ND              ND              1.0               5.6                 4.8                   5.4 
1:1280            ND              ND              1.0               5.2                 3.8                   4.6 
 
Proliferation of horse PBMC in response to addition of cell culture fluids from cells 
transfected with native equine pIL-15 (IL-15), pIL-15 (SRLSS) (15SR), pIL-15 (SSLSS) 
(15SS), pSushi IL-15 (Sushi15), pSushi IL-15 L+1, (Sushi15L+1) and pSushi IL-15 L+2, 
(Sushi15L+2) were determined by [
3
H]-thymidine incorporation.  Results are expressed in 
the form of a stimulation index with culture fluids used at final dilutions of 1:4 to 1:1280.  
ND = Not Done. 
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3.2:  Assessment of Immune Responses to DNA Vaccination in ELA-A1 Possessing 
Ponies 
 
Physical Responses of ELA-A1 Ponies to Intradermal Inoculation with pSYNSU 
Immunizations 
Injection sites were monitored for inflammatory responses in terms of redness, 
swelling, heat, or soreness after each intradermal inoculation with plasmid DNA 
vaccines.  Inflammatory reactions reported during this preliminary trial were transient.  
At no time did inoculation with naked pSYNSU elicit physical responses in B33.  Mild to 
moderate side effects, pertaining to heat and swelling at inoculation sites, were noted 
from all five ponies receiving PEI in the DNA vaccine regimen.  Local reactions were 
more pronounced after each inoculation among recipients of the intradermal injections 
containing cytokines (D49, 9954, and D55), than among the two recipients receiving 
DNA injections without cytokines (D47 and B29).  The presence of heat after 
immunization was determined subjectively by touching the injection sites.  Heat was 
noted in three ponies after V1 and in all five ponies after V2 and V3 with vaccines 
containing PEI.  While firm nodules at the injection sites were observed in all five ponies 
receiving vaccine regimens with PEI, DNA vaccines with cytokines caused increased 
swelling of the skin after each vaccination.  Firm nodules were detected in ponies D47 
and B29, inoculated with PEI and antigen, for three weeks after V1 and for two weeks 
after V2 and V3 (Table 3.3).  While no redness was detected at the injection sites in these 
ponies, they both responded with flinching of the skin when any pressure was applied to 
the nodules.  In contrast, ponies in the pSYNSU immunization group with IL-15 and/or 
IL-2/Ig exhibited increased side effects.  All three ponies receiving cytokine expression 
plasmids developed large nodules at all of the injection sites that persisted for 
approximately four weeks after each inoculation (Table 3.3).  The diameter of swelling at 
injection sites in D49 ranged from 11-53 mm after V1 and 15-80 mm after V2 and V3 
(Table 3.3).  Similarly, nodules approximately 65-82.5 mm in diameter were measured in 
ponies 9954 and D55 after each inoculation but decreased in size significantly four weeks 
later (Table 3.3).  The swelling that formed at the injection sites caused the ponies to 
flinch and pin their ears back when the nodules were touched, which was indicative of 
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soreness from the immunizations.  However, no evidence of redness or purulent 
discharge consistent with bacterial infections was observed at any injection site. 
 
 
Table 3.3 
 
Physical Responses of ELA-A1 Ponies to pSYNSU Immunizations 
 
 
 
Horse Vaccination 
 
Duration of heat 
(weeks) 
 
Swelling 
(mm) 
Duration of swelling 
(weeks) 
 V1 None None None 
D33 V2 None None None 
 V3 None None None 
 V1 2 14-30 3 
D47 V2 2 25 2 
 V3 2 25 2 
 V1 2 12-32 3 
B29 V2 2 10-25 2 
 V3 2 10-25 2 
 V1 None 11-53 4 
D49 V2 2 16-80 4 
 V3 2 15-78 4 
 V1 None 10-65 4 
9954 V2 2 16-80 4 
 V3 2 15-78 4 
 V1 1 11-81 4 
D55 V2 2 25-82.5 3 
 V3 2 15-78 4 
 
Physical responses to vaccination were monitored weekly until they completely subsided.  
Heat was determined by warmth of the skin to the touch.  The swelling represents 
maximal and minimal measurements assessed in mm after each vaccination. 
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Immunoblot Reactivity Following pSYNSU Immunizations 
As predicted from previous studies (Cook, Cook et al. 2005), antibodies were not 
detectable in immunoblot assays following three i.d. inoculations with „naked‟ or 
unprotected SYNSU plasmid DNA (Figure 3.15).  A similar lack of responsiveness was 
observed in one (D47) pSYNSU + PEI recipient (Figure 3.15).  Although antibody 
responses were visible in the second member of this group (B29) following just two 
immunizations, these declined rapidly with no evidence of boost to the third vaccination 
(Figure 3.15).  However, antibodies were detectable after two immunizations in ponies 
receiving pSYNSU + PEI, pIL-2/Ig, pIL-15 (SRLSS) or pSYNSU + PEI, pIL-15 
(SSLSS).  These levels increased significantly at three weeks post V3, although there was 
evidence of a progressive decline after this time point (Figures 3.16-3.18).  
 
Equine IgG Subclass-Specific ELISA 
Equine IgGA and IgGT subclasses induced following pSYNSU immunization 
were monitored by Enzyme-Linked Immunosorbant Assays (ELISA).  Not surprisingly, 
there was a general concordance between the IgGA ELISA data and the results from the 
immunoblot assays.  Amounts of IgGA did not rise above background levels (Figure 
3.19.) in B33, inoculated with naked pSYNSU, or in D47 (Figure 3.20), inoculated with 
pSYNSU + PEI.  Serological responses detected in the second pSYNSU + PEI vaccinate 
(B29) two weeks after V2 were short-lived, with no increase in antibody levels detected 
following the third immunization (Figure 3.21).  The highest IgGA responses were 
observed in the pSYNSU + PEI, pIL-2/Ig, pIL-15 (SRLSS) recipient 9954 (Figure 3.16.).  
This antibody subclass increased almost 3-fold above the pre-immunization base-line 
value at one week post V2 (Figure 3.16.), although these levels did not persist and 
declined 50% by three weeks post V2.  In contrast to B29, 9954 was responsive to further 
antigenic stimulation with levels of IgGA to SYNSU increasing about 2-fold three weeks 
post V3 (week 15) (Figure 3.16.).  At this peak, amounts of IgGA attained approximately 
70% of the level detected in serum from a long-term EIAV infected horse showing the 
typical, very strong humoral reactivity to SYNSU.   
A very similar pattern of reactivity was observed in the second member (D55) 
(Figure 3.17) of the IL-2/Ig + IL-15 (SRLSS) group and in D49 (Figure 3.18), an IL-15 
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(SSLSS) recipient.  Nonetheless, these responses were a significant improvement, 
compared with animals receiving pSYNSU without PEI or cytokines (B33, (Cook, Cook 
et al. 2005)).  The IgGT subclass was not detectable in sera from any of the vaccinated 
animals, including the high IgGA responders 9954 and D55, with the notable exception of 
the pIL-15 (SSLSS) recipient D49 (Figure 3.18). 
 
 
Figure 3.15 
Analysis of SU-Specific Serum Antibody Reactivity from ELA-A1 Ponies on IgG 
Immunoblot 
 
 
Serum samples collected at 0, 4 and14 weeks after immunization from ponies B33 (A.), 
D47 (B.), B29 (C.), D49 (D.), D55 (E.) and 9954 (F.) were diluted 1:20 and analyzed by 
immunblot analysis against SDS-disrupted EIAVPV for detection of SU-specific 
antibodies.  
A. B. C. D. E. F. 
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Figure 3.16 
Analysis of SU-Specific Serum Antibody Reactivity from Pony 9954 on IgG 
Immunoblot (A.), IgGA ELISA (B.) and IgGT ELISA (C.) 
 
 
 
 
Serum samples collected at 0, 3, 4, 5, 12, (13, 14), 15, 16, 17, and 21 weeks after DNA 
immunizations from pony 9954 (IL-2/Ig + IL-15 (SRLSS) pSYNSU immunization 
group) were diluted 1:20 and analyzed by immunblot analysis against SDS-disrupted 
EIAVPV  for SU-specific antibodies and diluted 1:40 and 1:80 for analysis by ELISA for 
IgGA and IgGT antibody levels.  Significant increases (P<0.05) after V2 and V3 are 
denoted (*), as determine by the Mixed Procedures of SAS. 
B. 
A. 
C. 
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Figure 3.17 
Analysis of SU-Specific Serum Antibody Reactivity from Pony D55 on IgG 
Immunoblot (A.), IgGA ELISA (B.) and IgGT ELISA (C.) 
 
 
 
 
Serum samples collected at 0, 3, 4, 5, 12, (13, 14), 15, 16, 17, and 21 weeks after DNA 
immunizations from pony D55 (IL-2/Ig + IL-15 (SRLSS) pSYNSU immunization group) 
were diluted 1:20 and analyzed by immunblot analysis against SDS-disrupted EIAVPV  
for SU-specific antibodies and diluted 1:40 and 1:80 for analysis by ELISA for IgGA and 
IgGT antibody evels.  Significant increases (P<0.05) after V2 and V3 are denoted (*), as 
determine by the Mixed Procedures of SAS. 
  
B. 
A. 
C. 
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Figure 3.18 
Analysis of SU-Specific Serum Antibody Reactivity from Pony D49 on IgG 
Immunoblot (A.), IgGA ELISA (B.) and IgGT ELISA (C.) 
 
 
 
 
 
Serum samples collected at 0, 3, 4, 5, 12, (13, 14), 15, 16, 17, and 21 weeks after DNA 
immunizations from pony D49 (IL-15 (SSLSS) pSYNSU immunization group) were 
diluted 1:20 and analyzed by immunblot analysis against SDS-disrupted EIAVPV for SU-
specific antibodies and diluted 1:40 and 1:80 for analysis by ELISA.  Significant 
increases (P<0.05) after V2 and V3 are denoted (*), as determine by the Mixed 
Procedures of SAS. 
B. 
A. 
C. 
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Figure 3.19 
Analysis of SU-Specific Serum Antibody Reactivity from Pony B33 on IgGA ELISA 
(A.) and IgGT ELISA (B.) 
 
 
 
 
 
Serum samples collected at 0, 3, 4, 5, 12, 13, 14, 15, 16, and 21 weeks after DNA 
immunizations from pony B33 (naked DNA pSYNSU immunization group) were 
analyzed by ELISA against EIAVPV for SU-specific IgGA and IgGT antibodies.   
B. 
A. 
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Figure 3.20 
Analysis of SU-Specific Serum Antibody Reactivity from Pony D47 on IgGA ELISA 
(A.) and IgGT ELISA (B.) 
 
 
 
 
 
Serum samples collected at 0, 3, 4, 5, 12, 13, 14, 15, 16, and 21 weeks after DNA 
immunizations from pony D47 (PEI pSYNSU immunization group) were analyzed by 
ELISA against EIAVPV for SU-specific IgGA and IgGT antibodies.   
B. 
A. 
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Figure 3.21 
Analysis of SU-Specific Serum Antibody Reactivity from Pony B29 on IgGA ELISA 
(A.) and IgGT ELISA (B.) 
 
 
 
 
 
Serum samples collected at 0, 3, 4, 5, 12, 13, 14, 15, 16, and 21 weeks after DNA 
immunizations from pony B29 (PEI SYNSU immunization group) were analyzed by 
ELISA against EIAVPV for SU-specific IgGA and IgGT antibodies.   
B. 
A. 
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SU-specific Lymphocyte Proliferative Responses Induced by Gradient Purified EIAV 
pSYNSU Immunization Groups 
Induction of ex vivo SU-specific T-cell proliferative responses were measured 
using PBMC isolated from each pony two weeks following the third immunization.  The 
relative levels of lymphoproliferation were compared in the form of a stimulation index 
(SI) representing [
3
H] - thymidine incorporation of gradient-purified EIAV antigen 
stimulated cultures divided by [
3
H] - thymidine incorporation of unstimulated cultures.  
No significant increases in lymphocyte proliferation were detected in PBMC cultures 
from the naked DNA or PEI pSYNSU immunization groups. However, significant 
lymphoproliferative activity to EIAV antigen was detectable in two of the cytokine 
recipients, 9954 and D49, in a dose-dependent manner (Figure 3.22).   
 
Figure 3.22 
 
Lymphocyte Proliferation of ELA-A1 Ponies in Response to in Vitro 
Stimulation 
 
 
PBMC collected from ELA-A1 ponies at 2 weeks after the third pSYNSU immunization 
were stimulated in vitro with concentrations of EIAVPV ranging from 10, 5, and 1 µg/ml 
or Con A (10 µg/ml) for 72 h. PBMC were labeled for 18 h with [
3
H]-Thymidine.  
Significant interactions (P<0.05) from unstimulated controls are marked by stars. 
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Gamma Interferon Expression following Stimulation of PBMC with the SU RW-12 
Peptide Antigen 
Prior to PBMC incubation with RW-12 peptide or PMA/Ionomycin treatments, 
the viability of cryopreserved PBMC for each animal was determined to be between 90-
95% with a Vi-Cell cell viability analyzer.  PBMC populations collected from each pony 
prior to the first immunization (pre-vacc.) and two weeks after the third immunization 
(post-vacc.) were incubated with the RW-12 peptide (McGuire, Leib et al. 2003) (10 
µg/ml) for 48 h at 37º C prior to RNA isolation, cDNA synthesis, and quantitation of 
IFN-γ mRNA by real-time RT-PCR.  PBMC populations from each time point incubated 
in vitro without RW-12 peptide were used as negative controls.  Positive control wells to 
measure maximum IFN-γ expression were treated with PMA (25 ng/ml) and ionomycin 
(1 µM).  IFN-γ mRNA expression levels were calculated based on RQ values using the 
media control for each sample as a calibrator and equine β-GUS as a housekeeping gene.  
No significant increases in IFN-γ mRNA levels, relative to the media control, were 
observed in PBMC incubated with the RW-12 peptide that were collected from the naked 
DNA pSYNSU recipient (B33) or PEI pSYNSU recipients (B29 and D47) (data not 
shown).  However, IFN-γ expression was significantly elevated by incubation with this 
peptide in post V2 samples collected from cytokine recipient ponies, 9954, D55, and D49 
(Figure 3.23).  The most dramatic (56-fold) increases in IFN-γ expression were observed 
in 9954 (Figure 3.23). 
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Figure 3.23 
 
IFN-  mRNA Expression Levels of PBMC from ELA-A1 Ponies Inoculated with 
pSYNSU Immunizations Following In Vitro Stimulation with the RW-12 Peptide 
 
 
 
 
 
PBMC from Pony 9954 (A), D55 (B), and D49 (C) were collected  
Results are expressed as the relative quantification (RQ) mean (+S.E.) values.  
Significant differences (P<0.05) between PBMC collected prior to V1 (Pre-vacc.) and 
two weeks after V3 (Post-vacc.) are indicated (   ). 
B. 
A. 
C. 
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3.3:  Assessment of Humoral Immune Responses to pSYNSU Immunization in 
Horses and Ponies Possessing Diverse ELA-Haplotypes 
 
Physical Responses following DNA Vaccination 
Adverse reactions to genetic immunization were assessed in each of the 30 horses 
and ponies, after vaccination (V1-V4).  Heat was detected at the injection sites of all 
inoculated animals after each immunization.  Vaccines expressing naked DNA antigen, 
without PEI, elicited mild physical responses in ponies after each of the DNA 
vaccinations.  While soft nodules were noted ranging in average diameter from 65-114 
mm, the average duration of swelling only persisted for 1-2 weeks in these vaccinates: 
heat from the skin nodules was also observed for similar durations of time (Table 3.4).  
Although vaccination with PEI + pSYNSU resulted in a comparable duration of heat 
released from the injection sites and swelling of skin nodules, the persistence of swelling 
was evident for 4-5 weeks after each immunization (Table 3.4).  This suggestive of 
enhanced inflammatory responses to DNA vaccination in these animals.  However, the 
addition of cytokines to the PEI + pSYNSU vaccine further augmented the physical 
responses to vaccination that were observed for most vaccinates.  For recipients of pIL-7, 
and pIL-12 + pIL-18, heat and swelling were noted for several more weeks after V1 and 
V2, than after V3 and V4 in these animals (Table 3.4).  A similar trend was observed in 
horses from the IL-15 (SRLSS) group, with average skin nodules ranging in size from 
63-96 mm after each vaccination (Table 3.4).  In contrast, vaccines expressing pIL-2/Ig 
and pIL-15 (SSLSS) + IL-2/Ig caused increased swelling of the skin after each 
vaccination (Table 3.4).  Members of these vaccine groups demonstrated comparable 
physical responses to vaccination with duration of heat detection (3-5 weeks) and size of 
swelling in the skin (73-144 mm in diameter), although the average duration of swelling 
persisted for longer periods of time after vaccination with pIL-15 (SRLSS) + pIL-2/Ig 
(Table 3.4).  Interestingly, immunization with DNA vaccines expressing pIL-15 (SSLSS), 
pSushi IL-15, or pIL-15 (SRLSS) evoked the largest physical responses in these horses, 
with very large skin nodules, ranging in diameter from 106-143 mm, after each 
intradermal inoculation (Table 3.4).  Local reactions in these recipients were extremely 
sore and warm to the touch, but exhibited no signs of redness or purulence 
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Table 3.4 
 
Physical Responses of 30 Horses or ponies to Different pSYNSU DNA 
Immunization Protocols 
 
pSYNSU Immunization 
Group 
Vaccination Duration of 
Heat (weeks) 
Mean Swelling 
(mm) 
Mean Duration 
of Swelling 
(weeks) 
naked DNA V1 3 81 2 
 V2 3 101 1 
 V3 1 65 1 
 V4 2 114 2 
PEI V1 3 65 5 
 V2 2 79 4 
 V3 3 67 5 
 V4 3 86 4 
IL-2/Ig V1 4 119 7 
 V2 4 116 6 
 V3 5 92 6 
 V4 3 73 4 
IL-7 V1 4 76 5 
 V2 6 121 6 
 V3 3 91 3 
 V4 2 98 3 
IL-12 + IL-18 V1 6 97 9 
 V2 5 100 7 
 V3 2 106 3 
 V4 2 97 3 
IL-15 (SSLSS) V1 3 106 5 
 V2 2 109 4 
 V3 3 133 5 
 V4 2 118 4 
IL-15 (SSLSS) + IL-2/Ig V1 5 87 8 
 V2 6 86 7 
 V3 3 86 8 
 V4 4 144 6 
IL-15 (SRLSS) V1 3 108 6 
 V2 3 121 3 
 V3 3 133 4 
 V4 1 124 3 
IL-15 (SRLSS) + IL-2/Ig V1 4 99 6 
 V2 4 131 9 
 V3 7 153 4 
 V4 5 105 7 
Sushi IL-15 V1 4 133 5 
 V2 6 124 3 
 V3 3 143 2 
 V4 4 140 4 
 
Physical responses to vaccination were monitored weekly after V1-V4, until they 
completely subsided.  Heat was determined by warmth of the skin to the touch.  Average 
values for duration of heat and size and duration of swelling of vaccine group members 
are represented. 
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Serological Responses to DNA Immunization 
Humoral immune responses following immunization with pSYNSU or pSYNSU 
+ PEI, with and without co-administration of immunostimulatory cytokine plasmids, 
were evaluated by immunoblot analysis and ELISA to detect IgGA and IgGT subtypes.  
The initial immunization did not elicit a significant difference in the specific SU antibody 
levels among any of the individuals in the ten pSYNSU immunization groups; however, 
after the second immunization, antibody responses were detectable in 13 of the 30 
animals.  None of the horses or ponies inoculated with the naked pSYNSU vaccine or 
vaccines expressing pIL-12/pIL-18 or pSushi IL-15 elicited antibody responses to antigen 
after the second injection (Figure 3.28, 3.33).   
Overall, the antibody responses in vaccinates receiving naked DNA 
immunizations were decreased in reactivity to EIAVPV on immunoblot analysis, 
compared to immunizations containing PEI.  A minimum of three vaccinations were 
required before humoral immune responses were detected on immunoblot analysis, and 
these responses were short-lived being undetectable by week 24 at time of V4 (Figure 
3.24).  All of the ponies in the naked DNA group responded to V4 with apparent boosts 
in antibody response levels (Figure 3.24).  These were greatly diminished by four weeks 
after V4 and not detectable when serum antibody levels were re-examined 26 weeks after 
V4 (Figure 3.24).   
In the ELA-A1 pilot study, low-level reactivity was seen in one of two recipients 
following three immunizations with pSYNSU and PEI.  In contrast, all three recipients in 
the expanded pilot study responded with detectable antibody responses to DNA 
vaccination containing pSYNSU and PEI, although variation between individuals with 
C06 and F36 showed higher reactivity at most time points examined than C10 (Figure 
3.25).  All members of the PEI vaccine group responded after V3, however, responses in 
C10 were relatively weak (Figure 3.25).  Nonetheless, these antibody responses were still 
detectable 12 weeks later at time of V4 in all three animals (Figure 3.25).  Despite the 
differences in antibody levels between individuals in the PEI group after V3 and V4, all 
three animals maintained strong, long-lived, anamnestic responses to V4 in all animals 
(Figure 3.25).  Even in C10, the lowest antibody responder, humoral immune responses 
to SYNSU, just as with the high responder F36, were still detectable nine months after 
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V4 (Figure 3.25).  This demonstrated the stimulation of long-term SU-specific antibody 
production in the horse.  Unfortunately, C06 could not be retained in the trial, although it 
might be predicted from the intensity of the reaction at three weeks post V4 that he too 
would have detectable SU antibody responses at week 60 (Figure 3.25).   
Although all three horses in the IL-2/Ig pSYNSU immunization group responded 
with antibody production to pSYNSU, there was considerable variation between 
individuals with diverse ELA haplotpyes (Figure 3.26).  Reactivity was easily detectable 
in E13 and D07, but only after V4, whereas robust antibody responses in D15 were 
observed by one week post V2 (Figure 3.26).  SU-specific antibody responses from the 
IL-2/Ig pSYNSU immunization group were weaker than humoral responses detected 
from the PEI pSYNSU immunization group.  Only D07 was retained for long-term 
observation, and antibody responses were still detectable at week 60, with an equivalent 
intensity to that detected at week 27 (Figure 3.26). 
Although responses varied between individuals, the IL-2/Ig, IL-7, IL-12 + IL-18, 
IL-15 (SRLSS) + IL-2/Ig, and IL-15 (SSLSS) + IL-2/Ig pSYNSU immunization groups 
demonstrated similar overall responses to the PEI pSYNSU immunization group after V3 
and V4 (Figures 3.26-3.30).  Almost all of the animals in these groups showed improved 
responses compared to the naked DNA pSYNSU vaccinates, and 55% of the subjects 
tested had SU-specific antibodies at 35 weeks post V4 (Figures 3.26-3.30).  Ponies in the 
IL-7 pSYNSU immunization group exhibited considerable variation between individuals 
in antibody response to DNA vaccination, with G22 exhibiting low antibody response 
levels (Figure 3.27).  Although G23 and G30 elicited higher humoral immune responses, 
there was no qualitative indication of improvement in antibody expression over animals 
from the PEI pSYNSU immunization group (Figure 3.27).  Equine sera from the IL-12 + 
IL-18 pSYNSU immunization group were also analyzed by immunoblot analysis for the 
presence of SYNSU-specific antibody production.  Although, all of the vaccinated 
animals responded with antibody production by two weeks post V3 (Figure 3.28), there 
was no qualitative indication of improvement in immune responses over responses 
detected in the PEI pSYNSU immunization group.  A sustained response was also only 
evident in one animal, G26, at six months after V4 (Figure 3.28).  
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In animals co-immunized with pIL-15 (SRLSS), SU-specific antibodies were 
detectable in E08 following V2 and after V3 in E03 and D77 (Figure 3.31).  Strong 
anamnestic responses were seen in E08 after V2, V3, and V4, or after V3 and V4 in the 
cases of E03 and D77 (Figure 3.31).  Furthermore, antibodies against SU were still 
present in serum samples from these recipients at 36 weeks post V4 (Figure 3.31), and 
the intensity of the reactions appeared similar to those seen in horses or ponies receiving 
pSYNSU + PEI (Figure 3.25). 
From animals in the IL-15 (SRLSS) + IL-2/Ig pSYNSU immunization group, SU-
specific serum antibodies were detectable by immunoblotting from horse 309 following 
V2 or after V3 in E12 and E15 (Figure 3.29).  Anamnestic responses were also observed 
in all members of this group post V4 (Figure 3.29).  However, the level of humoral 
reactivity was below that encountered in the pSYNSU + PEI vaccinated animals (Figure 
3.25).  Furthermore, SU reactive antibodies were only minimally apparent in pony F41 at 
36 weeks post V4 (Figure 3.25). 
Similar responses were observed in immunoblot analysis of serum samples 
collected from horses that received vaccines containing pIL-2/Ig + pIL-15 (SSLSS) 
(Figure 3.30).  Once again, none of the animals in this group possessed the ELA-A1 
haplotype (Table 2.2) and SU-specific humoral immune responses were lower than 
responses seen in pSYNSU + PEI recipients at each of the time points analyzed (Figure 
3.25).  However, SU reactivity was still visible at 36 weeks post V4 in all three horses 
(Figure 3.30). 
In contrast, all animals [none of which possessed the ELA-A1 haplotype, Table 
2.2] administered vaccines containing pIL-15 (SSLSS) in the absence of pIL-2/Ig had 
detectable SU-specific humoral responses in immunoblot analysis just after V2 and 
showed strong anamnestic responses following both V3 and V4 (Figure 3.32).  
Furthermore, all the members of this group remained seropositive to SU at 36 weeks post 
V4 (Figure 3.32).   
The results from the in vitro assays demonstrate that the pSushi IL-15 construct is 
expressed at high levels in transfected HEK293 cell cultures.  Therefore, it was predicted 
that this modified form of IL-15 might have very powerful adjuvant effects when 
simultaneously administered with pSYNSU + PEI.  However, humoral immune 
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responses to SU in this pSYNSU immunization group appeared to be very similar to 
those observed in the naked pSYNSU recipients (Figure 3.33).  Antibodies to SU were 
not detectable in immunoblots until after V3, and while there was evidence of anamnestic 
responses following V4, these declined rapidly (Figure 3.33).   
Unfortunately, it was not possible to retain all vaccinates beyond 36 weeks post 
V4.  However, of the 25 animals that were retained, 16 elicited notable, sustained 
antibody responses against SYNSU.  Surprisingly, humoral responses were still 
detectable eight months after V4, by Western blot analysis.  These long-term antibody 
levels were only detected in animals that had received PEI and were not evident in ponies 
from the naked DNA pSYNSU immunization group.  Furthermore, differences in 
response levels between vaccinated animals receiving PEI or PEI and cytokine 
expression constructs were not discernible, thereby demonstrating the influence of PEI on 
the maintenance of long-lived antibody production with DNA vaccination.  
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Figure 3.24 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
Naked DNA pSYNSU Immunization Group on IgG Immunoblot 
 
Pony 600 
 
 
Pony F37 
 
 
 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the naked 
DNA pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot 
analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 
1:20 was used as antibody control. 
Pony F41 
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Figure 3.25 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
PEI pSYNSU Immunization Group on IgG Immunoblot 
 
Horse C06 
 
 
Horse C10 
 
 
Pony F36 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks after from the PEI 
pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot analysis 
against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 1:20 was 
used as antibody control. 
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Figure 3.26 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-2/Ig pSYNSU Immunization Group on IgG Immunoblot 
 
Horse D07 
 
 
Horse D15 
 
 
Horse E13 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the IL-2/Ig 
pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot analysis 
against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 1:20 was 
used as antibody control. 
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Figure 3.27 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-7 pSYNSU Immunization Group on IgG Immunoblot 
 
Pony G22 
 
 
Pony G23 
 
 
Pony G30 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the IL-7 
pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot analysis 
against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 1:20 was 
used as antibody control. 
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Figure 3.28 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-12 + IL-18 pSYNSU Immunization Group on IgG Immunoblot 
 
Pony G21 
 
 
Pony G26 
 
 
Pony G35 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the IL-12 + 
pIL-18 pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot 
analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 
1:20 was used as antibody control. 
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Figure 3.29 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-15 (SRLSS) + IL-2/Ig pSYNSU Immunization Group on IgG Immunoblot 
 
Horse 309 
 
 
Horse E12 
 
 
Horse E15 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the IL-15 
(SRLSS) + IL-2/Ig pSYNSU immunization group were diluted 1:20 and analyzed by 
immunoblot analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse 
serum diluted 1:20 was used as antibody control. 
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Figure 3.30 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-15 (SSLSS) + IL-2/Ig pSYNSU Immunization Group on IgG Immunoblot 
 
Horse E05 
 
 
Horse F84 
 
 
Horse F85 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the IL-15 
(SSLSS) + IL-2/Ig pSYNSU immunization group were diluted 1:20 and analyzed by 
immunoblot analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse 
serum diluted 1:20 was used as antibody control.   
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Figure 3.31 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-15 (SRLSS) pSYNSU Immunization Group on IgG Immunoblot 
 
Horse D77 
 
 
Horse E03 
 
 
Horse E08 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the IL-15 
(SRLSS) pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot 
analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 
1:20 was used as antibody control. 
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Figure 3.32 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-15 (SSLSS) pSYNSU Immunization Group on IgG Immunoblot 
 
Horse 311 
 
 
Horse D16 
 
 
Horse G75 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the IL-15 
(SSLSS) pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot 
analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 
1:20 was used as antibody control. 
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Figure 3.33 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
Sushi IL-15 pSYNSU Immunization Group on IgG Immunoblot 
 
Horse F06 
 
 
Horse F18 
 
 
Horse G04 
 
 
Serum samples collected at 0, 3, 12, 13, 14, 24, 25, 27, and 60 weeks from the Sushi IL-
15 pSYNSU immunization group were diluted 1:20 and analyzed by immunoblot 
analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse serum diluted 
1:20 was used as antibody control. 
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Induction of IgGA and IgGT Specific Responses by Different pSYNSU Immunization 
Protocols 
One month prior to V3, ponies from the IL-7 and IL-12 + IL-18 pSYNSU 
immunization groups received their yearly rabies vaccination.  This was not expected to 
have any impact on SU-specific humoral responses after V3.  However, high levels of 
serum IgGA responses were detected in all six ponies, prior to immunization, because of 
aberrant reactivity to cellular proteins (from virus preparation) in the EIAVPV capture 
antigen (data not shown).  Therefore, only the remaining eight pSYNSU immunization 
groups were included in the statistical analysis of the IgGA ELISA data after V3 and V4.  
Based on statistical similarities (P>0.05) of mean IgGA responses between pSYNSU 
immunization groups over time (after V3 and V4), four statistically similar groups were 
identified.  In general, statistical analysis of the IgGA ELISA data mirrored the qualitative 
results from immunoblotting.  The Sushi IL-15 pSYNSU immunization group was 
indistinguishable at all time points from the naked DNA pSYNSU immunization group, 
with the lowest overall levels of IgGA (Figure 3.34.).  Significantly higher (P<0.05) IgGA 
responses after V3 and V4 were observed in the PEI, IL-2/Ig, and IL-15 (SRLSS) 
pSYNSU immunization groups (Figure 3.34.).  The IL-2/Ig + IL-15 (SRLSS) and IL-2/Ig 
+ IL-15 (SSLSS) pSYNSU immunization groups also had higher IgGA levels than 
pSYNSU vaccinated animals, but differed from the subjects in group 2 in having 
significantly greater responses following V3 (Figure 3.34).  However, the highest IgGA 
titers were observed in the pIL-15 (SSLSS) vaccinates.  Significant responses (P<0.05), 
identified by the Mixed Procedures of SAS, initially occurred two weeks post V3 and 
continued through V4, with significant differences still detected at the final week 28 time 
point (Figure 3.34).  In contrast to enhanced levels of IgGA, the ELISA results determined 
that there were no detectable levels of IgGT present in serum samples collected from any 
of the DNA vaccinated horses and ponies at any time point.  
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Figure 3.34 
 
IgGA ELISA Reactivity of pSYNSU DNA Immunization Treatment Groups 
 
 
 
 
Average serum IgGA reactivity of each pSYNSU immunization group was determined by 
ELISA at 1:40 dilutions.  Serum was analyzed at 0, 3, 12, 13, 14, 15, 16, 24, 25, 26, 27, 
and 28 weeks from individual DNA vaccinated animals and represented as the mean for 
each pSYNSU immunization group.  Individual points are indicated by a letter on the 
graph.  Statistical analysis was performed by Xia Yu at the University of Kentucky, 
Department of Statistics, using SAS PROC MIXED.  Vaccine groups that were not 
statistically different from one another were subcategorized into four groups, as indicated 
by black (D=IL-15 (SSLSS), red (A=PEI, B=IL-2/Ig, C=IL-15 (SRLSS)), blue (E=IL-15 
(SRLSS), F=IL-15 (SSLSS), and green (I=naked DNA, J=Sushi IL-15) lines.   
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Neutralizing Antibody Responses 
To determine if SU-specific antibodies induced by different pSYNSU 
immunization protocols possessed viral neutralizing activity, serum samples collected 
prior to immunization, at two weeks post V3, and at three weeks post V4 were analyzed 
in a homologous neutralization assay against EIAVPV.  Neutralizing antibody activity was 
undetectable in all of the serum samples when measured against a viral dose of 
100TCID50, although this was detectable in serum samples from an EIAVPV infected 
control animal (data not shown). 
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3.4:  Analysis of Cellular Immune Responses in DNA Vaccinated Horses and Ponies 
Possessing Diverse ELA-Haplotypes 
Optimization of Lymphoproliferative Responses to SU-specific Peptide Pools 
(i) Effect of DMSO 
Since DMSO has a potential for toxicity in cell culture, the effect of this 
amphipathic solvent on equine PBMC was determined.  Incubation of equine PBMC 
from an EIAV infected control horse (D64) for 3 days in increasing amounts of DMSO, 
from 0% to 10.5%, decreased the viability of live cells significantly in culture with 
straight DMSO and peptide pool 5, reconstituted in DMSO.  Pool 5 was selected for this 
optimization assay because it contained peptide 20 with the RVED epitope.  Cell viability 
was compromised only in high concentrations of DMSO (3.5-10.5%), while 
concentrations of DMSO below 3.5% did not induce cell death (Figure 3.35).  In view of 
the toxicity of DMSO, it is not surprising that lymphocyte proliferation following 
stimulation with 21 µg/ml concentrations of peptide pool 5 declined as DMSO 
concentrations increased.  However, a DMSO concentration of 1.05% had the opposite 
effect and increased the background level of lymphocyte proliferation compared to 
PBMC incubated in media alone (Figure 3.35).  
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Figure 3.35 
Effects of Increasing DMSO and Peptide Pool 5 Concentrations on PBMC 
Viability in Vitro 
 
PBMC cultures from an EIAV infected horse (D64) were incubated with 2.1-210 µg/ml 
DMSO or Peptide Pool 5 for 72 h.  Cell viability was determined by a Vi-Cell Cell 
Viability Analyzer. 
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(ii) Fresh vs. cryopreserved PBMC 
To evaluate the effect of cryopreservation on the subsequent proliferative ability 
of equine PBMC, a comparative study was conducted with freshly isolated and 
cryopreserved PBMC from an EIAV infected horse, D64.  In terms of trypan blue 
exclusion, the overall cell viability of fresh PBMC as determined by a ViCell counter was 
97.6%, compared with 92.9% for cryopreserved PBMC.  In addition to the 4.7% decrease 
in overall cell viability, significant differences (P<0.05) were evident with mitogenic 
stimulation by Con A between the mean proliferative response of cryopreserved (15,001 
+/- 1417 ccpm) and fresh PBMC (21,647 +/- 2475 ccpm).  Despite this difference, a 
similar blastogenic potential of fresh and frozen lymphocytes was observed 
microscopically.  Furthermore, no significant differences (P>0.05) in lymphoproliferation 
were detected in response to EIAVPV and SU-specific peptide pool stimulation between 
fresh (17,418 +/- 1143 for EIAVPV stimulation and 13,709 +/- 1303 for peptide pool 
stimulation) and frozen (17,190 +/- 857 for EIAVPV stimulation and 13,261 +/- 1172 for 
peptide pool stimulation) cell populations, as measured by the incorporation of [
3
H]-
thymidine.   
 
(iii) Comparison of lymphoproliferative responses to peptides from different 
manufacturers  
 
Although a majority of the peptides utilized in these studies was synthesized at 
the University of Pittsburgh, replacement peptides and the RW-12 peptide were produced 
by GenScript.  Representative peptides from each manufacturer were selected to compare 
their stimulatory potentials on equine PBMC in vitro.  The peptides received from the 
University of Pittsburgh were HPLC-purified and
 
confirmed by mass spectrometry, but of 
unspecified purity, while the peptides synthesized by GenScript were at least 85% pure.  
Optimization studies with these individual peptides were initially performed on PBMC 
from an EIAV infected horse, D64, prior to use in lymphoproliferative assays with 
PBMC from DNA vaccinated animals.  Since D64 possessed the ELA-A1 haplotype, 
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increased reactivity to peptides containing the RVED epitope was expected.  This 
epitope, contained within peptide 20, was synthesized at the University of Pittsburgh 
(Peptide Synthesis Facility), while a custom RW-12 peptide, also containing this epitope, 
(McGuire, Fraser et al. 2004) was synthesized by GenScript (Table 2.7).   
The effects on lymphoproliferation of fresh and cryopreserved PBMC, collected 
at equivalent time points, from D64 were evaluated in response to peptides 20 and RW-
12.  Lymphocyte proliferation responses to the peptides were comparable in D64 with SI 
values of 2 for peptide 20 and 2.7 for RW-12 stimulation (Figure3.36).  These results 
were very similar for fresh and cryopreserved PBMC (Figure3.36).  To account for the 
effect of size differences between peptides 20 and RW-12 on PBMC stimulation, a 
similar experiment was also performed with equivalent numbers of molecules, based on 
the molecular weight of each peptide.  A peptide molecular weight (MW) calculator from 
www.Biopeptide.com was used to calculate the MW of each peptide.  PBMC from D64 
were incubated with 2.45 M of each peptide with the extent of lymphocyte proliferation 
evaluated by [
3
H]-Thymidine incorporation as outlined above.  Once again, the 
stimulation indexes (2.2 for peptide 20 and 2.6 for RW-12 peptide) were very similar, 
suggesting the source of the peptide used in this study was not a significant factor in 
determining the outcome of the results 
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Figure 3.36 
Lymphocyte Proliferation of Fresh and Cryopreserved Equine PBMC 
Cultures to Peptides 20 and RW-12 in Vitro 
 
Mean stimulation indexes representing lymphocyte proliferation responses of fresh and 
cryopreserved PBMC cultures from an EIAV infected horse (D64) to 72 h stimulation 
with 21 µg/ml peptide 20 or peptide RW-12.   
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(iv) Effects of priming with equine IL-2 on lymphoproliferative responses 
Experiments were also conducted to determine if pre-incubation of PBMC 
cultures with recombinant equine IL-2 would augment proliferative responses to SU-
specific peptide pools after subsequent incubation.  Interestingly, IL-2 at concentrations 
of 0.1 ng/ml (low) and 1.0 ng/ml (high) doses induced lymphoproliferative responses in 
the positive control cells, SI=3.12 and SI=2.94, respectively, compared with cells that 
were not treated with this cytokine.  However, no differences were observed between 
media controls and the addition of peptides at any of the IL-2 concentrations tested (data 
not shown). 
 
(v) Effects of priming with gradient purified EIAV or Con A on lymphoproliferative 
responses  
Similar experiments were performed to test the priming potential of gradient 
purified EIAVPV or Con A on PBMC from D64.  Cells stimulated with virus or Con A 
alone responded in a dose-dependent manner, however, addition of peptides produced no 
additional proliferative activity (data not shown).  Similarly, when PBMC were initially 
incubated with peptide pool 5 or 8 at 21 µg/ml and then stimulated with varying 
concentrations of Con A, the same results were observed.  Lymphocyte populations 
proliferated in a dose-dependent response to Con A stimulation and not to peptide pools 
(data not shown).  It was determined from the optimization assays that the 
lymphoproliferation to peptide pools could not be enhanced by pre-stimulation of PBMC 
with antigen-specific (EIAV) or mitogenic (Con A or IL-2) stimulants.  Therefore, based 
on these optimization studies, lymphocyte proliferation assays with equine PBMC from 
pre- and post-vaccinated horses and ponies were conducted using cryopreserved cell 
populations incubated in vitro with peptide pools at 21 µg/ml. 
 
Effects of Gradient Purified EIAVPV on Lymphoproliferative Responses of PBMC 
Cultures from DNA Vaccinated Animals 
Cryopreserved PBMC collected at preinoculation and one week after the third and 
fourth inoculations, from all 30 horses and ponies in the 10 pSYNSU immunization 
groups, were tested concurrently for their ability to proliferate in vitro to SU-specific 
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peptide pools (21 µg/ml) or gradient purified EIAVPV (10 µg/ml).  Significant 
lymphoproliferative responses were induced following immunization with pSYNSU, 
although as predicted with diverse animal groups, there was considerable variation 
between individual horses and ponies (Figure 3.37).  The stimulation indexes to EIAVPV 
were as high in 2/3 ponies from the pSYNSU immunization group as they were in the 
pSYNSU immunization groups, PEI, IL-15 (SRLSS), IL-15 (SSLSS), and IL-2/Ig + IL-
15 (SSLSS), following V3 and V4 (Figure 3.37).  This demonstrated that in contrast to 
humoral immunity, short-term lymphoproliferative responses were not improved by 
either PEI or any of the cytokine adjuvants at the doses used in this study (Figure 3.37).  
Proliferative responses from members of the Sushi IL-15 pSYNSU immunization group 
were also similar to the naked DNA pSYNSU immunization group (Figure 3.37).  In 
contrast, no significant lymphocyte proliferation was observed in animals receiving IL-7 
and only very low proliferative levels were detected in the IL-2/Ig, IL-12 + IL-18, and 
IL-15 (SRLSS) + IL-2/Ig pSYNSU immunization groups (Figure 3.37).   
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Figure 3.37 
 
Lymphoproliferative Responses of PBMC from DNA Vaccinates to EIAVPV 
 
 
 
 
Lymphocyte Proliferation Responses to EIAVPV from animals in the A. naked DNA, B. 
PEI, C. IL-2/Ig, D. IL-12 + IL-18, E. IL-15 (SSLSS) + IL-2/Ig, F. IL-15 (SRLSS) + IL-
2/Ig, G. IL-15 (SSLSS), H. IL-15 (SRLSS), and I. Sushi IL-15 pSYNSU immunization 
groups in the form of stimulation indexes.  All represented stimulation indexes at 13 and 
25 weeks of 2 or above have been determined to be statistically significant (P<0.05), by 
SAS PROC MIXED from Xia Yu at the University of Kentucky, Department of 
Statistics. 
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Effects of EIAV SU-specific Peptide Pools on Lymphoproliferative Responses of PBMC 
Cultures from DNA Vaccinated Animals 
Preliminary short-term proliferation assays were performed by using EIAV SU-
specific peptide pools as stimulants in a standard thymidine-incorporation
 
lymphoproliferation assay.  Significant lymphoproliferative responses, in cells collected 
one week after both V3 (week 13) and V4 (week 25), were detected in all animals 
receiving IL-15 (SRLSS) and in two of the three animals receiving IL-15 (SSLSS) 
(Figure 3.38).  However, the stimulation indexes in pIL-15(SSLSS), pIL-15 (SRLSS), 
and pSushi IL-15 recipients did not exceed those in the pSYNSU immunized animals, 
600 and F37 (Figure 3.38). 
Animals in the IL-7, IL-2/Ig, IL-15 (SSLSS) + IL-2/Ig, and IL-15 (SRLSS) + IL-
2/Ig pSYNSU immunization groups did not display any proliferative activity in response 
to SU-specific peptide pools (data not shown).  Of the remaining groups, PBMC 
proliferation from the immunized horses and ponies at weeks 13 and 25 was generally 
low and variable among pSYNSU immunization group members (Figure 3.38).  
Significant [
3
H]-thymidine incorporation was detected to one of the pools tested in one of 
the three pSYNSU (F41) and pIL-12 + pIL-18 (G35) vaccinates (Figure 3.38).  Two of 
the three animals receiving pIL-15 (SSLSS) demonstrated significant proliferative 
responses to two peptide pools (Figure 3.38).  In contrast, two of the three Sushi IL-15 
recipients and all three members of the IL-15 (SRLSS) pSYNSU immunization group 
displayed significant lymphoproliferative responses to multiple pools (Figure 3.38). 
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Figure 3.38 
 
Lymphoproliferative Responses of PBMC from DNA Vaccinates to EIAV 
SU-specific peptide pools  
 
 
Lymphocyte Proliferation Responses to EIAV SU peptide pools from DNA vaccinates: 
A. F41, B. C06, C. G35, D. 311, E. D16, F. F06, G. F18, H. D77, I. E03, and J. E08 in 
the form of stimulation indexes.  All represented stimulation indexes of 2 or above at 
Weeks 13 and 25 were determined to be statistically significant (P<0.05), by SAS PROC 
MIXED from Xia Yu at the University of Kentucky, Department of Statistics. 
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Optimization studies with initial priming of EIAV-infected (D64) PBMC with EIAVPV 
followed by subsequent stimulation with SU-specific total peptide pool 
Stimulation of PBMC from D64 with EIAVPV or the total peptide pool for 1-6 
days resulted in significant increases in IL-2 and IFN-γ expression (Figure 3.39).  IL-2 
expression was significantly upregulated after a one day incubation with virus or peptide 
pools, while IFN-γ expression was not observed until a four day incubation with virus or 
peptide pools (Figure 3.39).  Initial priming of PBMC with virus did not enhance 
cytokine expression in response to SU-specific total peptide pool stimulation for any of 
the time points examined (data not shown).  Based on the peak IL-2 and IFN-y cytokine 
expression levels, it was concluded that cell stimulation experiments with DNA 
vaccinated PBMC would utilize stimulation with peptide pools alone for one day to 
measure IL-2 expression and four days to evaluate IFN-  mRNA levels. 
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Figure 3.39 
 
Real Time RT-PCR Analysis of IL-2 and IFN-  Expression in EIAV Infected (D64) 
PBMC after Total Peptide Pool or EIAVPV In Vitro Stimulation  
 
 
 
 
 
Relative quantification (RQ) of IL-2 (A.) or IFN-γ (B.) gene expression in equine PBMC 
from EIAV infected D64 in response to incubation with total peptide pool or EIAVPV in 
vitro for 1-6 days. 
 
A. 
B. 
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SU-specific IFN-  and IL-2 mRNA Expression in PBMC Cultures from pSYNSU 
Vaccinates 
Preliminary Real-Time RT-PCR assays were conducted to determine IL-2 and 
IFN-  mRNA expression levels of PBMC from selected pSYNSU immunization groups 
after in vitro stimulation with SU-specific peptide pools.  Cryopreserved PBMC, 
collected at time of inoculation (V1) and one week post V4, were evaluated from 12 
horses and ponies in four pSYNSU immunization groups; naked DNA, PEI, IL-15 
(SSLSS) and Sushi IL-15.  Con A mitogen was used as a positive control, and negative 
control wells contained 1.05% DMSO, equivalent with the final concentration present in 
each peptide pool.  
A relative quantification (RQ) value of 2.0 was defined as the lower limit of 
cytokine expression.  As expected, there was no indication of increased IL-2 or IFN-  
expression in preimmunization PBMC from any of the 12 horses or ponies when they 
were stimulated with each peptide pool (data not shown).  Stimulation with SU-specific 
peptide pools did not elicit IL-2 expression in the naked DNA pSYNSU immunization 
group (mean RQ values between 0.5-1.6 for odd, even, and total pools), after 24 h 
stimulation in vitro (Figure 3.40).  In the PEI pSYNSU immunization group, IL-2 
expression in F36 and C10 increased by 17.5- and 4.8-fold in response to stimulation 
with the odd numbered peptide pool along with 13.9- and 2.5-fold increases to the 
complete peptide pool (Figure 3.40).  The RQ values for the third member of the group 
(C06) remained below 2.0 (Figure or Table) (Figure 3.40).  Interestingly, IL-2 expression 
was not detected in the IL-15 (SSLSS) pSYNSU immunization group (mean RQ values 
between 0.4 and 0.9) and was only detected (an 8-fold increase) following stimulation 
with the odd numbered SU-peptide pool in one member F06 of the Sushi IL-15 pSYNSU 
immunization group (Figure 3.40).  
Levels of IFN-γ mRNA present after stimulation of equine PBMC by SU-specific 
peptide pools for 96 h were also investigated in these four pSYNSU immunization groups 
one week post V4.  As expected from the analysis of IL-2 expression, IFN-  levels were 
not detected in PBMC collected prior to immunization, upon incubation with any of the 
peptide pools (data not shown).  However, when peptide pools were incubated in vitro 
with equine PBMC from the pSYNSU vaccinated group, 5- and 6.5-fold increases of 
125 
 
IFN-γ expression levels were detected in two ponies (F37, F41) to odd pool stimulation 
(Figure 3.41).  There was also a mean 3.7-fold change in IFN-  expression over 
unstimulated PBMC for the group (Figure 3.41).  In contrast to the naked DNA pSYNSU 
immunization group, peptide stimulation of lymphocyte cultures from animals in the PEI 
pSYNSU immunization group resulted in 10.1- and 5.4-fold changes in IFN-γ expression 
levels to odd and total peptide pools, respectively (Figure 3.41).  A similar trend in IFN-  
expression was detected in the Sushi IL-15 pSYNSU immunization group to stimulation 
with peptide pools, with mean fold changes for the group between 3.4 and 5.7 in response 
to all three peptide pools (Figure 3.41).  Interestingly, 12.3- to 24.4-fold increases in IFN-
 expression levels to odd, even, and total peptide pool stimulation were detected for all 
three horses in the group (Figure 3.41).  While G75 was a low responder to odd peptide 
pool stimulation, IFN-  levels were still 2.4-fold higher than unstimulated PBMC (Figure 
3.41).   
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Figure 3.40 
 
Real Time RT-PCR Analysis of IL-2 Expression in Equine PBMC from 
pSYNSU immunization groups after V4 
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Relative quantification (RQ) of IL-2 gene expression in equine PBMC from DNA 
pSYNSU immunization groups after V4 in response to incubation with peptide pools in 
vitro: 1.A. RQ of Odd pool, 1.B. Mean RQ of odd pool, 2.A. RQ of Even Pool, 2.B. 
Mean RQ of even pool, 3.A. RQ of Total pool, 3.B. Mean RQ of total pool 
 
1.A. 1.B. 
2.A. 2.B. 
3.B. 
Odd Peptide Pool Stimulation 
3.A. Total Peptide Pool Stimulation 
Even Peptide Pool Stimulation 
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Figure 3.41 
 
Real Time RT-PCR Analysis of IFN-  Expression in Equine PBMC from pSYNSU 
Immunization Groups after V4 
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Relative quantification (RQ) of IFN-  gene expression in equine PBMC from pSYNSU 
immunization groups after V4 in response to incubation with peptide pools in vitro: 1.A. 
RQ of Odd pool, 1.B. Mean RQ of odd pool, 2.A. RQ of Even Pool, 2.B. Mean RQ of 
even pool, 3.A. RQ of Total pool, 3.B. Mean RQ of total pool 
1.A. 1.B. 
2.A. 2.B. 
3.B. 3.A. 
Odd Peptide Pool Stimulation 
Total Peptide Pool Stimulation 
Even Peptide Pool Stimulation 
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3.5:  DNA immunization protocols and maintenance of long-term immune memory 
in animals 
 
Physical Responses to pSYNSU Immunization after V5 
After administration of V5, heat was detectable in all 15 animals for 2-3 weeks 
and swelling of the skin was noted for 3-4.5 weeks in all vaccinates (Table 3.5).  
However, differences in the sizes of skin swelling were very evident between groups.  
Members of the IL-7 and IL-15 (SRLSS) pSYNSU immunization groups demonstrated 
weak physical responses to vaccination, with the average diameter of skin nodules 
ranging in size from 85-86 mm (Table 3.5).  In contrast, moderate areas of swelling (111 
mm) at the injection sites were observed in both animals in the IL-12 + IL-18 group 
(Table 3.5).  The largest inflammatory reactions were observed in the naked DNA, PEI, 
and the IL-15 (SSLSS) pSYNSU immunization groups, with swelling ranging from 122-
127 mm in diameter (Table 3.5). 
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Table 3.5 
 
Physical Responses of Horses or ponies to Different pSYNSU DNA 
Immunization Protocols after V5 
 
pSYNSU 
Immunization Group 
 
Duration of Heat 
(Weeks) 
Average Swelling 
(mm) 
Average Duration 
of Swelling (Weeks) 
naked DNA 
 
2 137 
 
3 
 
PEI 
 
3 128 
 
4 
 
IL-7 
 
3 85 
 
4 
 
IL-12 + IL-18 
 
3 111 
 
5 
 
IL-15 (SSLSS) 
 
2 122 
 
3 
 
IL-15 (SRLSS) 
 
2 86 
 
4 
 
 
Physical responses to vaccination were monitored weekly after V5, until they completely 
subsided.  Heat was determined by warmth of the skin to the touch.  The average size and 
duration of swelling and the duration of heat represent averages among pSYNSU 
immunization group members. 
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Humoral Immune Responses to pSYNSU Immunization (V5) 
 (i.) Immunoblot Analysis  
Antibodies to SU were undetectable by immunoblot assay in Ponies 600 and F37 
and only barely visible in F41 at week 90, immediately prior to V5 (Figure 3.42).  This 
fifth pSYNSU immunization without PEI induced easily detectable anamnestic responses 
in all three recipients (Figure 3.42).  However, subsequent serum samples collected at 10 
and 16 weeks post V5 suggested that these responses were subject to a rapid decline, as 
judged by their relative intensities (Figure 3.42). 
In contrast to the naked DNA pSYNSU immunization group, SU-specific 
antibodies were readily apparent at 60 weeks post V4 in the two remaining members of 
the PEI pSYNSU immunization group (C10 and F36) (Figure 3.43).  Despite the 
presence of these very long-lived antibody responses, both animals had clearly defined 
anamnestic responses to V5 (Figure 3.43).  Furthermore, in the case of C10 that was 
retained for long-term observations, SU antibodies were still readily apparent at 59 weeks 
post V5 (Figure 3.43).  A very similar result was seen with horses or ponies in the IL-15 
(SRLSS) (Figure 3.44) or IL-15 (SSLSS) (Figure 3.45) pSYNSU immunization groups.  
SU-specific antibodies were still detectable in all these vaccinates at 66 weeks post V4, 
and all animals, with the exception of G75, had anamnestic responses to V5 (Figures 
3.44-3.45).   
The only other ponies that could be retained for the study were two in the IL-7 
pSYNSU immunization group (G22 and G23) and two ponies in the IL-12 + IL-18 
pSYNSU immunization group (G26 and G35).  Considerable individual variation was 
observed in these animals.  Antibodies against SU were present in G23 and G26 
immediately prior to V5 (Week 90) (Figures 3.46-3.47), but not in G22 or G35 (Figures 
3.46-3.47).  Although all four ponies showed some evidence of an anamnestic response to 
V5, this varied in intensity (Figures 3.46-3.47.  Furthermore, SU antibodies were not 
readily apparent in G22 or G35 at 59 weeks post V5, while they were clearly present by 
immunoblot analysis at this time point in G23 and G26 (Figures 3.46-3.47).  
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Figure 3.42 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
Naked DNA pSYNSU Immunization Group on IgG Immunoblot 
 
 
 
 
 
 
 
Plasma samples collected at 0, 27, 50, 90, 97, 100, and 106 weeks after immunization 
from the naked DNA pSYNSU immunization group (600, F37, F41) were diluted 1:20 
and analyzed by immunoblot analysis against SDS-disrupted EIAVPV.  A reference anti-
EIAV horse serum diluted 1:20 was used as antibody control. 
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Figure 3.43 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
PEI pSYNSU Immunization Group on IgG Immunoblot 
 
 
 
 
 
Plasma samples collected at 0, 27, 50, 90, 97 (for F36), 100, 106 (for F36), and 149 (for 
C10) weeks after immunization from the PEI pSYNSU immunization group (C10, F36) 
were diluted 1:20 and analyzed by immunoblot analysis against SDS-disrupted EIAVPV.  
A reference anti-EIAV horse serum diluted 1:20 was used as antibody control 
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Figure 3.44 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-15 (SRLSS) pSYNSU Immunization Group on IgG Immunoblot 
 
 
 
 
 
 
 
Plasma samples collected at 0, 27, 50, 90, 100, and 149 weeks after immunization from 
the IL-15 (SRLSS) pSYNSU immunization group (D77, E03, E08) were diluted 1:20 and 
analyzed by immunoblot analysis against SDS-disrupted EIAVPV.  A reference anti-
EIAV horse serum diluted 1:20 was used as antibody control 
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Figure 3.45 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-15 (SSLSS) pSYNSU Immunization Group on IgG Immunoblot 
 
 
 
 
 
 
 
Plasma samples collected at 0, 27, 50, 90, 100, and 149 weeks after immunization from 
the IL-15 (SSLSS) pSYNSU immunization group (311, D16, G75) were diluted 1:20 and 
analyzed by immunoblot analysis against SDS-disrupted EIAVPV.  A reference anti-
EIAV horse serum diluted 1:20 was used as antibody control 
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Figure 3.46 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-7 pSYNSU Immunization Group on IgG Immunoblot 
 
 
 
 
 
Plasma samples collected at 0, 27, 50, 90, 100, and 149 weeks after immunization from 
the IL-7 pSYNSU immunization group (G22, G23) were diluted 1:20 and analyzed by 
immunoblot analysis against SDS-disrupted EIAVPV.  A reference anti-EIAV horse 
serum diluted 1:20 was used as antibody control. 
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Figure 3.47 
 
Analysis of SU-Specific Serum Antibody Reactivity from Immunized Ponies in the 
IL-12 + IL-18 pSYNSU Immunization Group on IgG Immunoblot 
 
 
 
 
 
Plasma samples collected at 0, 27, 50, 90, 97 (for F36), 100, 106 (for F36), and 149 (for 
C10) weeks after immunization from the IL-12 + IL-18 pSYNSU immunization group 
(G26, G35) were diluted 1:20 and analyzed by immunoblot analysis against SDS-
disrupted EIAVPV. A reference anti-EIAV horse serum diluted 1:20 was used as antibody 
control 
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 (ii.) Analysis of neutralizing antibodies 
To investigate if antibodies induced by immunization with pSYNSU or pSYNSU 
+ PEI possessed viral neutralizing activity, serum samples collected two weeks post V5 
were analyzed in a homologous neutralization assay against EIAVPV.  No neutralizing 
activity was detected in these samples when measured against a viral dose of 100 TCID50 
(data not shown). 
 (iii.) Quantitation by IgGA ELISA of V5 induced anamnestic humoral responses 
Specific anti-SU IgGA end-point titers in serum samples pre- and post-V5 were 
measured by ELISA.  Statistical analysis of the data was performed by Xia Yu at the 
University of Kentucky, Department of Statistics, using the mixed procedure with Sas.   
The IgGA ELISA results supported the immunoblot analysis, demonstrating that all 
SYNSU DNA immunization protocols tested were capable of inducing very long-lived 
(>1 year) memory B-cell populations, as evidenced by the anamnestic responses post V5 
(Figure 3.48).  Furthermore, the highest relative anamnestic responses were observed in 
the naked DNA and PEI pSYNSU immunization groups (P<0.05) (Figure 3.48), 
suggesting the potentiating effects of IL-15 (SSLSS) seen after V3 and V4 are not 
permanent, but may instead depend on the co-administration of this cytokine.  
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Figure 3.48 
 
IgGA ELISA Reactivity of pSYNSU Immunization Groups after V5 
 
 
 
 
 
Average serum IgGA reactivity at 1:40 dilution of pSYNSU immunization groups after 
V5, as determined by ELISA.  Serum was collected at 0, 12, 90, 91, 92, 93, 94, 95, 97, 
99, 106, 110, 114, 118, and 122 weeks from the following pSYNSU immunization 
groups: (a) PEI, (b) IL-15 (SRLSS), (c) IL-15 (SSLSS), (d) IL-7, (e) IL-12 + IL-18, and 
(f) naked DNA.   
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IFN-  mRNA Expression Levels in PBMC Populations post V5 
PBMC collected at 5 days post V5 were incubated with SU-specific odd number, 
even number, and a total pool consisting of all 44 overlapping peptides encompassing 
SU.  Amounts of IFN-  or IL-2 mRNA were determined by real-time RT-PCR.  There 
was no significant increase in IL-2 mRNA expression (RQ<2.0) in PBMC stimulated 
with SU-specific peptide pools in any of the pSYNSU immunization groups (Figure 
3.49).  However, significant increases in IFN-  mRNA production were observed in SU-
peptide pool stimulated PBMC in both remaining pSYNSU + PEI recipients, all three 
members of the IL-15 (SRLSS) pSYNSU immunization group, and in one horse (311) in 
the IL-15 (SSLSS) pSYNSU immunization group (Figure 3.50).  Furthermore, low but 
significant (RQ>2.0) increases in IFN-  mRNA expression were induced in SU-peptide 
pool stimulated PBMC collected from animals in the IL-7 and IL-12 + pIL-18 pSYNSU 
immunization groups (Figure 3.50).  In contrast, IFN-  mRNA production was not 
enhanced in PBMC from any of the naked DNA pSYNSU immunization group members 
following incubation with SU peptide pools, suggesting this plasmid construct without 
PEI does not induce strong CTL responses (Figure 3.50). 
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Figure 3.49 
 
Real Time RT-PCR Analysis of IL-2 Expression in Equine PBMC from pSYNSU 
Immunization Groups after V5 
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Figure 3.50 
 
Real Time RT-PCR Analysis of IFN-  Expression in Equine PBMC from pSYNSU 
Immunization Groups after V5 
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Lymphocyte Proliferation Responses in PBMC Populations post V5 
Despite no detectable enhancement in IFN-  expression, PBMC harvested 5 days 
post V5 from all of the naked DNA pSYNSU vaccinates did exhibit lymphocyte 
proliferative responses.  PBMC from all members of this group (600, F37, F41) had 
significant SI levels>2.0 when incubated with gradient purified virus (Figure 3.51), while 
pony F37 responded to peptides within four separate pools (4, 5, 6, 7) and pony 600 
responded to peptides within pools 3 and 7 (Figure 3.52). 
Lymphocyte proliferation responses to gradient purified preparations of EIAVPV 
were also detected in the PEI (C10, F36), IL-7 (G22, G23), and IL-15 (SSLSS) pSYNSU 
immunization group members (Figure 3.51).  However, SI values in these animals did not 
exceed those observed in the naked DNA pSYNSU immunization group (Figure 3.51).  
Lymphocyte proliferative responses (SI<2.0) could not be detected in the IL-12 + IL-18 
and IL-15 (SRLSS) pSYNSU immunization group members (Figure 3.51.). 
In addition to two of the pSYNSU recipients mentioned above (600, F37) 
lymphocyte proliferative responses (SI>2.0) to the SU peptide pools were observed in 
both members of the PEI, IL-7, and one member of the IL-15 (SSLSS) (G75) pSYNSU 
immunization group (Figure 3.52).  Furthermore, despite the lack of reactivity against 
gradient purified EIAVPV, two horses in the IL-15 (SRLSS) pSYNSU immunization 
group also demonstrated weak reactivity to some SU peptide pools (Figure 3.52).  
However, in contrast to the broad reactivity observed following V4 (Figure 3.38), this 
was much more restricted post V5 (E03 reacted to SU pools 3 and 5, whereas D77 
reacted to pools 1 and 2; Figure 3.52), suggesting some loss in responsiveness.  
Interestingly, the opposite was apparent in the IL-7 pSYNSU immunization group, as 
both ponies exhibited low but detectable lymphocyte proliferation to all seven peptide 
pools (Figure 3.52) 
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Figure 3.51 
 
Lymphoproliferative Responses of PBMC from pSYNSU Vaccinates to EIAVPV 
 
 
 
Lymphocyte proliferation responses to EIAVPV from animals in the A. naked DNA, B. 
PEI, C. IL-7, and D. IL-15 (SSLSS) pSYNSU immunization groups in the form of 
stimulation indexes at Week 0 and Week 91.  All represented lymphoproliferation data at 
week 91 are statistically significant (P<0.05). 
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Figure 3.52 
 
Lymphoproliferative Responses of PBMC from pSYNSU Vaccinates to EIAV SU-
specific peptide pools 
 
 
 
Lymphocyte proliferation responses to EIAV SU peptide pools from DNA vaccinates at 
Week 0 and Week 91: A. 600, B. F37, C. C10, D. F36, E. D77, F. E03, G. G75, H. G22, 
I. G23 in the form of stimulation indexes.  All represented lymphoproliferation data at 
week 91 are statistically significant (P<0.05). 
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Chapter IV:   Discussion 
 
DNA vaccination has shown great promise and offers a novel approach for 
stimulating protective humoral and cell-mediated immune responses against a number of 
viral, protozoal, and bacterial pathogens.  Initially, DNA vaccines were investigated 
because of their potential to induce CTL, as a consequence of antigen expression within 
cells of vaccinated animals.  In fact, this technology has been demonstrated to effectively 
induce CTL in mice, monkeys, and humans.  However, the full potential of DNA 
vaccines has yet to be realized in all species.  A crucial limitation of naked DNA vaccines 
in larger animals, such as the horse, is its weak immunogenicity.  Many of the immune 
responses elicited by DNA vaccination are not as potent as those induced by other 
vaccine methods.  The reasons for the reduced efficacy of these vaccines are not known, 
but may involve lower distribution and uptake of DNA and/or differences in how 
antigens expressed from DNA vaccines are processed and presented in large animals.   
Cell-mediated immune responses are believed to play a key role in providing 
protection against some pathogenic infections in large animals.  While DNA vaccines 
have frequently been reported to generate humoral immune responses in the horse, the 
induction of cellular immunity is generally not indicated in the literature.  Despite the 
limitations of this technology, the successful application of an equine DNA vaccine 
against West Nile Virus fueled the DNA vaccine platform in the development of 
strategies to produce robust immune responses to immunization and better understand the 
nature of protective immunity against other equine pathogens.  It is clear that 
improvements need to be implemented for this technology to be widely adopted for 
commercial application in veterianry medicine.   
Many potential approaches have been explored to optimize DNA vaccine-induced 
immunity.  In this dissertation, we have focused on and adapted three main successful 
strategies from murine and non-human primate model systems to enhance the 
immunogenicity of DNA vaccination, using EIAV SYNSU as an antigen expression 
system.  These strategies include: (1) the use codon optimization of plasmid DNA to 
increase in vivo expression levels; (2) the formulation of DNA with a cationic polymer, 
PEI, to protect DNA from nuclease degradation and facilitate cellular transfection; and 
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(3) the incorporation of immunostimulatory cytokine plasmids to the SYNSU DNA 
vaccines to further modulate immune responses.  PEI is reported to facilitate a 1000-fold 
increase in cellular transfection of DNA in genetic engineering experiments in vitro in 
mice.  Surprisingly, prior to this work, the adjuvant effects of PEI on vaccination had not 
been tested in horses or any other species.  Therefore, the use of PEI as an adjuvant for 
the equine DNA vaccination studies described in this work represents a novel and 
practical application for this polymer.  Additionally, while the adjuvant effects of many 
different cytokines on DNA vaccinations have been demonstrated in other species, the 
results have been modest when used in horses (Reviewed in Weiner et al., 2008, Nature 
Reviews).  Thus, this work sought to develop comprehensive DNA vaccine approaches 
that would bolster equine immune responses to immunization.   
A key finding of this dissertation work is that plasmid DNA vaccines, encoding 
the SYNSU antigen expression construct, formulated with PEI generates cellular and 
long-lived humoral immune responses in the horse, with relatively low doses (250-500 
µg) of plasmid.  In contrast, previous work has demonstrated that weak 
lymphoproliferative and moderate antibody responses can be generated in ponies against 
codon optimized EIAV envelope sequences with multiple, high (1.5 mg) doses of DNA 
vaccines (Cook, Cook et al. 2005).  We also show that the addition of codon optimized 
IL-15 gene constructs further augment IgGA antibody responses, expand 
lymphoproliferative responses, and increase the expression of IFN-y mRNA levels with 
in vitro stimulation of PBMC from immunized animals.  This may facilitate the 
development of novel, safer and more effective vaccine adjuvants for use in DNA 
vaccination of horses against other pathogens.   
 
4.1. In Vitro Effects of Codon Optimization 
 
4.1.1. Effect of codon optimization on the expression levels of cytokine constructs 
Codon optimization has become a commonly utilized approach to improve the 
immunogenicity of DNA vaccines. This technique alters the codon bias of a gene without 
changing the original amino acid sequence of the protein (Kim, Oh et al. 1997; zur 
Megede, Chen et al. 2000).  Thus, it can result in the enhanced expression of cloned 
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genes and production of larger quantities of the foreign protein in the immunized 
individual.  The successfulness of codon optimization in stimulating strong immune 
responses has been demonstrated in several experimental animal models (Nagata, 
Uchijima et al. 1999; Egan, Charini et al. 2000).  When the immunogenic effects of 
synthetic genes were compared to those of wild-type genes in mammalian DNA 
immunization trials, the codon-optimized genes elicited robust immune responses in vivo, 
compared to low or moderate responses generated by wild-type genes (Uchijima, 
Yoshida et al. 1998; Stratford, Douce et al. 2000).   
While the approach of codon optimization of antigen and cytokine expression 
constructs has been commonly utilized in mouse, monkey, and human DNA vaccine 
models, it has not been used extensively in the horse.  Many equine lentivirus sequences 
and native cellular genes are poorly expressed in vivo when utilized with DNA 
vaccination techniques.  This may correspond with low level protein expression in vitro 
(Cook, Cook et al. 2005).  However, work done in our laboratory has shown that codon 
optimization of a lentivirus sequence encoding for EIAV SU markedly improved in vitro 
protein expression, compared to native SU gene sequences, in DNA vaccine studies 
(Cook, Cook et al. 2005).  DNA immunization with codon optimized SU gene sequences 
also enhanced humoral and lymphoproliferative responses in the horse (Cook, Cook et al. 
2005).   
As a strategy to further enhance equine immune responses to DNA vaccination, 
we also generated a number of synthetic cytokine plasmids, to use concurrently with the 
codon optimized antigen expression construct SYNSU.  Due to codon bias, a careful 
balance needed to be maintained between codon optimization and G/C content 
optimization in the synthesis of these constructs.  Codon optimization can affect negative 
cis acting sites such as A/T and G/C-rich strectches, which may negatively influence 
expression.  Therefore, prior to producing synthetic constructs, thorough computational 
analyses were conducted to compare equine gene sequences to highly expressed 
sequences across many different species to determine modifications which might 
maximize expression in the immunized host.  Although „optimized codons‟ for protein 
synthesis may be different depending on the species, most mammals have very similar 
codon usage (Nakamura, Gojobori et al. 2000).   
148 
 
Native equine cytokine coding sequences for IL-2, IL-7, and, in particular, IL-15 
resemble lentivirus sequences in being A/T rich.  Therefore, gene sequences for equine 
IL-2/Ig, IL-7, and three variants of IL-15 (SRLSS, SSLSS, and Sushi), with different in 
vitro protein expression levels, were modified to conform to a codon usage bias that is 
similar to highly expressed genes in other mammalian species, including the horse.  In 
addition, gene sequences for IL-12 and IL-18 were also codon-optimized  
Although codon optimization also improved expression of equine IL-2, IL-2/Ig, 
and IL-7, compared to native sequences, the effects were more modest.  This 
demonstrates that A/T rich sequences trending towards an unusual codon-usage bias are 
not always synonymous with very low protein expression levels.  The presence of 
secondary structural motifs, alternative or cryptic RNA splice sites, and/or adenosine rich 
instability elements may have more of an impact on protein expression.   
This work has also demonstrated that IL-15 sequences are relatively easy to 
manipulate, resulting in vastly different effects.  Codon optimization, along with 
replacement of native peptide leader sequences, was essential to generate detectable 
expression of the equine IL-15, in the context of the pCi vector.  A „family‟ of IL-15 
plasmids were created that represent low (IL-15 (SRLSS)), moderate (IL-15 (SSLSS)), 
and high (Sushi IL-15) level expression constructs.  A single amino acid substitution at 
residue 121, changing the sequence from SRLSS to SSLSS, produces significant effects 
on the expression of this cytokine.  Since higher expression levels were detected with the 
SSLSS variant, it is likely that an arginine residue was assigned to amino acid position 
121 in equine IL-15 because of an automatic base-calling error and that serine is the 
correct amino acid at this site.  However, by far the most unexpected results were seen 
with Sushi IL-15 in vitro expression levels.  The attachment of the human TPA and Sushi 
domain to the IL-15 (SSLSS) plasmid resulted in dramatic enhancement of protein 
expression in HEK 293 transfected cells compared to expression levels seen for IL-15 
(SSLSS).   
Gene sequences for IL-12 and IL-18 were also codon-optimized.  Moderate levels 
of the synthetic IL-12 (p40/p35) fusion protein were detected in culture supernatants from 
transfected HEK 293 cell cultures by immunoblotting, thereby demonstrating that this 
modified construct was secreted from cells.  The synthetic IL-18 construct was also 
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detected in conditioned medium from HEK 293 transfected cells by immunoblotting.  
The lower apparent molecular weight protein secreted from transfected cells, compared to 
the intracellular product, provided strong evidence that the TPA signal peptide was 
cleaved prior to being exported from transfected cells.   
The level of protein expression for the synthetic codon optimized IL-12 (p40/p35) 
fusion construct was not compared with native sequences.  However, immunoblot 
analysis suggested that significant amounts of this fusion protein were secreted into 
culture fluids from codon optimized pIL-12 transfected HEK 293 cell culture.  Cleavage 
of the signal peptide in the IL-18 protein was also confirmed by immunoblot analysis of 
conditioned medium from the synthetic equine pIL-18 transfected HEK293 cell cultures.  
Furthermore, the fact that these cultures were actively dividing and not showing obvious 
signs of apoptosis suggests that unlike native IL-18, cleavage of the replacement signal 
peptide from IL-18 was caspase-1 independent. 
Our results show that compared to the native sequences, codon optimization leads 
to the enhanced expression of the IL-2/Ig, IL-7 and IL-15 cytokine expression constructs.  
However, it is not known if the differences in synthetic or native cytokine expression 
levels are attributed to modifications in transcriptional regulation or alterations in the 
nuclear translocation of mRNAs.  Studies by other groups have shown that altering the 
codon usage bias of gag mRNAs removed multiple inhibitory sequences, eliminated 
export via the exportin-1 nuclear export pathway, enabled a Rev/RRE-independent 
expression of HIV-1 Gag, and subsequently increased protein expression, unlike wild-
type gag mRNAs which are Rev/RRE dependent for expression (Graf, Bojak et al. 2000; 
Kotsopoulou, Kim et al. 2000).  However, these alternatives were not investigated as part 
of this dissertation work.   
4.1.2. Effect of codon optimization on the biological activity of cytokine constructs 
In contrast to native equine IL-15, both codon optimized IL-15 forms, SSLSS and 
SRLSS, are biologically active in vitro.  However, the IL-15 (SRLSS) is significantly less 
active at inducing lymphoproliferation of equine PBMC than IL-15 (SSLSS).  This result 
mirrors the expression pattern observed by immunoblotting for these constructs.  
Surprisingly, the Sushi IL-15 construct induced proliferation of equine PBMC, even at a 
1:1280 dilution of cell culture supernatant.  By comparison, the biological activity of 
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human IL-15 was only increased 10-fold in vitro by the covalent attachment of the sushi 
domain from the human IL-15Rα chain (Mortier, Quemener et al. 2006).  Therefore, this 
level of enhancement in protein expression represents another novel finding of this study. 
Although bio-assays were not performed on the protein expressed from codon 
optimized IL-12, this construct is identical at the amino acid level to that described by 
McMonagle et al., 2001, and has been previously shown to be biologically active 
(McMonagle, Taylor et al. 2001).  Biological activity has also been previously 
demonstrated for the equine IL-18 construct (O'Donovan, McMonagle et al. 2004).  
Therefore, it was not tested in these assays.   
 
4.1.3. Effect of codon optimization on differential glycosylation of cytokine constructs 
Interestingly, proteins expressed from codon optimized pIL-2 and to a lesser 
extent codon optimized pIL-7 had different migrational characteristics in terms of 
apparent higher MW in SDS-PAGE, compared with the equivalent proteins derived from 
native sequences.  Differential glycosylation is the most likely explanation for these 
differences.  This laboratory has shown the four potential N-linked glycosylation sites 
contained within equine IL-7 are probably utilized, and that PNGase F treatment of 
supernatants from cells transfected with this construct resulted in a single predominant 
band (Cook, Cook et al. 2008).  Equine IL-2 contains two potential N-linked 
glycosylation sites.  The increased shift in molecular weight and multiple banding 
patterns observed with codon optimized IL-2 were clearly shown to be from differential 
glycosylation by treatment with PNGase F.  This finding suggests that altering the codon 
usage bias of mRNA may influence its intracellular processing, transport and final 
destination.  There are no published accounts describing the effects of codon optimization 
on the glycosylation of IL-2.  Similarly, codon optimization may also affect the 
glycosylation pattern of equine IL-7, causing the upward shift in apparent molecular 
weight visualized in vitro.  
Alternatively, the lower molecular weight species observed for codon optimized 
IL-7 may be produced as a result of an RNA splicing event.  Many mammalian 
expression vectors, including pCi (Promega), which contain the human cytomegalovirus 
(CMV) major immediate-early gene enhancer/promoter, also possess a downstream 
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chimeric intron.  The presence of this structure flanking the multiple cloning site 
generally increases expression of ligated exogenous sequences (Brinster, Allen et al. 
1988; Choi, Huang et al. 1991; Palmiter, Sandgren et al. 1991).  Therefore, because of 
this arrangement, the 5‟ splice donor site in the pCi vector may become joined by 
spliceosomal reactions to one of many potential cryptic splice accepter sites (An A/G 
motif preceded by pyrimidine-rich tracts) present in native horse IL-7 sequences (Cook, 
Cook et al. 2008).  Although further studies are required to confirm this hypothesis, 
modern codon optimization algorithms are designed to eliminate most of the cryptic 
splice donor or acceptor sites present in native sequences.  This is, however, a plausible 
explanation for the apparent absence of an equivalent protein species in culture fluids 
from synthetic IL-7 transfected cells.   
Examination of the native equine IL-15 coding sequences revealed they were A/T 
rich (65%), with an abberant codon-usage bias similar to that seen in EIAV.  
Furthermore, the unusually long (48 amino acids) signal peptide contains two proteolytic 
sites.  While cleavage at the second site results in the mature secreted form of IL-15, 
utilization of the first site causes the resultant 19 amino acid longer variant of the protein 
to be retained in the cell (Kurys, Tagaya et al. 2000).  Therefore, in addition to codon 
optimization for expression in equine cell-types, a process that increased the G/C content 
to 55.8%, the native signal peptide was replaced with that from human TPA.  Since the 
predicted molecular weight of the mature form of equine IL-15 is approximately 13 kDa 
(Vector NTI), it is likely that the larger predominant species detected by immunoblotting 
is glycosylated.   
In addition to the very high protein expression observed with Sushi IL-15 from 
transfected cell cultures, multiple band sizes were also observed on immunoblot analysis.  
This could be representative of different Sushi IL-15 species, which may be attributed to 
differential patterns of glycosylation.  It should be noted that in addition to three potential 
N-linked glycosylation sites within equine IL-15, two additional sites occur within the 
Sushi domain. 
 
4.1.4. Potential applications for the Sushi domain attachment to gene sequences 
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The overexpression of Sushi IL-15 in vitro raised the question of whether this 
phenomenon is specific to this particular cytokine construct, or whether it is a general 
phenomenon.  More specifically, could the TPA sequence and Sushi domain be linked to 
pSYNSU, other cytokine expression constructs, or indeed any other ORF, to substantially 
enhance subsequent protein expression?  If this were a general effect, then the addition of 
TPA and the equine IL-15Rα chain protein coding Sushi domain to alternative sequences 
would be a very powerful tool in situations where high-level expression of polypeptide 
was required.  This could potentially be utilized as a gene therapy tool.  Alternatively, it 
could also be used for the increased production of cytokines or other proteins in cell 
culture, useful for drug or enzyme studies. However, many questions remain to be 
answered: (1) Do the TPA and/or Sushi sequences act as downstream enhancers?,  (2) Do 
the TPA and Sushi elements make the mRNA more stable?,  (3) Is the protein 
overexpression induced from post-transcriptional effects, such as more efficient nuclear 
export to the rER and Golgi complex or increased translational effects?  . 
 
4.2. SYNSU DNA Vaccination Trials  
 
4.2.1. Preliminary investigation of the immunogenicity of PEI and cytokine expression 
constructs on SYNSU DNA vaccination in ELA-A1 expressing ponies 
Individually, the IL-2/Ig and IL-15 plasmid expression constructs have been 
shown to enhance the immunogenicity of DNA vaccines in mice and monkeys.  DNA 
vaccines expressing an IL-2/Ig plasmid further augmented immune responses in both 
species, compared to native plasmid IL-2 (Barouch, Santra et al. 1998; Barouch, Craiu et 
al. 2000; Barouch, Santra et al. 2000).  The combination of IL-2/Ig + IL-15/Ig was also 
found to result in significant enhancement of immune responses in the mouse model over 
either cytokine alone (Ferrone, Perales et al. 2006).  However, these cytokines have not 
been previously investigated in equine DNA vaccination.   
Therefore, a small pilot study was initiated to determine if PEI, IL-2/Ig, and IL-15 
could improve the immunogenicity of DNA vaccines in the horse, using EIAV SYNSU 
as a model antigen expression system.  Several ponies were screened and only those that 
possessed the ELA-A1 haplotype were selected to be vaccine recipients.  We expected 
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that these ponies would all recognize the RW-12 CTL epitope in the pSYNSU DNA 
vaccines (McGuire, Leib et al. 2003)  There is a danger of introducing bias into the 
results when such small group sizes are utilized, especially since individual variation in 
immune responses is a common problem in large animal vaccine studies.  However, we 
hoped that a common ELA type might lessen variability in responses to immunization.  
Although it was difficult to differentiate whether ponies were high or low responders to 
the DNA vaccines, the data clearly indicated that the addition of cytokines to the vaccine 
regimen augmented humoral and cellular immune responses.   
In the only published information about potential strategies to enhance immune 
responses to DNA vaccination in horses, rabies DNA vaccination was formulated with 
the cationic lipid DMRIE–DOPE [N-(1-(2, 3-dimyristyloxypropyl)-N, N-dimethyl-(2-
hydroxyethyl) ammoniumbromide/dioleoyl phosphatidylethanolamine] to examine the 
effects on anti-rabies serological responses induced in the horse (Fischer, Minke et al. 
2003).  They demonstrated protection could improve anti-rabies serological responses in 
this species (Fischer, Minke et al. 2003; Minke, Fischer et al. 2006).  However, 
alternative cationic polymers, such as PEI, had not been evaluated, even though for some 
applications, this secondary amine was shown to be superior to DMRIE-DOPE 
(Densmore, Orson et al. 2000).  Therefore, the immunogenic effects of PEI on equine 
immune responses to SYNSU DNA vaccinations were examined in this trial. 
Naked DNA pSYNSU immunizations elicited weak humoral and cell-mediated 
immune responses in the horse.  These results are entirely consistent with previous 
findings (Cook, Cook et al. 2005).  In contrast, serological responses to SU were 
detectable after the second immunization in one of the pSYNSU + PEI recipients (B29), 
suggesting the cationic polymer may potentially augment immune responses to DNA 
vaccines in at least some animals.  However, significant enhancement of SU-specific 
antibody responses was observed in animals immunized with IL-2/Ig + pIL-15 (SRLSS) 
(D55, 9954) or with IL-15 (SSLSS) (D49) pSYNSU, receiving 250 µg doses of each 
plasmid DNA.   
In addition to induction of antibodies against SU, there is also strong evidence for 
the existence of SU-specific CMI responses in the ELA-A1 possessing ponies receiving 
cytokine plasmids.  Significant lymphoproliferative responses to in vitro incubation with 
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gradient purified EIAVPV was observed in PBMC harvested two weeks post V3 from 
9954 and D49. Furthermore, significant increases in IFN-  mRNA levels were induced 
by incubation with the RW-12 peptide in PBMC isolated from all three cytokine 
recipients.  These results strongly suggest that just three immunizations with pSYNSU + 
PEI + pIL-2/Ig + pIL-15 (SRLSS) or pSYNSU + PEI + pIL-15 (SSLSS) stimulated both 
humoral and CMI responses, whereas, in this pilot study, no SU-specific reactivity was 
detectable following three immunizations with naked pSYNSU.  
There is always a danger with very small experimental group sizes that results can 
be unduly influenced by unusually high or low responders.  However, this preliminary 
data provided strong encouragement to proceed with more extensive studies, a high 
priority of which was to confirm these preliminary findings.  In addition, as stated 
previously, the pilot study was initiated prior to the discovery of the effects of the SRLSS 
and SSLSS motifs on equine IL-15 expression.  Therefore, it was not known if the 
enhanced immune responses seen in 9954 and D55 were the result of synergistic effects 
between IL-2/Ig and IL-15 (SRLSS) or if this variant of IL-15 was expressed at such low 
levels that it was not biologically active in vivo. 
 
4.2.2. PEI and cytokine expression constructs as pSYNSU vaccine adjuvants in horses 
and ponies with divergent MHC haplotypes 
Results from the preliminary DNA vaccine trial in ponies suggested that the 
addition of PEI to plasmid DNA did not enhance immune responses in all DNA 
immunized animals.  However, significant increases in immune responses against the 
SYNSU antigen were detected following delivery of the IL-2/Ig + IL-15 (SRLSS) and 
IL-15 (SSLSS) plasmid constructs in ponies possessing the ELA-A1 MHC haplotype.  
The objective of this study was to compare the effects of PEI and selected 
immunostimulatory molecular adjuvants with a DNA vaccine comprised only of 
pSYNSU in a diverse population of animals possessing many of the known different 
ELA haplotypes.  An important aim of the second immunization trial was to confirm the 
results of the pilot study demonstrating enhancement of immune responses by pSYNSU 
+ PEI + pIL-2/Ig + pIL-15 (SRLSS) or pSYNSU + PEI + pIL-15 (SSLSS), compared to 
inoculations with pSYNSU or pSYNSU + PEI.  In addition, possible synergistic effects 
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between pIL-2/Ig and pIL-15 (SSLSS) were investigated.  The effects of pIL-2/Ig, pIL-15 
(SRLSS), and pIL-15 (SSLSS) constructs on immune responses were also individually 
investigated, along with IL-7, IL-12 + IL-18, and Sushi IL-15.   
Due to the availability of animals and the design of the vaccine trial, three horses 
or ponies with different MHC haplotypes were assigned to each group.  We had hoped 
that the formulation of pSYNSU DNA vaccines with PEI, with or without cytokine 
plasmids, would generate similar humoral or cellular immune responses amongst group 
members, despite the divergent genetic composition of the animals. However, differences 
were still observed between individual members in many of the vaccine groups in the 
intensity of immune responses elicited.  Some animals were much higher or lower 
responders than others.  For future studies, it may be possible to replace serological ELA-
typing methods with the analysis of polymorphic microsatellites (Tseng, Miller et al. 
2010). This recently developed technique has the advantage in that it provides 
information about MHC class II alleles, in addition to MHC class I.  Therefore, the use of 
this assay should provide a more rational basis on which to interpret humoral and CMI 
responses to DNA or any other vaccination strategy.  
 
4.2.3. Antigen expression vector or immune-modulator-driven humoral responses 
A potentially significant difference in the second immunization trial was the 
decision to increase the amount of pSYNSU per dose to 500 µg from 250 µg used 
previously (Cook, Cook et al. 2005) and in the pilot study.  It was anticipated that this 
might induce more uniform immune responses between the individual members of a 
vaccine group.  Although the 2-fold increase in DNA induced no apparent improvements 
in immune responses for all three recipients compared with previous studies (B33, (Cook, 
Cook et al. 2005)) during the first three immunizations with naked pSYNSU, it did 
appear to have a significant effect when plasmid DNA was complexed with PEI. 
In mice, single IM injections of plasmid DNA between 10 and 100 µg doses have 
generated vigorous immune responses to a multitude of antigens (Ulmer, Donnelly et al. 
1993; Davis and Whalen 1995; Davis, Brazolot Millan et al. 1997; Fu, Guan et al. 1998). 
Also, in horses, two 250 µg i.d. immunizations of plasmid DNA expressing the VSV G 
protein induced neutralizing antibody responses against VSV (Cantlon, Gordy et al. 
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2000), and four to five doses of pCi SYNSU at 250 µg elicited immune responses in 
ponies (Cook, Cook et al. 2005).  In addition, two 500 µg i.d. injections of bovine 
herpesvirus-1 glycoprotein D plasmid DNA induced neutralizing antibody responses in 
cattle (van Drunen Littel-van den, Braun et al. 1998).  Furthermore, it is not uncommon 
for very high doses (2-5 mg) of plasmid DNA to be used in the DNA vaccination of 
monkeys (Barouch, Powers et al. 2005; Boyer, Robinson et al. 2007; Rosati, Valentin et 
al. 2008).  Therefore, the 500 µg dose of each plasmid, used for DNA immunizations, 
was within a reasonable dose range of efficacy that has stimulated immune responses in 
other animal models. 
In contrast to the pilot study, humoral immune responses were easily detectable in 
all three pSYNSU + PEI recipients following the second or third immunization.  
Furthermore, when measured over the duration of the trial, IgGA antibody responses in 
the PEI pSYNSU immunization group equaled or exceeded those detected in many of the 
animals receiving cytokine expression vectors.  This includes animals in the pIL-2/Ig + 
pIL-15 (SRLSS) pSYNSU immunization group that appeared so successful in the pilot 
study.  Antibody responses of this magnitude had not been previously observed in 
animals immunized with pSYNSU.  Therefore, it is plausible that antigen expression 
from PEI complexes containing 250 µg of pSYNSU is below the threshold required to 
trigger immune responses in a majority of the horse population.  It is also presumed that 
at this plasmid dose, co-immunization with cytokine expression constructs, such as pIL-
2/Ig + pIL-15 (SRLSS) will significantly augment the development of immune responses.  
In the initial pilot study with animals possessing the ELA-A1 haplotype, very strong 
antibody responses to SU were observed in the two ponies (9954 and D55) co-immunized 
with IL-2/Ig + IL-15 (SRLSS).  Weak responses were also detected in ponies receiving 
250 µg doses of pSYNSU DNA vaccines formulated with PEI, similar to those seen in 
ponies immunized with naked SYNSU DNA.  However, a very different picture emerged 
during the second IL-2/Ig + IL-15 (SRLSS) co-immunization experiment, in horses that 
possessed diverse ELA haplotypes.  By increasing the dose of pSYNSU in each vaccine 
to 500 μg, robust humoral and cellular responses were detected in all three animals 
receiving vaccines formulated with PEI.  These responses greatly surpassed those 
detected from the horses immunized with 500 μg doses of IL-2/Ig + IL-15 (SRLSS).  
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This suggests that the immune responses elicited after DNA immunization may be 
dependent on the plasmid dose.   
It is possible that a 2-fold increase in pSYNSU complexed with PEI may generate 
enough antigen to induce immune responses independently of the majority of cytokines 
utilized in this second trial, at least at the single DNA dose level of cytokine expression 
vectors tested.  Therefore, the enhanced immune responses may be antigen driven and not 
cytokine driven.  In fact, in terms of humoral immunity, only pIL-15 (SSLSS) induced 
consistently higher responses than PEI in conjunction with 500 µg of pSYNSU.  
Interestingly, animals receiving immunizations formulated with PEI maintained very 
long-lived humoral responses after four and five DNA imunizations, in comparison to the 
naked DNA group.  This is a very significant finding.  The production of robust, 
anamnestic antibody responses, from the inclusion of PEI in DNA vaccine regimens, may 
be important to confer protection against some pathogenic microorganisms.  
Consequently, these results demonstrate for the first time that the addition of PEI can 
significantly enhance immune responses to DNA vaccines in the horse.  Furthermore, 
these responses are augmented by the administration of specific equine cytokine 
expression vectors, such as IL-15 (SSLSS). 
 
4.2.4. Dose effects of antigen or cytokine expression constructs on immune responses 
There may be complex relationships between immune responses, the dosage of an 
antigen expression vector, and the augmentation of these responses by molecular 
adjuvants, such as cytokines.  These relationships need to be more fully investigated in 
future studies.  For example, high levels of antigen expression may overwhelm or act 
antagonistically against the effects of exogenously expressed cytokines with the possible 
exception of IL-15 (SSLSS).  Therefore, titration of the antigen expression vector may 
need to be conducted in vivo to fully evaluate the potential beneficial effects of molecular 
adjuvants. 
In addition, titration of putative molecular adjuvants is also required.  This is 
clearly demonstrated in the case of IL-15 (SSLSS) and Sushi IL-15.  While IL-15 
(SSLSS) enhanced the immunogenicity of pSYNSU + PEI, pSushi IL-15 appeared to 
produce antagonistic effects against those stimulated by the cationic polymer and 
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suppress humoral responses, such that they were indistinguishable from the naked DNA 
pSYNSU immunization group.  As Sushi IL-15 demonstrated very strong 
lymphoproliferative potential in vitro, it is likely that local overexpression of this 
molecule may account for its ability to suppress humoral responses in vivo, rather than 
structural changes affecting for example receptor signaling.   
Since the efficacy of IL-15 as a vaccine adjuvant in maintaining anamnestic, high-
avidity T cell responses to antigens expressed from DNA vaccination has been well 
documented in rodent and monkey models, similar results were anticipated in the horse.  
However, the variability shown in humoral and cellular immune responses to the IL-15 
family members was unexpected.  Different expression levels of equine IL-15 can affect 
in vitro biological activity and might exhibit similar in vivo effects to promote or 
antagonize immune responses to pSYNSU.  To maximize the adjuvant effects of IL-15 in 
genetic vaccines, it will be critical to determine the appropriate dose for administration.  
Co-immunization of rhesus monkeys with various IL-15 doses in an influenza DNA 
system produced very different immune effects to influenza DNA immunization (Yin, 
Virology, 2009).  In that study, low dose (250 µg) co-expression of IL-15 enhanced 
CD4+ and CD8+ T cell proliferation, IFN-  production, and central memory T cell levels 
in proliferating CD8+ T cells (Yin, Virology, 2009), while high doses of IL-15 (4 mg) 
produced inhibitory effects (Yin, Virology, 2009).  This work demonstrated the 
importance of optimizing cytokine adjuvants for gene-based vaccination experiments and 
may be applicable to many other species. Conducting initial titrations on cytokine doses, 
prior to use in DNA vaccination, may also help increase the overall immunogenicity of 
this technique in the horse.    
In the studies described in this dissertation, plasmid IL-15 family members 
augmented humoral and cellular immune responses.  In particular, the co-expression of 
IL-15 (SSLSS) increased SU-specific IgGA antibody responses and IFN-  expression 
levels after V4.  The high IgGA levels were indicative of a TH1-type response, defined by 
the cytokine production of IFN- and IL-2 (Mosmann and Sad 1996).  Cell-mediated 
immunity has been associated with increased levels of TH1-type cytokine production 
from CD4+ T cells.  Plasmid IL-15 (SSLSS) may act as a potent immunomodulatory 
element to augment T-cell responses to DNA vaccination.  Furthermore, the low level 
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expression construct, IL-15 (SRLSS), when co-expressed with pSYNSU + PEI DNA 
vaccines, expanded the T cell recognition repertoire for lymphoproliferative responses.  
This was observed, to a lesser extent, with the Sushi IL-15 vaccine group after V4.  
Although immunization with the IL-15 constructs produced expanded 
lymphoproliferative responses in vitro to SU-specific peptide pools, they did not augment 
short-term lymphocyte proliferative responses to EIAVPV stimulation.  Interestingly, the 
IL-7 vaccine group also demonstrated an expansion in epitope recognition after V5.  If 
confirmed in future equine studies, this could have a profound effect on vaccine design 
for larger animals.  The ability to respond to multiple epitopes could be extremely 
important in the case of pathogens, such as lentiviruses, that have intrinsically high 
mutation rates.   
While lower doses of IL-15 may be more effective at eliciting robust immune 
responses in DNA immunization studies, the opposite may be true for some of the other 
cytokines used in this study.  For example, in rhesus monkeys, at least four multigenic 
HCV DNA vaccinations, co-delivering 800 µg of hIL-7 plasmid via electroporation, was 
required to increase HCV-specific T cell responses, within a 5 month time frame (Park, 
Song et al. 2010).  Furthermore, in a tumor model using LCMV infected mice, 10 µg of 
exogenous recombinant IL-7 protein administered daily for two weeks was necessary to 
augment and sustain anti-tumor responses (Pellegrini, Calzascia et al. 2009).  Therefore, 
it is possible the 500 µg dose level of pIL-7 plasmid DNA was not sufficient to enhance 
antibody and all CMI responses to PEI + pSYNSU.  However, future experiments to 
evaluate pIL-7 dose levels would also need to be conducted using a range of pSYNSU + 
PEI concentrations.  
No significant lymphocyte proliferation was observed in animals receiving IL-7 
and only very low proliferative levels were detected in the IL-2/Ig, IL-12 + IL-18, and 
IL-15 (SRLSS) + IL-2/Ig vaccine groups.  It is difficult to believe that all animals in these 
groups were inherently low responders and so it is possible that immunization with these 
cytokine plasmids (at the 500 µg/ml dose level), exerts inhibitory effects on short-term 
(one week post vaccination) lymphocyte proliferative responses to EIAVPV in vitro.  The 
effectiveness of these cytokines have been shown in DNA vaccine studies with other 
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species, therefore, it would be worthwhile to determine if different doses of DNA could 
also enhance the immunogenicity of DNA vaccines in horses.   
 
4.2.5. Timing of molecular adjuvants 
In addition to dosage considerations, effects on immune responses have also been 
observed with the timing of cytokine administration in other animal models.  The 
administration of pIL-2/Ig, either before or coincident with an HIV antigen expression 
vector, suppressed DNA vaccine-elicited immune responses, relative to vaccination 
without pIL-2/Ig DNA (Barouch, Santra et al. 1998).  However, the injection of this 
cytokine two days after inoculation with the HIV plasmid DNA substantially augmented 
antibody, proliferative, and CTL responses (Barouch, Santra et al. 1998).  Barouch et al., 
2000 has also shown that the administration of plasmid IL-2/Ig subsequent to DNA 
vaccination amplifies antigen-specific immune responses, compared to the simultaneous 
delivery of cytokine and antigen expression constructs (Barouch, Craiu et al. 2000).  A 
plausible explanation is that the IL-2 receptor was upregulated in these cells by the initial 
DNA vaccination, which enabled a more robust response after IL-2/Ig delivery.  Since 
IL-2 exerts direct effects on T cells, the timing of cytokine delivery in relation to immune 
priming might be critical.  The same might be true for other molecular cytokine 
adjuvants.   
Antigen presenting cells and T cells receive signals by pro-inflammatory 
molecules that stimulate adjuvant effects before, during, and/or after antigenic 
presentation to T cells by MCH complexes.  In a comprehensive study with various pro-
inflammatory cytokines, proper timing of the adjuvant cytokine DNA relative to the 
antigen was paramount in determining the magnitude of the immune response and the 
clinical effects in mice (Ferrone, Perales et al. 2006).  Future experiments need to be 
conducted in the horse to determine whether immune responses to DNA vaccination can 
be augmented by administering antigen and cytokine expression plasmids concurrently or 
at different time frames.  These optimizations may also depend on the antigen expression 
system utilized.  The immune system might first need to be primed with a specific 
antigen prior to cytokine amplification to achieve optimal enhancement of immune 
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responses.  This might be critical to optimize the magnitude of the immune responses in 
vivo and improve the overall immunogenicity of DNA vaccines in horses.   
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Summary 
Only limited reports on the immunomodulatory effects of cytokines adjuvants in 
the DNA vaccination of horses are available in the literature.  The present study differs 
from previous reports of DNA vaccination in horses in several ways.  First, we used the 
cationic polymer PEI as a known transfection agent in vitro to greatly improve the weak 
immunogenicity of pSYNSU in equine DNA vaccination and compared it to the effects 
induced by pSYNSU alone.  The only previous study with a cationic lipid, DMRIE-
DOPE, in rabies DNA vaccination of horses showed no comparison of the immune 
responses to a „naked‟ DNA vaccine group or indication of enhanced cellular responses 
in vaccinates (Fischer, Minke, 2003).  In a later report, a molecular adjuvant, GM-CSF, 
administered with EHV-1 expression constructs and DMRIE-DOPE, were shown to 
produce potent neutralizing antibody responses when compared to naked DNA (Minke, 
Fischer et al. 2006).  However, the effects of DMRIE-DOPE on the immunogenicity of 
EHV-1 DNA without GM-CSF were not tested in that model system.   Our studies 
showed that both arms of the adaptive immune response were induced by PEI, relative to 
DNA only.  Second, we have shown that PEI with or without IL-15 can simultaneously 
modulate multiple immune parameters, such as antibody, lymphocyte proliferation, and 
IL-2 and IFN-  cytokine secretion activity.  PEI alone can also significantly impact the 
onset, intensity, and duration of antigen-specific serological responses, although this may 
be dependent on the dose level of the pSYNSU antigen expression vector.  Third, we 
have compared the adjuvant properties of a comprehensive panel of plasmid cytokines on 
immune responses to DNA vaccination and have demonstrated significant augmentation 
with the IL-15SSLSS construct.  Although the effects of native IL-2, IL-6, and IL-12 
have been previously investigated in independent DNA vaccine studies, they either 
affected only humoral responses or were not concluded to be effective molecular 
adjuvants.  The administration of 200 µg of native pIL-2 in an EAV gene-based protocol 
elicited substantial humoral responses, however the immunogenic effects of plasmids 
encoding EAV antigens in the absence of pIL-2 were not investigated (Giese, Bahr et al. 
2002).  Therefore, this was not a true test of cytokine efficacy. The gene gun approach 
has also been utilized with influenza DNA vaccines co-expressing IL-6 to enhance 
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immunity in horses, but the immune responses were primarily directed towards a Th2-
type response (Soboll, Horohov et al. 2003).  In addition, IL-12 (500ug) has been tested 
as a molecular adjuvant with Rhodococcus and EIAV (p15/p26) DNA vaccine protocols 
(500ug of each plasmid), with no apparent augmentation in immune response (Mealey et 
al., 2007).  Fourth, we have demonstrated very long-lived, anamnestic memory B and T 
cell immune responses resultant from pSYNSU DNA vaccination of horses and ponies.  
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Chapter V:   Conclusions 
 
This study has confirmed that gene codon optimization can affect the post-
translational modification of the encoded antigen, and documented that the addition of 
the TPA signal peptide and the sushi domain from equine IL-15Rα dramatically enhances 
IL-15 expression in vitro.  In addition, for the first time, DNA vaccination of horses has 
been demonstrated to induce potent CMI responses, in conjunction with robust antibody 
responses, simply by the formulation of plasmid DNA with PEI.  In the immunogenicity 
trials, PEI induced strong IFN-  and IL-2 mRNA expression levels, high anamnestic 
IgGA-specific antibody responses, and moderate lymphoproliferation to pSYNSU in all 
animals after three and four immunizations.  This indicates that PEI improved levels of in 
vivo plasmid transfection and pSYNSU gene expression, compared to controls with 
equivalent numbers of immunizations. However, many questions remain.  The dose level 
of the antigen expression plasmid clearly plays a major role as shown by differences in 
results in pSYNSU + PEI recipients in the pilot (250μg) and secondary (500μg) 
immunization studies.  Indeed multiple exposures to naked DNA eventually results in an 
improved immune response as seen in the naked DNA pSYNSU immunization group 
post V5.  Therefore, additional experiments will be required to evaluate the dose of both 
the antigen expression vector and vectors encoding potential molecular adjuvants such as 
cytokines.  Although IL-2/Ig + IL-15 (SRLSS) and IL-15 (SSLSS) augmented responses 
to immunization with 250μg pSYNSU + PEI, only the latter produced significant effects 
when the dose of pSYNSU + PEI was increased to 500μg.  Interestingly, at this higher 
dose of antigen expression vector, IL-15SSLSS and Sushi IL-15 had completely opposite 
effects on humoral immune responses following co-immunization with 500μg of 
pSYNSU + PEI 
Taken together, these are very important findings, which have not been previously 
demonstrated for gene-based vaccines in horses.  Furthermore, the fact that co-
immunization with some cytokine molecular adjuvants appears to expand epitope 
recognition in cellular immune responses to DNA vaccination may if confirmed, have 
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significant implications for the design of vaccines against pathogens with high mutational 
capacity such as EIAV and HIV-1.  
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